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BACKGROUND
Age-related macular degeneration (AMD) is a complex, multifactorial disease affecting the 
central retina. It is characterized by progressive changes to the macula eventually leading 
to central vision loss. In western countries, AMD is the leading cause of visual impairment 
among elderly people.1 AMD and its accompanying vision loss are associated with difficulties 
performing daily activities, increased emotional distress and depression. It negatively 
influences the quality of life, not only of the affected individual but often also that of close 
relatives.2 Since 2006, the number of people with visual impairment secondary to AMD 
has decreased in Europe. This is most probably due to the introduction of anti-vascular 
endothelial growth factor treatment for a subset of AMD patients along with healthier 
lifestyles.3 However, as a consequence of the ageing population, the number of patients 
worldwide is expected to increase substantially from 196 million in 2020 to 288 million in 
2040. Therefore, AMD remains a significant public health problem.4 
STAGES OF AMD
Early and intermediate AMD
The major hallmark of the early and intermediate AMD stages are yellowish deposits 
between the retinal pigment epithelium (RPE) and Bruch’s membrane, known as drusen.5 
These drusen consist of various lipids and proteins, and are considered to be cellular residues 
and debris from RPE cell degeneration constituting chronic inflammation.6-8 The appearance 
of drusen varies greatly and several subtypes can be distinguished.9 Drusen can be classified 
based on their diameter: small (<63 µm), intermediate (63-124 µm), and large drusen (≥125 
µm). Additionally, drusen can be categorized by their appearance: small hard drusen have 
sharp edges and uniform colour density, whereas soft drusen are less sharp demarcated, 
often larger in size, and can be distinct (uniform colour density) or indistinct (graded colour 
density).9-12 Larger soft drusen are associated with higher risk of developing advanced AMD,13-
16 whereas small hard drusen are considered to be normal changes related to aging as they 
are very common and confer minimal risk of development of advanced AMD.10 
A specific subtype of small drusen, known as cuticular drusen, can be distinguished (Figure 1A). 
These are numerous (≥50) discrete, small, round drusen scattered throughout the macula, 
often extending to the peripheral retina. Cuticular drusen are best visible on fluorescein 
angiography and have a typical “stars in the sky” appearance.9,17 This subphenotype has been 
associated with an earlier age of onset and is frequently clustered in families, suggesting 
a stronger genetic component in the development of cuticular drusen.18,19 Additionally, all 
drusen can undergo calcification. Calcified drusen, also known as refractile drusen, have a 
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characteristic glistening or crystalline appearance on color fundus imaging (Figure 1B), and 
have been associated with the development of geographic atrophy.20,21
Next to drusen, reticular pseudodrusen can be observed in AMD patients. These reticular 
pseudodrusen differ both phenotypically and anatomically from drusen. Reticular 
pseudodrusen are subretinal deposits, in contrast to genuine drusen that are located 
beneath the RPE. Phenotypically, reticular pseudodrusen can be recognized as grey-white 
spots arranged in a reticular network (Figure 1C). Also, they are more commonly located at 
the superotemporal quadrant of the macula.22 Reticular pseudodrusen are associated with 
development of advanced AMD, especially geographic atrophy.22-24 
Figure 1. Examples of different types of drusen
A. Cuticular drusen on color fundus photograph (left) and fluorescein angiography (right). B. Crystalline drusen on 
color fundus photograph (left) and infrared imaging (right). C. Reticular pseudodrusen on color fundus photograph 
(left) and infrared imaging (right).
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Other frequently observed features of early and intermediate AMD are hypo- and 
hyperpigmentations of the RPE.5 The presence of these pigmentary abnormalities together 
with intermediate drusen are associated with 4-fold increased risk of advanced AMD 
compared to intermediate drusen alone.14
Advanced AMD
In time, early and intermediate AMD can progress to advanced AMD. Two subtypes of 
advanced AMD can be distinguished: geographic atrophy and neovascular AMD. Geographic 
atrophy (GA) is characterized by the presence of a sharp demarcated hypopigmented area, 
corresponding with RPE cell atrophy and photoreceptor degeneration, in which choroidal 
vessels become increasingly visible.5 These atrophic areas enlarge gradually and cause slowly 
progressive vision loss.25 The distinctive characteristic of neovascular AMD is choroidal 
neovascularization (CNV), which is the formation of new fragile blood vessels originating from 
the choroid. These new vessels can cause fluid leakage and/or hemorrhage resulting in a 
serous RPE detachment accompanied by a rapid loss of vision, and eventually fibrovascular 
scarring occurs.26 
Table 1. Classification of AMD according to the CIRCL protocol based on color fundus photographs (CFP), spectral 
domain‐optical coherence tomography (SD‐OCT) and fluorescein angiography (FA)
Stage Description
No AMD No drusen and pigmentary changes
Small drusen (diameter <63 µm) or pigmentary changes only
Less than 10 small drusen and pigmentary changes
Early AMD 10 or more small drusen and pigmentary changes
1-14 intermediate drusen (diameter 63-124 µm)
Intermediate AMD 15 or more intermediate drusen
1 or more large drusen (diameter ≥125 µm)
RPE atrophy (diameter ≥175 µm) outside the central circle of the Early 
Treatment Diabetic Retinopathy Study (ETDRS) grid
Advanced AMD Any or all of the following: central geographic atrophy, or evidence of 
neovascular AMD
Geographic atrophy Sharply demarcated round or oval area of depigmentation of the RPE (diameter 
≥175 µm) with increased visibility of choroidal vessels within the central circle of 
the ETDRS grid secondary to AMD
Neovascular AMD Choroidal neovascular lesion within the ETDRS grid secondary to AMD with 
evidence of fluid, blood, or fibrovascular tissue on FP, signs of active or previous 
CNV on FA, and/or retinal or subretinal fluid and/or tissue secondary to AMD on 
SD-OCT
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AMD Classification
The various severity stages and large diversity of phenotypes in AMD ask for standardization. 
In clinical practice standardization is necessary for establishing an accurate diagnosis, and 
determining prognosis and management strategy. In research, standardization is essential for 
comparison of study results. A detailed grading system for AMD has already been published 
in 1991: “The Wisconsin Age-Related Maculopathy Grading System”.12 A few years later, the 
International Age-Related Maculopathy Epidemiological Study Group proposed a classification 
protocol and grading system for AMD.27 This classification system distinguishes ‘early’ and ‘late’ 
AMD. Early AMD is characterized by presence of drusen and RPE pigmentary abnormalities, 
and late AMD is characterized by the presence of GA of the RPE or neovascular AMD defined 
as RPE detachment, hemorrhages, and/or scars. Multiple classification protocols have been 
developed and adapted for epidemiological studies and clinical trials since then.10,11,15,28-31 
These classification systems are based on (detailed) evaluation of color fundus photographs, 
and include number and size of drusen, presence of pigmentary abnormalities and signs of 
GA or CNV. Grading of AMD in this thesis is based on the standard grading protocol of the 
Cologne Image and Reading Center and Laboratory (CIRCL; https://augenklinik.uk-koeln.de/
forschung/arbeitsgruppen-labore/circl/), and also includes evaluation of spectral domain-
optical coherence tomography and fluorescein angiography. A detailed description of the 
different AMD stages and corresponding examples of color fundus images are displayed in 
Table 1 and Figure 2, respectively. 
Figure 2. Visualization of disease progression and examples of different AMD stages according to the CIRCL 
protocol
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RISK FACTORS FOR DEVELOPMENT AND PROGRESSION OF AMD
Nongenetic risk factors
AMD is a multifactorial disease, which means that a combination of multiple environmental 
and genetic factors act together and trigger the development of AMD. Around one third of 
AMD risk is explained by nongenetic risk factors.32 As the name already suggests, age is the 
most important risk factor for AMD development. Population-based studies demonstrated 
that the prevalence of AMD increases significantly with age.3,33 A recent meta-analysis, 
combining data of 14 population-based studies in Europe, showed an increase in prevalence 
of early and intermediate AMD from 3.5% in people aged 55 to 59 years up to 17.6% in 
people 85 years and older. For advanced AMD, these prevalences increase from 0.1% to 9.8%, 
respectively.3
Smoking has also been consistently associated with development of AMD. Current smokers 
have a two- to three-fold increased risk of AMD.34-36 Although past smokers still have a higher 
risk compared to never smokers, cessation decreases the risk of AMD development even in 
elderly.35,36 Smoking cessation should therefore be encouraged by ophthalmologists to modify 
a patient’s risk of AMD. Other commonly reported nongenetic risk factors include low dietary 
intake of antioxidants and omega-3 fatty acids, obesity and reduced physical activity.34,37
Approximately 1 in 7 people will develop any kind of non-advanced AMD over the age of 
70,3 however not all of them progress to an advanced disease stage. Rates of progression 
to advanced AMD vary greatly in literature due to differences in follow-up time and study 
design.38-40 However, this conversion to advanced AMD is clinically very relevant as this is 
accompanied by vision loss and can have consequences for the management and monitoring 
of AMD patients. Nongenetic risk factors associated with progression to advanced AMD 
include age, smoking, and BMI.41,42 Additionally, phenotype is also considered a major 
predictor for progression to advanced AMD, with the more severe phenotype conferring the 
highest risk for progression.38,39,41,42
Family history
Family and twin studies have played an important role in understanding the genetic 
contribution of AMD. Already in the ‘90s it was reported that AMD aggregates in families, 
and also high concordance in twin studies led to the conclusion that there must be a familial 
component in AMD.43-48 This familial component could either be explained by shared genetic 
susceptibility, common exposure to environmental risk factors or a combination of both. 
First-degree relatives of an AMD patient have an increased risk of AMD development (odds 
ratio [OR] range, 2.4 to 19.3).43-45,49-52 Additionally, it has been suggested that siblings are 
more likely to develop the same advanced phenotype as their proband,53 although most 
studies report large phenotypic heterogeneity within families.54-56 
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Although at present a large proportion of the heritability of AMD has been explained, not all 
AMD families can be fully explained by known risk factors and family history seems to remain 
a (substitute) risk factor for development of AMD.57,58 
Genetic risk factors
The heritability of AMD is estimated to be 46-71%,32 and significant progress has been made 
in the identification of genetic variants associated with AMD risk. Since the identification 
of a risk-conferring common variant in the complement factor H (CFH) gene in 1995,59-61 
genome-wide association studies have identified many (mainly common) genetic variants 
that are associated with AMD. The largest genome-wide association study to date included 
16,144 advanced AMD cases and 17,832 control individuals, and reported 52 genetic variants 
distributed across 34 loci to be independently associated with AMD.62 Until now, both common 
variants with small to modest effect sizes and several low- to rare frequency variants have been 
identified to contribute to disease susceptibility (Figure 3). Together these variants explain 
more than half of the heritability.62 The remaining unexplained heritability may be (partly) 
attributed to additional rare genetic variants.63-65 Next-generation sequencing technology has 
provided an opportunity to discover these variants using whole-exome or whole-genome 
Figure 3. Genetic architecture of age‐related macular degeneration
Light blue triangles indicate rare variants, blue squares indicate low-frequency variants, and dark blue circles 
indicate common variants with population frequencies of <1%, 1-5%, ≥5% respectively. The area above dashed 
lines indicate the area with the highest feasibility of identifying genetic variants because of their high effect size. 
Common genetic variants with stronger effects can be detected in relatively small case-control studies, however to 
identify variants with modest to small effect sizes larger cohorts and high-resolution genotyping are needed (area 
between the dashed lines). To identify rare variants specific sequencing strategies using next-generation sequencing 
are necessary. Genetic variants associated with AMD depicted in this figure are derived from Fritsche et al.62
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sequencing methods. Sequencing of AMD families seems to be an ideal approach to further 
identify rare, more penetrant variants, as these families cannot completely be explained 
by clustering of known environmental and genetic risk factors. In recent years, already a 
number of rare genetic variants have been identified in AMD families.66-73 Rare variants with 
smaller risk effects will be hard to identify, and larger consortium-based studies are needed 
to identify these.
PATHWAYS INVOLVED IN AMD PATHOGENESIS
The complement system
The complement system is part of our innate immune system. It protects the host from 
invading pathogens by inducing inflammatory responses, opsonization of pathogens and 
lysis of foreign cells, but also contributes to host homeostasis by clearance of apoptotic cells 
and cellular debris.74 Activation of the complement cascade can be initiated through three 
distinct pathways (the classical, lectin, or alternative pathway), which eventually all merge 
into one terminal cytolytic pathway.74 In the eye there is a continuous low-level activation of 
the alternative pathway.75 This complement activity is initiated by spontaneous conversion of 
complement component 3, and leads to a cascade of conversions of inactive proteins to their 
active forms. Consequently, convertases (C3- and C5-convertase) and anaphylatoxins (C3a 
and C5a) are produced, and this cascade finally results in the formation of the membrane 
attack complex (Figure 4).74,76 To avoid tissue damage, complement activation is closely 
regulated by several complement inhibitory proteins. Factor H is an important inhibitor 
circulating in plasma and acts through several mechanisms: by acting as cofactor for factor I 
mediated proteolysis of C3b, accelerating decay of C3-convertase, and competing with factor 
B in binding to C3b and thereby preventing formation of C3-convertase.74,76
There is cumulative evidence that dysregulation of the alternative pathway of the 
complement system plays a pivotal role in AMD pathogenesis. First, histopathological studies 
demonstrated the presence of several complement proteins, complement activators, and 
complement regulatory proteins in drusen.6,7,77 Subsequently, genetic studies showed strong 
associations between AMD and complement genes, in particular the CFH gene.59-62 Moreover, 
the variants in complement-associated genes together account for nearly 60% of the AMD 
genetic risk.78 Finally, increased systemic levels of complement activation products have been 
consistently reported,79-82 suggesting that complement activation in AMD is not restricted to 
the eye. 
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Oxidative stress
Multiple sources of oxidative stress make the macula susceptible to oxidative damage. 
Reactive oxygen species (responsible for oxidative stress) are abundant in macular tissue due 
to its high metabolic activity, continuous photoreceptor shedding, and exposure to bright 
light.83,84 Increased oxidative stress is considered to contribute to AMD pathogenesis. Support 
for this theory mainly comes from epidemiological studies linking several environmental risk 
factors for AMD to oxidative stress. Smoking, one of the most important environmental risk 
factors, enhances production of reactive oxygen species thereby adding to oxidative stress.83,85 
Figure 4. Overview of the alternative pathway of the complement system
(1) Complement component 3 (C3) splits into C3a and C3b by spontaneous hydrolyzation or by the C3-convertase 
(C4bC2) resulting from activation of the classical or lectin pathway. (2) Factor B (FB) can bind C3b to form C3bB. (3) 
The bound factor B is then cleaved by factor D (FD) which results in the formation of the C3-convertase: C3bBb (4). 
This C3-convertase can cleave C3, which leads to more C3b and in turn increased formation of the C3-convertase 
(known as the C3 amplification loop). The C3-convertase can also bind another C3b molecule to form C3bBb3b, 
which is a C5-convertase (5). This C5-convertase can convert C5 into C5a and C5b. (6) C5b then sequentially binds 
C6, C7, C8, and multiple C9 molecules to form the terminal complement complex (SC5b-9), also known as the 
membrane attack complex. 
* The C3-convertase is inhibited by several complement regulators, among which decay accelerating factor (DAF) 
and factor H (FH).
** Factor I (FI) can breakdown C3b via several digestion steps to C3c and finally C3d. This protease activity, however, 
requires a cofactor, such as FH.
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Also, high dietary intake of antioxidants is associated with a reduced AMD risk,37,86 implicating 
imbalance of the oxidative stress system in AMD. Moreover, increased levels of oxidation 
products and decreased levels of antioxidants have been reported in AMD patients.87,88 
Genetic studies have suggested a role for oxidative stress in AMD as well. Mitochondria are 
an important source of reactive oxygen species formation and are highly susceptible for 
oxidative damage.84 A number of studies have associated variations in mitochondrial DNA 
with AMD and are suggestive of a pathogenic role of oxidative stress in AMD.89-91 Studies 
investigating variations in genes encoding antioxidant proteins have been inconclusive.92-95
Other pathways
Several other pathways have been implicated in AMD pathogenesis. These include lipid 
metabolism, extracellular matrix remodeling, and the angiogenesis signaling pathway. 
Lipids are abundantly present in drusen and altered systemic lipid measurements have 
been reported in AMD patients.96,97 Especially elevated high-density lipoprotein levels 
seem to be related with increased AMD risk.97-99 Involvement of lipid metabolism in AMD is 
further strengthened by genetic associations of lipid-related genes (e.g. APOE, CETP, LIPC, 
ABCA1).62,78 Genetic studies also points towards a role for the extracellular matrix pathway 
in AMD.62,78 An important extracellular matrix structure in the retina is Bruch’s membrane, 
located between the RPE and the choroid. Many histopathological studies have pinpointed 
alterations at Bruch’s membrane as the first changes in AMD.100
Another important pathway in AMD pathogenesis is the angiogenesis signaling pathway. 
Genetic associations have been reported for several genes encoding angiogenic growth 
factors involved in the initiation of neovascularization (e.g. VEGFA and TGFBR1).62 
TREATMENT 
Prevention
Lifestyle interventions can positively influence the natural course of AMD and slow down 
progression to an advanced disease stage. Smoking cessation is highly recommended and 
has been proven beneficial in reducing risk, even in elderly.35 Ensuring a healthy body weight, 
regular physical activity, and a diet rich in antioxidants (fruit and vegetables) may also confer 
protection against AMD progression.86,101-103 Additionally, nutritional supplementation can 
be beneficial for a subgroup of patients. The Age-related Eye Disease Study (AREDS) and its 
successor, the AREDS2, are the largest investigations into vitamin supplementation in AMD. 
In the AREDS, daily supplementation with vitamin C, vitamin E, β-carotene and zinc oxide 
reduced the risk for development of advanced AMD in 5 years with approximately 25% in 
patients with a high risk for progression.104 The AREDS2 was initiated to evaluate the effects 
of lutein, zeaxanthin and omega-3 fatty acids supplementation. Although no further risk 
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reduction was established when adding these nutrients to the original AREDS formulation, 
β-carotene was replaced by lutein and zeaxanthin because of the increased risk of lung 
cancer in smokers receiving β-carotene.105 The improved AREDS2 formula, containing 500 mg 
vitamin C, 400 IU vitamin E, 10 mg lutein, 2 mg zeaxanthin, 80 mg zinc oxide, and 2 mg copper 
is recommended for patients with intermediate or unilateral advanced AMD. 
Neovascular AMD
Although neovascular AMD affects the minority of AMD patients, it accounts for the majority 
of visually impaired AMD patients.106 Since the introduction of intravitreal injections with 
anti-vascular endothelial growth factor (VEGF) agents in 2006, the number of AMD patients 
with severe visual impairment has decreased significantly.107 Unfortunately, anti-VEGF 
treatment does not lead to improvement or stabilization of vision in every patient, and results 
in a declined visual acuity after one year in approximately 10% of the patients.108 Currently 
available anti-VEGF drugs include bevacizumab, ranibizumab, and aflibercept. Efficacy and 
safety of these drugs are comparable, however, aflibercept has the advantage that it can 
be injected every two months instead of monthly.108,109 Although bevacizumab use is not 
officially approved for treatment of neovascular AMD, it is often used off-label as first choice 
treatment by ophthalmologists due to its favorable cost-effective profile. 
Dry AMD
No treatment is yet available for the early, intermediate and advanced atrophic stages of 
AMD, together also referred to as ‘dry AMD’. Various clinical trials targeting different pathways 
are ongoing (Table 3). Promising results have been reported for complement inhibiting drugs, 
particularly for lampalizumab. Intravitreal administration of lampalizumab was associated 
with 20% reduction in atrophy growth in the MAHALO phase II clinical trial.110 The efficacy of 
lampalizumab was further evaluated in two large multicenter phase III trials. However, both 
the SPECTRI study (NCT02247531) and the CHROMA study (NCT02247479) did not meet 
their primary endpoint in reducing atrophy growth.111
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AIMS AND OUTLINE OF THIS THESIS 
The aim of this thesis is to increase our understanding of the clinical and molecular 
characteristics of AMD development and progression. Specifically, differences between 
AMD families and nonfamilial (sporadic) AMD were studied, and a prediction algorithm 
for conversion from early to advanced AMD was established to facilitate risk assessment 
and genetic counseling. Additionally, insights from molecular studies also facilitate genetic 
counseling and can contribute to identification of molecular drivers or biological pathways 
relevant for AMD. In this thesis, chapter 2 focuses on clinical studies, and chapter 3 on 
molecular studies. 
Clinical studies
Familial aggregation of AMD has been described and might imply a stronger genetic 
component and smaller contribution of environmental factors in familial AMD. Chapter 2.1 
evaluates potential differences between familial and sporadic AMD patients with respect to 
environmental risk factors for AMD. Additionally, phenotypical characteristics of familial and 
sporadic AMD are discussed. In clinical practice, particularly members of AMD families are 
interested in their risk of AMD. However, most prediction models have been established for 
AMD based on demographic, environmental and common genetic risk factors. Even though 
these factors can cluster in families, it is expected that densely affected families cannot 
be fully explained by known risk factors and may harbor rare genetic variants. Chapter 2.2 
assesses the proportion of AMD families that cannot be explained by common genetic and 
environmental risk factors and discusses risk prediction in AMD families. 
Additionally, identification of predictive factors for progression to advanced AMD may 
contribute to a more efficient and personalized approach in monitoring and support of 
patients already diagnosed with early or intermediate AMD. Chapter 2.3 presents a prediction 
model for conversion to advanced AMD including genetic, environmental, demographic risk 
factors and detailed phenotypic characteristics. 
Although no treatment exists yet for dry AMD, therapies are in development. It is important 
to select those patients that will most likely benefit from these therapies. Patients carrying a 
rare variant in complement-associated genes seem an ideal patient group for complement-
inhibiting therapies. Chapter 2.4 describes phenotypical characteristics of AMD patients 
carrying a rare variant in the CFH gene, which could help ophthalmologists to select patients 
for additional genetic testing and upcoming complement-inhibiting therapies. 
Molecular studies
Molecular biomarkers can help unravel mechanisms of disease and identify new targets for 
therapy. Chapter 3.1 provides an overview of systemic compounds investigated in relation 
General Introduction
25
1
to AMD and discusses their usefulness as AMD biomarker. The use of hypothesis-free 
techniques in biomarker detection holds great promise. Chapter 3.2 evaluates the metabolic 
profile of AMD patients using a targeted metabolomics approach, aiming to contribute to the 
identification of biomarkers and metabolic pathways for AMD.
With the rise of next-generation sequencing techniques, significant progress has been 
made in the discovery of low-frequency and rare genetic variants contributing to AMD risk. 
Using genetic data of approximately 40.000 individuals, the International AMD Genomics 
Consortium identified seven independent rare variants to be associated with AMD. Chapter 
3.3 describes the geographic distribution of these rare variants, as population-specific variants 
have implications for genetic counseling, carrier screening and personalized treatment. 
Finally, Chapter 3.4 evaluates the occurrence of genetic variants in genes underlying AMD-
mimicking dystrophies in a dry AMD cohort. The clinical utility of genetic screening for macular 
dystrophies in AMD patients is discussed, since it can be clinically difficult to distinguish dry 
AMD from AMD-mimicking dystrophies. 
General discussion and summary
Chapter 4 further discusses the studies described in this thesis and places them in a broader, 
future, perspective. Finally, chapter 5 provides a summary of the findings described in this 
thesis. 
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ABSTRACT
Purpose: We describe the differences and similarities in clinical characteristics and phenotype 
of familial and sporadic patients with age-related macular degeneration (AMD).
Methods: We evaluated data of 1828 AMD patients and 1715 controls enrolled in the 
European Genetic Database. All subjects underwent ophthalmologic examination, including 
visual acuity testing and fundus photography. Images were graded and fundus photographs 
were used for automatic drusen quantification by a machine learning algorithm. Data on 
disease characteristics, family history, medical history, and lifestyle habits were obtained by 
a questionnaire. 
Results: The age at first symptoms was significantly lower in AMD patients with a positive 
family history (68.5 years) than in those with no family history (71.6 years; P = 1.9x10-5). 
Risk factors identified in sporadic and familial subjects were increasing age (odds ratio [OR], 
1.08 per year; P = 3.0x10-51 and OR, 1.15; P = 5.3x10-36, respectively) and smoking (OR, 1.01 
per pack year; P = 1.1x10-6 and OR, 1.02; P = 0.005). Physical activity and daily red meat 
consumption were significantly associated with AMD in sporadic subjects only (OR, 0.49; 
P = 3.7x10-10 and OR 1.81; P = 0.001). With regard to the phenotype, geographic atrophy 
and cuticular drusen were significantly more prevalent in familial AMD (17.5% and 21.7%, 
respectively) compared to sporadic AMD (9.8% and 12.1%).
Conclusion: Familial AMD patients become symptomatic at a younger age. The higher 
prevalence of geographic atrophy and cuticular drusen in the familial AMD cases may be 
explained by the contribution of additional genetic factors segregating within families.
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INTRODUCTION
Age-related macular degeneration (AMD) is a multifactorial retinal disease leading to severe 
vision loss among the elderly. Advanced age, female sex, smoking, and obesity (body mass 
index [BMI] >30) are most commonly reported as important demographic and environmental 
risk factors for the development of AMD.1-6 In addition, several important genetic variants 
have been found to be associated with AMD, either as a risk factor or as a protective factor. 
The strongest associations have been reported for the single-nucleotide polymorphisms 
(SNPs) in the complement factor H gene (CFH Y402H; rs1061170) and in the age-related 
maculopathy susceptibility 2 gene (ARMS2 A69S; rs10490924), which strongly increase the 
risk of developing AMD.7-11
Previous studies have demonstrated aggregation of AMD in families.12,13 A family history of 
AMD has been reported as a significant risk factor for AMD.14 Individuals are at a higher risk of 
developing AMD when a first-degree relative is affected. Moreover, having an affected parent 
is associated with a higher risk than having an affected sibling.13,14 Shahid et al. showed an 
odds ratio (OR) for AMD of 27.8 in people with an affected parent and an OR of 12.0 for people 
with an affected sibling. Likewise, Luo et al. reported a relative risk for the development of 
AMD of 5.66 for people with an affected parent, and a relative risk of 2.95 for people with an 
affected sibling. 
A lower age at onset has been reported in familial AMD patients and heritability of AMD 
subtypes has been suggested.14,15 Even though environmental and genetic risk factors can 
cluster in families, the number of affected family members in large densely affected families 
cannot be fully explained by clustering of known risk factors.12 Several recent studies have 
shown that rare, highly penetrant genetic variants can strongly increase the risk of developing 
AMD in families with AMD, as well as in the AMD population in general.16-20 
Little is known about clinical differences and similarities between patients with and without a 
family history for AMD. The purpose of this study is to gain more insight into the clinical and 
phenotypic characteristics of familial and sporadic AMD patients, and to analyze if there are 
distinct clinical differences between these subgroups.
PATIENTS AND METHODS
Study Population 
The European Genetic Database (EUGENDA, available in the public domain at www.eugenda.
org) is a multicenter database for clinical and molecular analysis of AMD founded by the 
Radboud university medical center (Nijmegen, the Netherlands) and the Department of 
Ophthalmology of the University Hospital of Cologne (Cologne, Germany). This database 
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contains data of AMD patients and control individuals, including family history, environmental 
risk factors and ophthalmologic examination. For this retrospective study we evaluated data 
of 1828 Caucasian patients with AMD and 1715 Caucasian controls enrolled in EUGENDA of 
whom family history of AMD, smoking status, BMI, age, and sex data were available. 
This study was performed in accordance with the tenets of the Declaration of Helsinki and 
was approved by the local ethical committees at the Radboud university medical center 
and the University of Cologne. Written informed consent was obtained from all participants 
before enrolling in EUGENDA.
Questionnaire, Clinical Evaluation and Grading
Before enrollment in the EUGENDA database, all subjects were interviewed with a detailed 
questionnaire about disease characteristics (e.g., age at first symptoms), family history, 
medical history and lifestyle habits, such as smoking status, diet and physical activity. For 
each subject, BMI was calculated using body height and body weight as reported in the 
questionnaire. Based on years of smoking and number of cigarettes smoked per day we 
calculated the number of pack years. Each subject underwent an ophthalmologic examination, 
including Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing, dilated 
fundus examination and color fundus photography. The best corrected visual acuity (BCVA) 
was converted to Logarithm of the Minimal Angle of Resolution (logMAR) visual acuity for the 
purpose of statistical analysis. Two independent certified reading center graders evaluated 
color fundus photographs of both eyes of all subjects according to the standard protocol 
of the Cologne Image Reading Center and Laboratory (CIRCL).21 Digital nonstereoscopic 30° 
color fundus photographs centered on the fovea were performed with a Topcon TRC 50IX 
camera (Topcon Corporation, Tokyo, Japan). The diagnosis and grading of AMD was based on 
a classification and grading scheme as described previously.22 For all analyses in this study we 
used the grading of the worst affected eye, and subjects with only one gradable color fundus 
photograph were excluded. Additionally, in 1184 AMD subjects spectral-domain optical 
coherence tomography (SD-OCT, Spectralis; Heidelberg Engineering, Heidelberg, Germany) 
was available and evaluated for the presence of reticular pseudodrusen. In 677 subjects 
the presence of cuticular drusen was evaluated based on available fluorescein angiography, 
performed using the Spectralis HRA system (Heidelberg Engineering, Heidelberg, Germany).23 
The SD-OCT volume scans consisting of 19 or 37 parallel OCT B-scans were used for analysis, 
covering 6x4mm of the macula. For each OCT B-scan, 20 images were averaged using the 
automated real-time function.21 Evaluation of the presence of reticular pseudodrusen on SD-
OCT and cuticular drusen on fluorescein angiography was done by one senior grader.
Based on diagnosis and family history, the participants in this study were divided into four 
groups: sporadic AMD, sporadic control, familial AMD and familial control. We classified 
subjects as familial in case of confirmed or possible AMD in at least one close relative, defined 
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as a parent, sibling, or child. Sporadic subjects were defined as individuals who did not have 
a close relative with AMD.
Automatic Drusen Quantification
In addition to the human grading of AMD based on photographs, a machine learning 
algorithm for computer-aided diagnosis of AMD, was used for detection and quantification of 
drusen number and area (measured in pixels). This was described previously as accurate in 
detecting and quantifying drusen number and area on color fundus photographs of patients 
with nonadvanced AMD and control subjects,24. Patients with advanced AMD in the worst 
affected eye have been excluded for this specific analysis, because the automatic system 
was not designed to deal with images containing signs of advanced stage AMD. A quality 
score ranging from 0 to 1 was calculated, with 0 being the worst quality and 1 being the best 
quality. Only color fundus photographs were selected with a quality score of 0.3 or more, 
which corresponds to sufficient quality for human grading. 
Statistical Analysis
All statistical analyses were performed using IBM SPSS Statistics software, version 20.0 
(Released 2011; IBM Corp., Armonk, NY, USA). Each potential risk factor for the development 
of AMD obtained from the questionnaire was included separately in a logistic regression 
analysis adjusted for age, sex, smoking, and BMI. The ORs were calculated for familial subjects 
(familial AMD versus familial controls) and sporadic subjects (sporadic AMD versus sporadic 
controls). Significant differences between ORs for sporadic and familial subjects were 
identified by interaction analysis using binary logistic regressions. All continuous variables 
were analyzed using an independent sample t-test or one-way ANOVA. An univariate general 
linear model was used when continuous variables were analyzed with correction for other 
variables. Categorical variables were analyzed using a χ2 test. Differences with a P value less 
than 0.05 were considered statistically significant. Because multiple possible risk factors were 
analyzed and many tests of significance were performed in our study, Bonferroni correction 
was performed for the risk and interaction analysis of environmental factors.
RESULTS
Demographic characteristics of the cohort are shown in Table 1. All four groups were 
comparable for sex, smoking, and BMI. The mean age of the familial subjects was slightly 
lower than in sporadic subjects (69.6 and 73.0 years, respectively; P = 4.7x10-16), mainly due 
to younger familial control individuals. In 309 subjects who reported in the questionnaire 
to have a close relative with (possible) AMD, the ophthalmologically examined AMD status 
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of close relatives was available. To determine the degree of misclassification of subjects 
into familial or sporadic based on the questionnaire, we compared the family history with 
these examined data. In 3 of 309 cases where subjects reported in the questionnaire to 
have at least one close relative with AMD, no family members seemed to be affected upon 
ophthalmological examination. Therefore, these cases were incorrectly classified as familial. 
No ophthalmological information was available for relatives of sporadic subjects included in 
this study.
Familial and Sporadic AMD: Clinical Differences and Similarities
Information about the age at first symptoms was available in 703 AMD patients (469 sporadic 
subjects, 234 familial subjects, Table 2). The age at first symptoms was significantly lower (P 
= 1.9x10-5) in familial AMD patients (mean, 68.5 years; SD, 9.8) than in sporadic AMD patients 
(mean, 71.6 years; SD, 8.7) with a mean difference of 3.1 years (95% confidence interval [CI], 
1.7-4.5). When subdividing AMD in the presence or absence of the reticular pseudodrusen 
subtype, the age at first symptoms was also lower in familial AMD patients. In addition, AMD 
patients with reticular pseudodrusen have a significantly higher age at first symptoms than 
patients without reticular pseudodrusen, in both sporadic and familial patients (P = 4.4x10 -10 
Table 1. Demographic Characteristics 
 Sporadic Familial
 AMD Control Total AMD Control Total
Cases, n 1330 1405 2735 498 310 808
Sex, n(%)
Male 536 (40.3) 587 (41.8) 1123 (41.1) 181 (36.3) 132 (42.6) 313 (38.7)
Female 794 (59.7) 818 (58.2) 1612 (58.9) 317 (63.7) 178 (57.4) 495 (61.3)
Age, mean±SD* 75.6±9.1 70.5±7.3 73.0±8.6 74.0±8.4 62.6±10.2 69.6±10.7
Smoking, mean±SD† 14.6±20.1 11.6±16.6 13.1±18.4 14.5±17.9 12.2±15.9 13.6±17.2
BMI, n(%)
<25 600 (45.1) 638 (45.4) 1238 (45.2) 233 (46.8) 139 (44.8) 372 (46.0)
25-30 558 (42.0) 599 (42.6) 1157 (42.3) 208 (41.8) 124 (40.0) 332 (41.1)
>30 172 (12.9) 168 (12.0) 340 (12.4) 57 (11.4) 47 (15.2) 104 (12.9)
Examined family history, n (%) 
Familial
Sporadic
165(100)
164(99.4)
1(0.6)
144(100)
142(98.6)
2(1.4)
309 (100)
306 (99.0)
3 (1.0)
The study included 498 familial AMD patients deriving from 393 families (393 probands and 105 family members) 
and 310 controls deriving from 216 families (216 probands and 94 family members). In 309 familial cases information 
about ophthalmologic examination in their close relatives (parents, sibling, and/or children) was available and was 
compared to family history based on the questionnaire to determine the degree of misclassification. Familial, 
positive family history for AMD (confirmed or possible AMD in at least one close relative [parent, sibling or child]); 
sporadic, no positive family history.
* Age of participation in years
† Smoking in pack years
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and P = 0.002, respectively). In contrast, in AMD patients with the cuticular drusen subtype, 
the age at first symptoms was lower than in patients without cuticular drusen, in sporadic 
and familial patients (P = 1.26x10-6 and P = 0.074, respectively). However, no significant 
difference in age at first symptoms was observed between familial and sporadic patients with 
the cuticular drusen subtype (P = 0.740). 
Despite a younger age at first symptoms, BCVA of both eyes did not differ significantly between 
familial and sporadic AMD patients when subdivided in three age categories (data shown in 
Table 2). Also, if young patients (<60 years) were analyzed separately, no difference in BCVA 
was observed between familial and sporadic patients (data not shown). After distinguishing 
between advanced and nonadvanced AMD subjects, BCVA also was comparable between 
sporadic and familial patients.
To identify risk factors in our cohort, we analyzed several demographic and environmental 
factors (Table 3). Risk factors identified in sporadic and familial AMD patients were increasing 
Table 2. Clinical Features and Staging of Sporadic and Familial AMD patients
Sporadic AMD
mean±SD
Familial AMD
mean±SD P
Age at first symptoms, y
AMD, total* 71.6±8.7 68.5±9.8 1.9x10-5
AMD, reticular pseudodrusen† 76.2±7.2 72.5±7.3 0.008
AMD, cuticular drusen‡ 65.8±9.2 64.5±17.7 0.740
Visual acuity per age category§
<70 0.12±0.27 0.09±0.25 0.293
70-80 0.19±0.29 0.26±0.36 0.107
>80 0.40±0.40 0.38±0.46 0.814
Visual acuity per stage§
Nonadvanced 0.05±0.14 0.03±0.13 0.367
Advanced 0.33±0.37 0.37±0.42 0.314
Grading, n(%)
Early
Intermediate
Advanced
GA
CNV
Mixed
301 (22.6)
250 (18.8)
779 (58.6)
76 (9.8)
660 (84.7)
43 (5.5)
94 (18.9)
90 (18.1)
314 (63.1)
55 (17.5)
234 (74.5)
25 (8.0)
0.158
3.0x10-4
* Data on age of first symptoms were available in 469 sporadic and 234 familial AMD patients
† Data on age of first symptoms were available in 75 sporadic and 45 familial AMD patients with reticular 
pseudodrusen
‡ Data on age of first symptoms were available in 32 sporadic and 19 familial AMD patients with cuticular drusen
§ Visual acuity defined as best-corrected logMAR visual acuity
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age (P = 3.0x10-51 and P = 5.3x10-36) and smoking (P = 1.1x10-6 and P = 0.005). Interaction 
analysis showed a significant difference between sporadic and familial subjects for increasing 
age (P = 9.4x10-7). 
In terms of comorbidity (Table 3), allergy was significantly associated with a decreased risk 
of AMD for sporadic and familial subjects (P = 0.002 and P = 0.024, respectively). Diabetes 
mellitus was a risk factor for the development of AMD in sporadic patients (OR, 1.34; 95% CI, 
1.02-1.75; P = 0.035), but not in familial cases (P = 0.704). No significant interaction between 
family history and allergy or diabetes was present. Cardiovascular disease, renal disease, and 
auto-immune disease were no significant risk factors for AMD in our cohort. 
With regard to dietary factors, we observed that eating red meat a few times per week or 
daily is a significant risk factor in sporadic AMD patients (OR, 1.24; 95% CI, 1.05-1.48; P = 
0.013 and OR, 1.81; 95% CI, 1.30-2.54; P = 0.001, respectively), but not in familial subjects. 
A protective factor for AMD in sporadic patients was eating fruit a few times per week (OR, 
0.60; 95% CI, 0.40-0.90; P = 0.013). Intake of fruit every day did not seem to further decrease 
the risk of AMD (OR, 0.74; 95% CI, 0.52-1.04; P = 0.085). However, consumption of fruit was 
not significantly associated with a decreased risk of AMD in familial subjects. 
Regular physical activity, one or two times a week, was significantly associated with a 
decreased risk for AMD in the sporadic AMD subgroup (OR, 0.67; 95% CI, 0.56-0.81; P = 
2.6x10-6) and the familial AMD subgroup (OR, 0.62; 95% CI, 0.42-0.94; P = 0.022). 
After Bonferroni correction of the demographic and environmental risk factors for AMD, the 
association of increasing age with AMD in familial and sporadic subjects remained significant, 
as well as the association of female sex, smoking, allergy, daily red meat consumption and 
physical activity in sporadic patients only.
Familial and Sporadic AMD: Phenotypic Differences and Dimilarities
The prevalence of early, intermediate, and advanced stage AMD was similar in the familial and 
sporadic AMD patient group (Table 2). After differentiation of advanced AMD into geographic 
atrophy (GA), choroidal neovascularization (CNV) and mixed (GA and CNV in one patient), we 
found that GA was more prevalent in familial AMD patients (17.5%) than in sporadic AMD 
patients (9.8%; P = 3.0x10-4), despite a comparable SNP load of CFH Y402H and ARMS2 A69S 
between familial and sporadic patients with GA (data not shown). In 829 sporadic subjects 
and 355 familial subjects data on reticular pseudodrusen were available, and data on cuticular 
drusen were available in 520 sporadic subjects and 157 familial subjects. The prevalence 
of reticular pseudodrusen was comparable between familial (18.0%) and sporadic subjects 
(18.8%; P = 0.749), whereas the prevalence of cuticular drusen was significantly higher in 
familial AMD (21.7%) compared to sporadic AMD (12.1%; P = 0.003). 
Clinical studies
45
2
Ta
bl
e 
3.
 R
is
k 
an
d 
In
te
ra
cti
on
 A
na
ly
si
s 
fo
r 
D
em
og
ra
ph
ic
 a
nd
 E
nv
ir
on
m
en
ta
l F
ac
to
rs
 in
 S
po
ra
di
c 
an
d 
Fa
m
ili
al
 S
ub
je
ct
s
Sp
or
ad
ic
, n
(%
)
Sp
or
ad
ic
 A
M
D
 v
s.
 c
on
tr
ol
Fa
m
ili
al
, n
(%
)
Fa
m
ili
al
 A
M
D
 v
s.
 c
on
tr
ol
Fa
m
ili
al
 A
M
D
 v
s.
 
sp
or
ad
ic
 A
M
D
A
M
D
Co
nt
ro
l
O
R 
(9
5%
 C
I)*
P
A
M
D
Co
nt
ro
l
O
R 
(9
5%
 C
I)*
P
P
Ag
e 
†
13
30
 (1
00
)
14
05
 (1
00
)
1.
08
 (1
.0
7-
1.
09
)
3.
0x
10
-5
1 #
49
8 
(1
00
)
31
0 
(1
00
)
1.
15
 (1
.1
3-
1.
18
)
5.
3x
10
-3
6 #
9.
4x
10
-7
#
Se
x
M
al
e
53
6 
(4
0.
3)
58
7 
(4
1.
8)
re
fe
re
nc
e
18
1 
(3
6.
3)
13
2 
(4
2.
6)
re
fe
re
nc
e
Fe
m
al
e
79
4 
(5
9.
7)
81
8 
(5
8.
2)
1.
27
 (1
.0
7-
1.
51
)
0.
00
7
31
7 
(6
3.
7)
17
8 
(5
7.
4)
1.
33
 (0
.9
3-
1.
91
)
0.
12
0
0.
81
1
Sm
ok
in
g 
‡
13
30
 (1
00
)
14
05
 (1
00
)
1.
01
 (1
.0
1-
1.
02
)
1.
1x
10
-6
#
49
8 
(1
00
)
31
0 
(1
00
)
1.
02
 (1
.0
1-
1.
03
)
0.
00
5
0.
91
4
B
M
I
<2
5
60
0 
(4
5.
1)
63
8 
(4
5.
4)
re
fe
re
nc
e
23
3 
(4
6.
8)
13
9 
(4
4.
8)
re
fe
re
nc
e
25
-3
0
55
8 
(4
2.
0)
59
9 
(4
2.
6)
1.
04
 (0
.8
8-
1.
24
)
0.
63
5
20
8 
(4
1.
8)
12
4 
(4
0.
0)
0.
80
 (0
.5
6-
1.
16
)
0.
24
4
0.
31
4
>3
0
17
2 
(1
2.
9)
16
8 
(1
2.
0)
1.
21
 (0
.9
4-
1.
56
)
0.
14
9
57
 (1
1.
4)
47
 (1
5.
2)
0.
70
 (0
.4
1-
1.
17
)
0.
17
2
0.
05
1
Co
m
or
bi
di
ty
Ca
rd
io
va
sc
ul
ar
 d
is
ea
se
§
51
9 
(4
3.
0)
54
5 
(4
2.
2)
0.
84
 (0
.7
1-
1.
00
)
0.
05
3
20
0 
(4
1.
7)
83
 (2
7.
9)
1.
31
 (0
.9
0-
1.
90
)
0.
16
3
0.
01
9
D
ia
be
te
s
15
7 
(1
1.
8)
11
3 
(8
.0
)
1.
34
 (1
.0
2-
1.
75
)
0.
03
5
41
 (8
.3
)
17
 (5
.5
)
0.
88
 (0
.4
6-
1.
70
)
0.
70
4
0.
36
5
Re
na
l d
ise
as
e 
72
 (5
.4
)
60
 (4
.3
)
1.
15
 (0
.7
9-
1.
66
)
0.
48
0
28
 (5
.7
)
11
 (3
.5
)
0.
98
 (0
.4
3-
2.
24
)
0.
95
9
0.
95
4
A
ut
oi
m
m
un
e 
di
se
as
e 
ІІ
10
1 
(7
.6
)
93
 (6
.6
)
1.
11
 (0
.8
1-
1.
51
)
0.
52
0
54
 (1
0.
9)
16
 (5
.2
)
1.
82
 (0
.9
1-
3.
64
)
0.
09
1
0.
15
0
A
lle
rg
y
23
9 
(1
8.
0)
37
1 
(2
6.
4)
0.
74
 (0
.6
1-
0.
89
)
0.
00
2#
88
 (1
7.
8)
92
 (2
9.
7)
0.
63
 (0
.4
3-
0.
94
)
0.
02
4
0.
29
4
D
ie
t
U
se
 o
f b
utt
er
/o
il
Bu
tt
er
/m
ar
ga
ri
ne
10
1 
(1
5.
8)
10
5 
(1
4.
3)
re
fe
re
nc
e
53
 (1
7.
6)
30
 (1
3.
5)
re
fe
re
nc
e
Lo
w
-f
at
 m
ar
ga
ri
ne
58
 (9
.1
)
45
 (6
.1
)
1.
40
 (0
.8
4-
2.
33
)
0.
19
5
49
 (1
6.
3)
50
 (2
2.
5)
0.
92
 (0
.4
4-
1.
95
)
0.
83
6
0.
22
5
Ve
ge
ta
bl
e 
oi
l
25
5 
(4
0.
0)
41
1 
(5
6.
1)
0.
77
 (0
.5
5-
1.
08
)
0.
12
7
78
 (2
5.
9)
84
 (3
7.
8)
0.
74
 (0
.3
8-
1.
44
)
0.
37
3
0.
79
5
O
th
er
22
6 
(3
5.
3)
17
2 
(2
3.
5)
1.
34
 (0
.9
4-
1.
93
)
0.
11
0
12
1 
(4
0.
2)
58
 (2
6.
1)
1.
35
 (0
.6
9-
2.
66
)
0.
38
4
0.
99
9
Fi
sh
 
O
nc
e 
a 
w
ee
k 
or
 le
ss
87
1 
(7
3.
9)
10
15
 (7
4.
2)
re
fe
re
nc
e
35
7 
(7
7.
4)
24
4 
(7
8.
7)
re
fe
re
nc
e
Fe
w
 ti
m
es
 a
 w
ee
k
30
0 
(2
5.
4)
34
6 
(2
5.
3)
0.
99
 (0
.8
2-
1.
20
)
0.
94
1
10
3 
(2
2.
3)
65
 (2
1.
0)
0.
84
 (0
.5
6-
1.
27
)
0.
41
2
0.
76
5
Ev
er
y 
da
y
8 
(0
.7
)
7 
(0
.5
)
0.
80
 (0
.2
7-
2.
38
)
0.
68
4
1 
(0
.2
)
1 
(0
.3
)
0.
26
 (0
.0
1-
10
.3
7)
0.
47
0
0.
67
7
Chapter 2
46
Sp
or
ad
ic
, n
(%
)
Sp
or
ad
ic
 A
M
D
 v
s.
 c
on
tr
ol
Fa
m
ili
al
, n
(%
)
Fa
m
ili
al
 A
M
D
 v
s.
 c
on
tr
ol
Fa
m
ili
al
 A
M
D
 v
s.
 
sp
or
ad
ic
 A
M
D
A
M
D
Co
nt
ro
l
O
R 
(9
5%
 C
I)*
P
A
M
D
Co
nt
ro
l
O
R 
(9
5%
 C
I)*
P
P
Re
d 
m
ea
t
O
nc
e 
a 
w
ee
k 
or
 le
ss
43
4 
(3
6.
7)
60
2 
(4
4.
3)
re
fe
re
nc
e
11
8 
(2
5.
7)
75
 (2
4.
3)
re
fe
re
nc
e
Fe
w
 ti
m
es
 a
 w
ee
k
63
8 
(5
3.
9)
68
0 
(5
0.
1)
1.
24
 (1
.0
5-
1.
48
)
0.
01
3
27
3 
(5
9.
3)
18
8 
(6
0.
8)
0.
92
 (0
.6
2-
1.
39
)
0.
70
2
0.
14
2
Ev
er
y 
da
y
11
2 
(9
.5
)
76
 (5
.6
)
1.
81
 (1
.3
0-
2.
54
)
0.
00
1#
69
 (1
5.
0)
46
 (1
4.
9)
1.
16
 (0
.6
6-
2.
05
)
0.
60
5
0.
07
4
Fr
ui
t
O
nc
e 
a 
w
ee
k 
or
 le
ss
84
 (7
.1
)
75
 (5
.5
)
re
fe
re
nc
e
36
 (7
.8
)
26
 (8
.4
)
re
fe
re
nc
e
Fe
w
 ti
m
es
 a
 w
ee
k
13
8 
(1
1.
7)
20
7 
(1
5.
1)
0.
60
 (0
.4
0-
0.
90
)
0.
01
3
73
 (1
5.
8)
70
 (2
2.
6)
0.
85
 (0
.4
0-
1.
79
)
0.
66
1
0.
37
0
Ev
er
y 
da
y
96
2 
(8
1.
3)
10
93
 (7
9.
5)
0.
74
 (0
.5
2-
1.
04
)
0.
08
5
35
2 
(7
6.
4)
21
4 
(6
9.
0)
0.
73
 (0
.3
7-
1.
44
)
0.
36
1
0.
54
2
Ve
ge
ta
bl
es
N
ot
 e
ve
ry
 d
ay
18
9 
(1
6.
0)
24
4 
(1
7.
7)
re
fe
re
nc
e
61
 (1
3.
3)
54
 (1
7.
4)
re
fe
re
nc
e
Ev
er
y 
da
y
99
5 
(8
4.
0)
11
31
 (8
2.
3)
1.
11
 (0
.8
9-
1.
39
)
0.
34
8
39
9 
(8
6.
7)
25
6 
(8
2.
6)
0.
92
 (0
.5
6-
1.
52
)
0.
74
1
0.
92
2
Ph
ys
ic
al
 a
cti
vi
ty
(A
lm
os
t)
 n
ev
er
56
6 
(4
4.
1)
37
7 
(2
7.
2)
re
fe
re
nc
e
17
7 
(3
7.
0)
84
 (2
7.
2)
re
fe
re
nc
e
1-
2 
tim
es
 a
 w
ee
k
50
9 
(3
2.
1)
62
9 
(4
5.
4)
0.
67
 (0
.5
6-
0.
81
)
2.
6x
10
-6
#
22
7 
(4
7.
5)
17
4 
(5
6.
3)
0.
62
 (0
.4
2-
0.
94
)
0.
02
2
0.
94
2
3 
tim
es
 a
 w
ee
k 
or
 m
or
e
20
9 
(1
6.
3)
37
8 
(2
7.
3)
0.
49
 (0
.3
9-
0.
61
)
3.
7x
10
-1
0 #
74
 (1
5.
5)
51
 (1
6.
5)
0.
75
 (0
.4
4-
1.
27
)
0.
28
1
0.
08
7
* 
Th
e 
O
Rs
 w
er
e 
ad
ju
st
ed
 fo
r 
ag
e,
 s
ex
, s
m
ok
in
g,
 a
nd
 B
M
I.
† 
A
ge
 o
f p
ar
tic
ip
ati
on
 in
 y
ea
rs
.
‡ 
Sm
ok
in
g 
in
 p
ac
k 
ye
ar
s.
§C
ar
di
ov
as
cu
la
r 
di
se
as
e 
de
fin
ed
 a
s 
pr
es
en
ce
 o
r 
hi
st
or
y 
of
 h
yp
er
te
ns
io
n,
 a
ng
in
a 
pe
ct
or
is
, m
yo
ca
rd
ia
l i
nf
ar
cti
on
, c
on
ge
sti
ve
 h
ea
rt
 fa
ilu
re
 a
nd
/o
r 
st
ro
ke
/t
ra
ns
ie
nt
 is
ch
em
ic
 a
tt
ac
k.
ІІ 
A
ut
oi
m
m
un
e 
di
se
as
e 
de
fin
ed
 a
s 
pr
es
en
ce
 o
r 
hi
st
or
y 
of
 r
he
um
at
oi
d 
ar
th
ri
tis
 o
r 
sy
st
em
ic
 lu
pu
s 
er
yt
he
m
at
os
us
.
# 
Si
gn
ifi
ca
nt
 a
ft
er
 B
on
fe
rr
on
i c
or
re
cti
on
Clinical studies
47
2
Data on the number of drusen and area of drusen within the macular area were available for 
689 sporadic subjects and 203 familial subjects (Table 4). Familial subjects showed a trend 
toward a higher number of drusen and a larger area of drusen in the macula as compared 
to sporadic patients, although this was only significant for the area of drusen in subjects 
with intermediate AMD (P = 0.043). After correction for age, sex, BMI, and smoking, the 
mean area of drusen in sporadic subjects with intermediate AMD was 1114.49 and 1415.63 
in familial subjects, which were no longer significantly different (P = 0.160).
Table 4. Number and Area of Drusen in Sporadic and Familial Control Individuals and Nonadvanced AMD Patients
Sporadic Familial
n Mean±SD n Mean±SD P
Control Drusen, n 159 2.25±6.0 24 2.85±3.4 0.633
Area of drusen* 159 81.65±149.6 24 128.86±129.5 0.145
Early Drusen, n 291 8.69±20.0 93 11.69±27.37 0.254
Area of drusen* 291 219.17±353.4 93 249.67±416.6 0.489
Intermediate Drusen, n 239 40.25±62.4 86 46.37±48.9 0.411
Area of drusen* 239 1167.90±1735.4 86 1598.70±1555.4 0.043
* Area of drusen in pixels
DISCUSSION
Familial and Sporadic AMD: Clinical Differences and Similarities
Familial AMD patients have a lower age at first symptoms compared to sporadic AMD patients. 
The phenomenon of a lower age at onset in patients with familial occurrence has been shown 
in other complex diseases with a significant genetic component, such as schizophrenia 
and Alzheimer’s disease.25,26 A lower age at onset in familial AMD patients has previously 
been reported by Shahid et al.14 (70.4 years in familial patients and 73.2 years in sporadic 
patients), and is in accordance with the mean difference of 3.1 years in our study. A significant 
difference in age of onset between familial and sporadic subjects also was observed in AMD 
patients with reticular pseudodrusen, but not in patients with cuticular drusen. However, 
as a result of a positive family history, familial subjects may have an increased awareness of 
visual symptoms which can lead to an earlier visit at a physician for evaluation. Therefore, 
it should be noted that the lower age at first symptoms in familial AMD patients may be 
partially attributed to an ascertainment bias.
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In our study, BCVA per age category did not differ between familial and sporadic AMD patients, 
suggesting that visual acuity does not decrease earlier or at a faster rate in familial patients, 
despite the lower age at first symptoms in familial AMD patients. Heightened awareness in 
familial patients may explain why no actual difference in BCVA was observed. 
Similar to other studies,1-3,6 smoking and advanced age were associated with the development 
of AMD in the current study, in sporadic and familial subjects. Furthermore, age was a more 
important risk factor for AMD in familial subjects as age shows a significant interaction with 
family history, resulting in a younger age at onset in familial subjects.
Ristau et al.22 have reported recently that allergy is associated with a reduced risk of AMD. We 
did not find a significant difference for the association of allergy with AMD between familial 
and sporadic subjects, so the protective effect of allergy does not seem to be influenced by 
family history. 
The pathogenesis of AMD as well as cardiovascular disease and diabetes have been linked 
to oxidative stress, inflammation and a vascular origin. Moreover, diabetes, cardiovascular 
disease, and its risk factors have been associated with the development of AMD, although 
this was not consistent among studies.1,27-30 In the current study we observed that sporadic 
subjects with diabetes have an increased risk for AMD. However, diabetes was no risk 
factor for familial AMD, which may be explained by the larger genetic component in the 
pathophysiology of familial AMD, while sporadic AMD may be associated with a larger 
contribution of environmental or lifestyle factors such as diabetes (and associated factors). 
Several studies reported an increased risk of AMD for patients with chronic renal 
disease.31,32 It has been shown that AMD and renal diseases, such as membranoproliferative 
glomerulonephritis type 2 and atypical hemolytic uremic syndrome, are related to the same 
genetic variants of the complement pathway, including the complement factor H gene.33-35 
Therefore, we evaluated whether renal disease might be correlated with AMD in familial 
subjects. However, we did not find a clear association between familial AMD and renal disease 
in our study population, possibly due to the low number of patients with renal disease. 
We also compared dietary factors between familial and sporadic subjects. It is interesting to 
investigate these dietary factors, since these are modifiable. The consumption of red meat 
at least a few times a week increased the risk of AMD in our sporadic patient cohort. This 
is supported by findings of Chong et al.,36 demonstrating that higher red meat intake was 
associated with the development of AMD. In our study consumption of fruit a few times 
a week was associated with a decreased risk for the development of AMD, but we did not 
observe such an association with frequent consumption of vegetables. In agreement with this 
finding, Cho et al.37 and Zerbib et al.38 described a protective effect of frequent consumption 
of fruits for exudative AMD, but no association with the consumption of vegetables. A study 
by Seddon et al.39 showed that intake of foods rich in carotenoids, in particular green leafy 
vegetables, decreased the risk of exudative AMD. Our study might be limited because we did 
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not discriminate between different kinds of vegetables and no risk calculation was performed 
for the progression to advanced AMD. This may explain why we did not observe a protective 
effect for the consumption of vegetables. Also, it must be considered that fruit consumption 
can be related to a more healthy lifestyle in general, and therefore, these results may be 
confounded by other factors, other than smoking and BMI, related to a healthy lifestyle.
In cuticular drusen, a clinical subtype of AMD that tends to cluster in families, differences in 
environmental and genetic risk factors have been reported compared to the AMD group as a 
whole.23,40 We previously reported that the association with smoking was significantly lower 
in patients with cuticular drusen compared to AMD patients without cuticular drusen.23 In this 
study, we observed no significant difference in environmental risk factors, such as smoking, 
between familial and sporadic AMD. However, several factors such as the consumption of red 
meat and frequent physical activity, tended to have a less important role in familial AMD than 
in sporadic AMD, supporting a stronger genetic component in the pathophysiology of AMD 
in families.
Familial and sporadic AMD: phenotypic differences and similarities
In our study population, GA was more prevalent in familial AMD patients than in sporadic 
patients. This cannot be explained by selection bias of familial patients, because if only 
the probands of the familial group (n = 262) were included in the analysis, GA was still 
significantly more prevalent in the familial AMD group than in the sporadic group (17.6% 
and 9.8%, respectively, P = 0.001). This finding may be explained by the stronger influence of 
genetic factors in the pathogenesis of familial AMD in certain phenotypic subtypes, such as 
GA. Previously Shahid et al.14 suggested heritability of AMD subtypes, but these investigators 
were not able to confirm this hypothesis due to low numbers of subjects. Sobrin et al.15 
showed that siblings are more likely to develop the same advanced subtype as their proband. 
This may suggest the contribution of genetic variants in these familial patients,16,35,41 which 
may increase the risk for developing GA rather than CNV. Affected members of densely 
affected families have been reported to bear a lower SNP load than expected based on five 
common known AMD risk variants; CFH (rs1061170 and rs1410996), ARMS2 (rs10490924), 
C2-CFB (rs641153 and rs9332739).10 This supports the hypothesis that rare genetic variants 
in these families may explain the high prevalence of AMD.
In this study, we reported a higher prevalence of cuticular drusen in familial AMD compared 
to sporadic AMD, which is in agreement with previous reports.40,42,43 However, in our cohort 
the prevalence of cuticular drusen was higher and 32% of the patients with cuticular drusen 
had a positive family history of AMD compared to 44% of the patients in a study of Grassi 
et al.40 Previously, our group demonstrated that heterozygous loss-of-function mutations 
in the CFH gene are found among family members with cuticular drusen.35,41 In addition, 
rare highly penetrant variants in the CFI gene have been identified in patients with cuticular 
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drusen.16,44 Therefore, the higher prevalence of cuticular drusen in families may be explained 
by segregation of rare, highly penetrant variants within these families. 
In addition to a possible ascertainment bias, caused by an increased awareness of 
disease-associated visual symptoms in familial subjects, another limitation of this study 
is the classification of subjects into familial or sporadic, based on the family history in the 
questionnaire, which may lead to misclassification. However, in a subset of the familial cases 
ophthalmologic examination data of their close relatives were available and compared to our 
classification based on the family history of the questionnaire. The degree of misclassification 
of the family history was very low in the familial subjects, as in only three cases (1.0%) no 
close relative with AMD was found by ophthalmologic examination. Unfortunately, no clinical 
data of family members of sporadic cases were available. The rate of misclassification may 
be some higher in sporadic individuals, as these subjects may not have been informed of 
the eye disease of close relatives or the relatives were asymptomatic and therefore, not yet 
diagnosed with AMD.
In conclusion, this study demonstrated that familial AMD patients have a lower age at first 
symptoms compared to sporadic patients. Our findings also indicate that familial AMD 
patients differ from sporadic patients in terms of risk factors and clinical features. The higher 
prevalence of GA and cuticular drusen in familial AMD patients may be explained by the 
contribution of additional genetic factors segregating within these families.
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ABSTRACT 
Importance: Many prediction models for age-related macular degeneration (AMD) have 
been established in non-familial AMD patients. However, individuals most interested in their 
risk of AMD are usually from densely affected AMD families. The question arises if these 
common risk factors can explain the aggregation of AMD in these families. 
Objective: To evaluate which proportion of AMD families cannot be explained by known 
environmental and common genetic risk factors. 
Design: Retrospective case-control and family study. 
Setting: Case-control and family datasets were extracted from the European Genetic 
Database (EUGENDA). Patient recruitment took place at the Ophthalmology department of 
the Radboud university medical center, Nijmegen, and University Hospital of Cologne from 
March 29, 2006, to April 26, 2013, and data collection from April 20, 2012, to July 27, 2017.
Participants: The case-control dataset (1188 cases, 1468 controls) was used for creation of 
a prediction model based on known common risk factors. Then, the model was applied to 
38 affected families. Based on the predicted probabilities within each family, the observed 
number of affected family members was compared with the expected number of affected 
family members. Thereafter, phenotypic differences were evaluated between families 
explained by common risk factors and families not explained by these common risk factors.
Main outcome measures: Proportion of families not explained by common risk factors.
Results: In most families (68.4%), the number of affected individuals was similar to expected 
based on the predicted probabilities within each family. Contrarily, we identified two families 
with significantly more affected family members than expected. A higher prevalence of 
hyperpigmentation was observed in families explained by common risk factors compared to 
families not explained by common risk factors (61.3% vs. 38.9%). 
Conclusions and relevance: Despite clustering of common risk factors in two-thirds of AMD 
families, a relatively large proportion of families is not readily explained by these risk factors 
and may harbor rare genetic variants. These families cannot be identified solely by phenotype. 
Individual risk prediction in AMD families remains therefore challenging and evaluation of 
multiple family members is recommended.
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INTRODUCTION
Age-related macular degeneration (AMD) is a multifactorial, progressive retinal disorder 
resulting in severe visual impairment. Advanced age is one of the most important risk factors 
for AMD,1,2 resulting in a rapidly growing burden of disease due to the aging population.3-5 
Numerous demographic, environmental and genetic risk factors have already been 
identified and many prediction models have been developed based on these common risk 
factors.6-12 Prediction models can aid in the identification of individuals with a high risk for 
disease, enabling personalized healthcare and early detection of disease. In clinical practice, 
particularly individuals with affected family members are interested in their individual risk of 
AMD, especially when more than one family member is affected. However, existing prediction 
models were mainly constructed in studies representing the general population and are 
based on environmental and common genetic risk factors in non-familial AMD patients. 
Aggregation of AMD in families has been reported,13-15 and not all of these AMD families can 
be fully explained by these common genetic risk factors.16,17 Moreover, rare genetic variants 
with a high risk for disease have been identified in such AMD families.18-20 Additionally, it 
has been reported that a common variant in the ARMS2 gene (p.Ala69Ser, rs10490924) 
associated with AMD in non-familial patients is not associated with AMD in densely affected 
families.21 These findings raise the question if the current models, based on environmental 
and common genetic risk factors, can be applied to individuals deriving from families affected 
with AMD. Therefore, the aim of this study was to evaluate the accuracy of prediction model 
based on environmental and common genetic risk factors in an AMD family cohort and to 
determine the proportion of families that cannot be explained by these known risk factors.
METHODS
Participants
For this study, an independent case-control dataset and a family dataset were extracted from 
the European Genetic Database (EUGENDA, www.eugenda.org), a large multicenter database 
for clinical and molecular analysis of AMD. All individuals provided written informed consent 
for data entry in EUGENDA. This research was approved by the local ethical committees at the 
Radboud university medical center and the University Hospital of Cologne and the study was 
performed in accordance with the tenets of the Declaration of Helsinki. 
The case-control dataset was used to create a model and included 1188 cases and 1468 
control individuals recruited at the department of Ophthalmology at the Radboud university 
medical center, Nijmegen and the Ophthalmology department of the University Hospital of 
Cologne. All individuals in this case-control dataset were unrelated. Additionally, a family 
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dataset was extracted from EUGENDA including 43 AMD families (125 cases, 39 control 
individuals). These AMD families had at least two first-degree relatives with AMD confirmed 
by color fundus photography. Final analyses included 38 AMD families; five families were 
excluded because data of one or two family members was incomplete.
Cases were defined as having at least 15 soft medium drusen (diameter ≥ 63µm), or advanced 
AMD (central geographic atrophy [GA] or choroidal neovascularization [CNV] secondary to 
AMD) in at least one eye. Control individuals were aged 65 years and above and did not exhibit 
any signs of AMD, or did not meet the criteria above (small hard drusen only, or less than 15 soft 
medium drusen). The diagnosis and grading of AMD was based on color fundus photographs 
of the more severely affected eye and was performed by independent certified reading center 
graders as described previously.22 To obtain more detailed phenotypic characteristics of the 
AMD families, additional phenotyping was performed by an independent certified grader 
according the Rotterdam grading protocol based on the Wisconsin Age-Related Maculopathy 
Grading System23 and the modified International Classification System.24
Information on lifestyle and other environmental factors was obtained through detailed 
interviewer-assisted questionnaires. Variables included in this study were: age at participation, 
sex (male/female), smoking status (never/past/current), body mass index (BMI) calculated as 
weight in kilograms divided by height in meters squared (normal [<25kg/m2]/overweight [25-
30 kg/m2]/obese [>30 kg/m2]), physical activity (no or almost never/1-2 times per week/3 or 
more times per week), education level (high school or less/more than high school) and family 
history of AMD (yes/no). 
Single nucleotide polymorphism genotyping
Genomic DNA was isolated from venous blood leukocytes and genotyping was performed 
for susceptibility single nucleotide polymorphisms (SNPs) in the following AMD-associated 
genes: ADAMTS9 (rs6795735),25 APOE (rs2075650,26 rs442063825), ARMS2 (rs10490924),27 
B3GALTL (rs9542236),25 C3 (rs433594,28 rs223019929,30), CCDC109B (rs4698775),25 
CETP (rs3764261),31,32 CFB (rs4151667,33 rs64115333), CFH (rs800292,34 rs1061170,35-
37 rs1214493938), CFI (rs10033900),39 COL8A1 (rs13081855),25 COL10A1 (rs3812111),25 
CYP24A1 (rs1570669),40 FADS1 (rs174547),32 GLI2 (rs6721654),26 GLI3 (rs2049622),26 IER3DDR 
(rs3130783),25 IGFR1 (rs2872060),41 LIPC (rs10468017),31,32 LPL (rs12678919),31,32 MYRIP 
(rs2679798),42 PON1 (rs705381),43 RAD51B (rs8017304),25 SKIV2L (rs429608),42 SLC16A8 
(rs8135665),25 TGFBR1 (rs334353),25 TIMP3 (rs9621532),31 TNFRSF10A (rs13278062),25 TYR 
(rs621313),26 and VEGFA (rs943080).44 SNPs were genotyped using competitive allele-specific 
PCR assays (KASP SNP Genotyping System, LGC).
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Statistical analyses
Data for all variables included in a prediction model are necessary in order to properly apply 
the model in a specific cohort. Due to one or more missing variables in our family dataset for 
existing prediction models for AMD, 6-8,11,12 these could not be applied. For the purpose of this 
study, first a prediction model similar to existing models was created based on the available 
case-control data in EUGENDA. 
This prediction model for the development of AMD was constructed using binary logistic 
regression analyses. Univariable logistic regression analyses were performed for five non-
genetic and 35 genetic variables to study associations between each single risk factor and 
AMD. Subsequently, all variables with a P value ≤ 0.10 were selected for inclusion in a 
multivariable model adjusted for age and gender. Backward multivariable regression analysis 
was performed and the final prediction model included only variables with a P value less than 
0.10 (Supplementary Table 1). The accuracy of the prediction model to discriminate between 
cases and controls was evaluated using a receiver operating characteristic (ROC) curve and 
calculation of the corresponding area under the curve (AUC). Risk scores (calculated as the 
sum of regression coefficients) and the predicted probability of AMD were then computed 
for all individuals in the family dataset. These statistical analyses were performed using IBM 
SPSS Statistics software, version 25.0 (IBM Corp., Armonk, NY, USA). 
Next, to determine the proportion of AMD families that cannot be explained by these known 
risk factors, we calculated the expected number of affected family members within a family 
using the RAND(‘BERNOULLI’,p) function in a simulation analyses. A probability distribution 
for the number of expected affected individuals was provided after running 1000 simulations 
with the predicted probabilities within each family. Based on these probabilities we 
calculated the expected number of affected individuals in each family and compared these 
with the observed numbers of affected family members. These analyses were performed 
using software package SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). Finally, phenotypic 
differences were evaluated between families explained by common risk factors and families 
not explained by these common risk factors using a chi-squared test.
RESULTS
Basic demographic characteristics of the case-control and family dataset are shown in Table 
1. From the univariable analysis 21 variables were selected for inclusion in the multivariable 
model adjusted for age and gender (data available upon request). Factors included in the 
final model are age, smoking status, physical activity, education, family history for AMD and 
eleven common genetic variants located in APOE (rs2075650), ARMS2 (rs10490924), C3 
(rs2230199), CETP (rs3764261), CFH (rs800292, rs1061170, rs12144939), FADS1 (rs174547), 
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SKIV2L (rs429608), TIMP3 (rs9621532), TNFRSF10A (rs13278062), and VEGFA (rs943080). 
The associations of these variables with AMD are shown in Supplementary Table 1. Based 
on these results, we calculated the predicted probabilities for each individual and analyzed 
the accuracy of this model. The model showed an area under the curve of 0.833 with a 95% 
confidence interval between 0.813-0.853. The model was then applied to the AMD family 
dataset to calculate the predicted probabilities for each individual in the family dataset. 
Table 1. Basic demographic characteristics of the case‐control and family dataset
Case‐control set Family set*
Case
(n=1188)
Control
(n=1468)
Case
(n=104)
Control
(n=36)
Age (age in years±SD) 76.4±8.4 72.4±6.64 73.8±8.4 70.3±4.5
Gender (n[%])
Male
Female
481 (40.5%)
707 (59.5%)
624 (42.5%)
844 (57.5%)
37 (35.6%)
67 (64.4%)
19 (52.8%)
17 (47.2%)
*Final analyses included 38 of the 43 AMD families. Five families were excluded from the simulation analyses 
because data of one or two family members was incomplete.
Abbreviations: SD, standard deviation.
Observed vs. expected number of affected family members
Further analyses included 38 of the 43 affected AMD families. In 26 out of 38 families 
(68.4%) the observed number of affected family members equaled the expected number 
of affected family members (Table 2). In 12 families the number of affected family members 
outnumbered the expected number of affected family members, and in two of these families 
(5.3%) this was significantly higher than expected based on the simulation (P<0.05). The 
predicted probabilities in each of the family members of these two families are shown in 
Figure 1. Therefore it is unlikely that these families can be explained by the common risk 
factors included in this model. 
Phenotypic differences between AMD families 
Next, phenotypic differences were evaluated between cases from the 26 families explained 
by common risk factors and cases from the 12 families not explained by these common risk 
factors (Table 3). AMD patients from families not explained by risk factors tended to have larger 
drusen, but did not reach statistical significance. A higher prevalence of hyperpigmentation 
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Table 2. Comparison of observed number of affected family members with the expected number of affected 
family members based on the predicted probabilities within each individual family
Family Observed number of affected 
individuals/Total number of 
family members
Expected number of affected 
individuals/Total number of 
family members
Probability that observed 
number of affected family 
members is true (0‐1)
#5 3/4 4/4 0.996
#38 2/3 3/3 0.987
#7 5/9 7/9 0.975
#36 2/2 2/2 0.972
#12 3/9 5/9 0.970
#16 2/4 3/4 0.966
#14 2/5 3/5 0.951
#21 3/5 4/5 0.949
#11 2/3 2/3 0.919
#17 3/3 3/3 0.915
#29 3/3 3/3 0.900
#13 3/4 3/4 0.890
#2 2/2 2/2 0.885
#33 2/2 2/2 0.881
#15 2/2 2/2 0.859
#28 2/2 2/2 0.846
#4 3/4 3/4 0.817
#19 4/5 4/5 0.788
#25 2/2 2/2 0.781
#37 2/2 2/2 0.776
#18 2/2 2/2 0.748
#31 2/3 2/3 0.734
#32 3/4 3/4 0.724
#34 3/3 3/3 0.662
#20 3/5 3/5 0.649
#26 2/2 2/2 0.597
#8 2/2 1/2 0.421
#6 2/3 1/3 0.397
#22 4/6 3/6 0.285
#3 3/3 2/3 0.252
#30 5/5 4/5 0.239
#23 4/6 3/6 0.221
#10 3/5 2/5 0.218
#27 3/3 2/3 0.177
#1 3/4 1/4 0.092
#9 3/4 1/4 0.076
#24 3/3 1/3 0.020
#35 2/2 0/2 0.010
In 26 families the observed number of affected family members was equal to or less than the expected number of 
affected family members based on the common risk factors in our model (light grey). In twelve families (white) the 
number of affected family members outnumbered the expected number of affected family members, in two of these 
families (dark grey) this was significantly higher than expected based on the simulation (P<0.05).
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Figure 1. Pedigrees of families #24 (A) and #35 (B), in which the observed number of affected family members is 
much higher than expected and therefore not explained by common risk factors
Squares indicate men; Circles, women; Slashes, deceased family members; Black symbols, AMD patients; Triangle, 
miscarriage. The predicted probabilities based on demographic, environmental and common genetic risk factors 
are displayed on the bottom line beneath the symbols. No data were available for the deceased family members.
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Table 3. Phenotypic characteristics in families explained by common risk factors versus families not explained 
by these risk factors. 
Phenotypic characteristics Cases from families 
explained by risk 
factors (n=67)*
Cases from families 
not explained by risk 
factors (n=37)** P-value
Any drusen outside grid Present 50 (79.4%) 28 (77.8%)
0.853
Absent 13 (20.6%) 8 (22.2%)
Predominant drusen type 
inside grid
Hard 2 (4.3%) 0 (0.0%)
0.100
Soft ≤125µm 9 (19.1%) 3 (10.3%)
Soft distinct, >125µm 12 (25.5%) 6 (20.7%)
Soft indistinct, >125µm 17 (36.2%) 19 (65.5%)
Reticular 7 (14.9%) 1 (3.4%)
Largest drusen inside grid < 63µm 2 (4.3%) 0 (0.0%)
0.066
< 125µm 10 (21.3%) 1 (3.4%)
< 250µm 12 (25.5%) 10 (34.5%)
≥ 250µm 14 (29.8%) 15 (51.7%)
Reticular 9 (19.1%) 3 (10.3%)
Retinal area covered by 
drusen central circle
< 10% 10 (45.5%) 8 (38.1%)
0.458
< 25% 4 (18.2%) 5 (23.8%)
< 50% 5 (22.7%) 2 (9.5%)
≥ 50% 3 (13.6%) 6 (28.6%)
Retinal area covered by 
drusen inner circle
< 10% 21 (56.8%) 16 (57.1%)
0.829
< 25% 8 (21.6%) 6 (21.4%)
< 50% 7 (18.9%) 4 (14.3%)
≥ 50% 1 (2.7%) 2 (7.1%)
Retinal area covered by 
drusen outer circle
< 10% 27 (58.7%) 16 (55.2%)
0.360
< 25% 12 (26.1%) 10 (34.5%)
< 50% 6 (13.0%) 1 (3.4%)
≥ 50% 1 (2.2%) 2 (6.9%)
Hyperpigmentation Present 38 (61.3%) 14 (38.9%)
0.032
Absent 24 (38.7%) 22 (61.1%)
Geographic atrophy Present 18 (27.7%) 11 (30.6%)
0.761
Absent 47 (72.3%) 25 (69.4%)
Neovascular AMD Present 28 (43.1%) 10 (27.8%)
0.128
Absent 37 (56.9%) 26 (72.2%)
*Cases from families #2, #4, #5, #7, # 11-#21, #25, #26, #28, #29, #31-34, #36-38
** Cases from families #1, #3, #6, #8-10, #22-24, #27, #30, #35
was detected in cases from families explained by common risk factors (38/67 cases; 61.3%) 
compared to cases from families not explained by common risk factors (14/37 cases; 38.9%, 
P = 0.032). However, other than this finding there were no statistically significant phenotypic 
differences between these families. 
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DISCUSSION
In this study, we demonstrated that a prediction model based on demographic, common 
genetic and environmental risk factors can be applied to most AMD families. Like other 
prediction models, common risk factors were included in the current study and the AUC was 
within range of the existing prediction models (AUC 0.68-0.94).6 Further evaluation of the 
individual families showed that the number of affected family members is similar to what 
is expected based on the known risk factors in the majority (68.4%) of families. This is in 
agreement with findings from Sobrin et al., who previously reported that in most AMD families 
the genotypic load for five common SNPs did not significantly differ from the expected load.17 
Previous studies reported that associations of risk factors in familial AMD may differ from 
non-familial AMD.16,17,21 A weaker association for a common genetic variant in ARMS2 
(rs10490924) was observed in familial AMD patients compared to non-familial AMD patients, 
moreover, in densely affected families this association was not significant anymore. In 
addition, certain lifestyle factors seem to play a less important role in familial AMD, such as 
red meat consumption and increased physical exercise.16 Furthermore, rare genetic variants 
with a high risk for disease have been identified in AMD families.18-20,45-49 Our results indicate 
that in the majority of families clustering of common genetic and environmental risk factors 
explains the aggregation of AMD in these families. By contrast, we also identified two AMD 
families in which the number of affected individuals was much higher than expected. These 
families may harbor rare, penetrant genetic variants responsible for the risk of disease, thus 
are of particular interest for additional genetic testing, such as whole exome sequencing.18,19 
However, it must be noted that these families might also carry other common genetic variants 
that were not included in this study which could explain their AMD risk. 
Since rare genetic variants could play an important role in the etiology of familial AMD, 
addition of such variants might improve risk prediction. Due to their low frequencies however, 
the additive predictive value of rare genetic variants in the general population is low.50 Hence, 
accurate risk prediction in AMD families remains difficult and it is recommended to evaluate 
risk factors not only individually, but throughout the family to accurately predict disease risk 
in AMD families. 
Limitations
Our study was limited in its cross-sectional design. Preferably, longitudinal data is used as it 
would allow more accurate risk prediction for progression of AMD. Also, due to lack of one 
or more missing variables in our dataset for existing prediction models for AMD, these could 
not be applied to our dataset. Therefore, first a prediction model was created based on the 
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available case-control data. A limitation of this study is that the model was not validated in 
an independent cohort. However, this model contains previously described risk factors, and 
were comparable to previously described models.6-8,11,12 
CONCLUSION
In conclusion, we have shown that approximately two-thirds of AMD families in this study can 
be explained by clustering of common genetic and environmental risk factors. However, in a 
subset of families the risk of advanced AMD is not explained by these common risk factors. 
This suggests that other factors, such as rare genetic variants conferring a high disease risk, 
play a key role in the development of advanced AMD in these families. These families cannot 
be identified solely by phenotype. Individual risk prediction based on existing prediction 
models in AMD families is therefore challenging and evaluation of multiple family members 
is recommended. 
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SUPPLEMENTARY MATERIAL 
Supplementary Table 1. Final multivariable model used for the prediction of advanced AMD
Regression coefficient OR (95% CI) P value
Age of participation (y) 0.10 1.10 (1.081-1.117) <0.001
Smoking status Never Reference Reference 
<0.001Past 0.15 1.158 (0.903-1.485)
Current 1.00 2.721 (1.704-4.345)
BMI (kg/m2) Normal (<25) Reference Reference
0.029Overweight (25-30) 0.13 1.139 (0.883-1.469)
Obese (>30) 0.53 1.701 (1.149-2.518)
Physical activity Less than once a week Reference Reference
<0.0011 or 2 times a week -0.37 0.688 (0.522-0.906)
3 or more times a week -0.72 0.485 (0.346-0.680)
Education Less than high school Reference Reference
<0.001
High school or more -0.45 0.639 (0.502-0.812)
Family history of AMD No Reference Reference
<0.001
Yes 0.82 2.265 (1.703-3.011)
APOE, rs2075650 A:A Reference Reference
0.047A:G -0.36 0.695 (0.521-0.923
G:G 0.02 1.1015 (0.338-3.070)
ARMS2, rs10490924 G:G Reference Reference
<0.001G:T 0.98 2.673 (2.082-3.434)
T:T 2.36 10.579 (6.927-16.158)
C3, rs2230199 C:C Reference Reference
0.014C:G 0.12 1.124 (0.875-1.443)
G:G 0.77 2.156 (1.281-3.630)
CETP, rs3764261 C:C Reference Reference
0.001C:A 0.45 1.564 (1.216-2.011)
A:A 0.47 1.596 (1.082-2.354)
CFH, rs800292 G:G Reference Reference
0.003G:A -0.51 0.601 (0.445-0.812)
A:A -0.55 0.577 (0.297-1.123)
CFH, rs1061170 T:T Reference Reference
<0.001T:C 0.05 1.045 (0.759-1.441)
C:C 0.80 2.216 (1.422-3.455)
CFH, rs12144939 G:G Reference Reference
<0.001G:T -0.65 0.523 (0.377-0.723)
T:T -0.73 0.480 (0.227-1.013)
SKIV2L, rs429608 G:G Reference Reference
<0.001G:A -0.70 0.496 (0.365-0.675)
A:A -0.51 0.598 (0.218-1.646)
TIMP3, rs9621532 A:A Reference Reference
0.017
A:C or C:C -0.54 0.586 (0.378-0.907)
TNFRSF10A, rs13278062 G:G Reference Reference
0.073G:T 0.06 1.065 (0.789-1.438)
T:T 0.34 1.411 (1.011-1.969)
VEGFA, rs943080 T:T Reference Reference
0.074T:C -0.22 0.800 (0.604-1.058)
C:C -0.39 0.678 (0.483-0.952)
Abbreviations: AMD, age-related macular degeneration; CI, confidence interval; OR, odds ratio; SD, standard 
deviation.
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ABSTRACT
Purpose: To evaluate the combined role of genetic, non-genetic and phenotypic risk factors 
for conversion from early and intermediate age-related macular degeneration (AMD) to late 
AMD. 
Methods: This study included genetic, non-genetic and phenotypic data of 232 patients 
with early/intermediate AMD from the European genetic database (EUGENDA) with follow-
up of at least five years. Baseline phenotypic characteristics were evaluated based on color 
fundus photography, spectral-domain optical coherence tomography and infrared images. 
Genotyping for 36 single nucleotide polymorphisms in AMD-associated risk genes and 
systemic lipid and complement measurements were performed. Multivariable backward 
logistic regression resulted in a final prediction model.
Results: During a mean follow-up of 5.9 years, 22.4% of patients progressed to late AMD. The 
multivariable prediction model included age, CFH variants (rs1061170, rs800292), pigment 
abnormalities, drusenoid pigment epithelial detachment (dPED), reticular pseudodrusen 
(RPD) and hyperreflective foci (HF). The model showed an area under the curve of 0.978 (95% 
Confidence Interval: 0.961-0.996) and adequate calibration (Hosmer-Lemeshow P= 0.712).
Conclusions and Relevance: In addition to advanced age and CFH variants, pigment 
abnormalities, dPED, RPD and HF are relevant imaging biomarkers for conversion to late AMD. 
In clinical routine, an intensified monitoring of patients with high risk phenotypic profile may 
be useful for early detection of progression to late AMD.
Clinical studies
73
2
INTRODUCTION
Age-related macular degeneration (AMD) is a complex progressive retinal disease and one 
of the leading causes of severe vision loss in the elderly population of the Western world.1 
The early stages of AMD are characterized by the presence of small, intermediate and/or 
large drusen and retinal pigmentary abnormalities. Early AMD can progress to late AMD, 
which is characterized by choroidal neovascularization (CNV) or geographic atrophy (GA). 
Identification of predictive factors for progression to late AMD may contribute to a more 
efficient and personalized approach in monitoring and support of patients with early AMD 
stages. Additionally, understanding disease progression is crucial for a better insight in the 
disease mechanisms and could potentially contribute to the development of new preventive 
strategies to delay the onset of late AMD stages.
Genomic heritability of AMD is estimated to be 46-71%.2 In recent years, 52 independently 
associated common and rare genetic variants at 34 loci have been associated with AMD, 
which together explain approximately half of the heritability. The AMD-associated genes are 
primarily involved in the modulation of the complement system, extracellular matrix and lipid 
metabolism.3 Nevertheless, the impact of these genetic variants on AMD progression has 
not been studied extensively. Several reports on AMD progression evaluated only a limited 
number of known AMD-associated variants.4-7 A recent report developed a genetic risk 
score for AMD progression including the top variants of all known 34 AMD risk loci.8 Besides 
genetic influence, also non-genetic risk factors (age,4,9 BMI,4,9,10 smoking4,8-11) and phenotypic 
characteristics such as presence of large drusen,12,13 central drusen location,11,14 pigmentary 
abnormalities,11,14 hyperreflective foci (HF)15,16 and reticular pseudodrusen (RPD)17,18 have 
been identified as individual risk factors for the progression to late AMD. However, there is 
a lack of studies on AMD progression investigating the combined effect of comprehensive 
genetic, environmental, demographic risk factors and detailed phenotypic characteristics 
based on multimodal imaging. 
Hence, this study aims to evaluate comprehensively the role of genetic, non-genetic and 
phenotypic characteristics based on multimodal imaging on conversion from early to late 
AMD over a period of at least five years. Furthermore, we aimed to create a multivariable 
prediction algorithm based on the factors and characteristics that were significantly 
associated with AMD progression.
METHODS
In this prospective observational study, we examined patients with early or intermediate 
AMD over a follow-up time of at least five years after baseline examination. The participants 
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were recruited from the European Genetic Database (EUGENDA, www.eugenda.org), a 
multicenter database of AMD patients from University Hospital in Cologne, Germany and 
Radboud university medical center in Nijmegen, the Netherlands. The study was approved by 
local ethics committees and was performed in accordance with the tenets of the Declaration 
of Helsinki. Before enrollment in EUGENDA, written informed consent was obtained from all 
participants. 
At baseline, a total of 605 patients who presented signs of early or intermediate AMD and 
no signs of late AMD (CNV or GA) were examined at the Department of Ophthalmology 
of the University Hospital of Cologne, Germany, and Radboud university medical center in 
Nijmegen, the Netherlands, between June 2008 and January 2012. After five years, 232 of 
the 605 participants underwent a follow-up examination at the same departments between 
April 2014 and November 2016. The remainder of 605 patients did not participate in the 
follow-up examination due to several reasons; 185 of the 605 patients did not respond to 
different attempts of contact, 115 declined participation or were unable to perform the visit 
due to other severe medical conditions, 23 had changed their residence, 47 had died and 
three were excluded due to bad image quality of the follow-up examination. None of the 
included subjects suffered from other severe retinal pathologies such as diabetic retinopathy/
maculopathy, high myopia (≥-6 diopters) or severe macular pucker. 
Spectral Domain Optical coherence tomography (SD-OCT), infrared images (IRs, Spectralis HRA 
system; Heidelberg Engineering, Heidelberg, Germany), digital color fundus photographs (FP; 
Cologne: Canon UVI fundus camera; Canon, Tokyo, Japan, and Nijmegen: Topcon TRC 50IX 
fundus camera; Topcon, Tokyo, Japan) and fluorescein angiography (FA) were performed at 
baseline. At the follow-up visit, patients underwent at least SD-OCT, IRs and FP examinations.
Further medical data, such as arterial hypertension (yes/no), cardiovascular diseases (yes/
no), allergy (yes/no) and BMI (normal <25/overweight ≥25), were obtained by standardized 
interviewer-assisted questionnaires for each patient. Sociodemographic characteristics (age, 
sex [male/female]) and smoking status (never/ever) were also included in this questionnaire. 
Grading Procedure
Severity staging was performed by grading of retinal images, including FP, SD-OCTs and IRs, 
according to the Beckman classification system19 by certified graders at baseline (LA, TS) and 
follow-up visit (VS, LA). Discrepancies between graders were solved by open adjudication. 
Presence of the following phenotypic characteristics were evaluated at baseline based on 
FP, SD-OCT and IRs: drusenoid pigment epithelial detachment (dPED; drusen size ≥360µm20), 
pigment abnormalities (hyper-or hypopigmentation areas in form of pigmentary clusters or 
sharply demarcated sections of the RPE14), reticular pseudodrusen (RPD; drusenoid deposit, 
located in the subretinal space above the RPE21), and HF (n<10/≥10 in all SD-OCT scans; small, 
highly-backscattering lesions within the neurosensory retina with greater reflectivity than the 
RPE22).
Clinical studies
75
2
Serum Measurements and Genotyping
Venous blood samples were collected at baseline visit for systemic lipid and complement 
measurements and genetic analyses. Serum lipid measurements included the following: 
total cholesterol, high-density lipoprotein-cholesterol (HDL), triglycerides, apolipoprotein B, 
apolipoprotein A1, Lipoprotein a and C-reactive protein (CRP). Complement activation levels 
were evaluated using the ratio between activation fragment C3d and complement component 
C3 levels (C3d/C3 ratio). Lipid levels and complement components were measured in 
serum samples as described before.23 Genotyping was performed for 36 single nucleotide 
polymorphisms (SNPs) in AMD-associated risk genes using the KASPar SNP Genotyping 
System (LGC Genomics, Berlin, Germany; Supplementary Table 1). 
Statistical Analysis
All demographic, environmental, phenotypic, non-genetic and genetic variables collected at 
baseline were assessed to determine their association with progression to late AMD using 
univariable logistic regression models adjusted for age and sex. Thereafter, variables with a 
P-value < 0.10 were selected for inclusion in multivariable logistic regression models. First, we 
developed multivariable models for phenotypic and genotypic factors separately (adjusted 
for age and sex). Age, sex and all variables with a P value < 0.10 in univariable analyses (both 
genetic and phenotypic factors) were selected for inclusion in a backward logistic regression 
resulting in a final prediction model. The discriminative accuracy of each model was evaluated 
using receiver operating characteristic (ROC) curves and calculation of their corresponding 
area under the curve (AUC). The Hosmer-Lemeshow goodness of fit test was performed to 
check the calibration of the models. Mann-Whitney U Test and Pearson’s chi-squared test 
were used to assess the differences in baseline characteristics between the included patients 
and the ones lost-to-follow-up.
All statistical analyses were performed using IBM SPSS Statistics software, version 22.0 (IBM 
Corporation, Armonk, NY, USA).
RESULTS
Baseline characteristics
Mean follow-up time of the 232 included patients with early or intermediate AMD at baseline 
examination was 5.9 years (range 4.5-10.4 years). Among these patients, 132 (56.9%) were 
female (mean age 69.2±6.2 years) and 100 (43.1%) were male (mean age 71.3±5.9 years). At 
baseline, 92 follow-up participants (39.7%) were categorized as early AMD and 140 (60.3%) 
as intermediate AMD. Further baseline characteristics of all participants in this study are 
shown in Table 1. Patients lost to follow-up were significantly older than included patients, 
reported less history of smoking, but suffered more frequently from cardiovascular disease.
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Table 1. Baseline Characteristics of all Participants
Included Patients Patients lost to
 follow‐up
P‐Value
Number of patients, n 232 373
Age, mean (SD), years 70.13 (6.17) 74.96 (8.67) 0.001a
Female sex, n (%) 132 (56.9) 236 (63.3) 0.119b
Follow up period, mean (SD), years 5.94 (0.91)
Ever smoked, n (%) 142 (61.2) 172 (46.1) 0.004b
Hypertension, n (%) 84 (36.2) 137 (36.7) 0.690b
Cardiovascular diseases, n (%) 44 (19.0) 102 (27.3) 0.011b
Allergy, n (%) 66 (28.4) 79 (21.2) 0.065b
BMI ≥25, n (%) 117 (50.4) 175 (46.9) 0.584b
C3d/C3 Ratio, mean (SD) 1.47 (0.36) 1.52 (0.41) 0.478a
Total cholesterol, mean (SD), mmol/l 5.78 (1.13) 5.69 (1.17) 0.369a
HDL cholesterol, mean (SD), mmol/l 1.54 (0.38) 1.53 (0.40) 0.822a
Triglyceride, mean (SD), mmol/l 1.63 (0.74) 1.67 (0.85) 0.736a
ApoB, mean (SD), mg/l 958.10 (227.76) 934.35 (215.65) 0.280a
ApoA1, mean (SD), mg/l 1730.42 (307.98) 1723.98 (324.62) 0.389a
Lp(a), mean (SD), U/l 312.85 (375.56) 339.39 (432.91) 0.485a
CRP, mean (SD), mg/l 5.40 (5.26) 5.67 (5.45) 0.376a
SD: Standard Deviation, BMI: Body Mass Index, C3d/C3 ratio: Complement Activation Level as the ratio of C3d and 
C3 fragments, HDL: High-Density Lipoprotein, ApoB: Apolipoprotein B, ApoA1: Apolipoprotein A1, Lp(a): Lipoprotein 
a, CRP: C-reactive protein
aPearson’s chi-squared test 
bMann-Whitney U test
Progression Rates to Late AMD
During the mean follow-up time of 5.9 years, 52 of 232 patients (22.4%) developed a late 
stage of AMD, hereafter referred to as “progressors”. The 180 patients who did not develop 
late AMD during follow-up are referred to as “non-progressors”.
At follow-up, 52 of the 140 patients (37.1%) with intermediate AMD at baseline converted 
to late AMD at the end of the study. None of the 92 patients with early AMD at baseline 
converted to late AMD. Of the progressors, 29 patients (55.8%) developed unilateral late 
AMD (25.0% CNV, 30.8% GA), while 23 (44.2%) presented a late stage in both eyes (5.8% CNV, 
21.2% GA, 17.3% mixed type). 
Predictive factors for the progression to late AMD
Demographic, environmental, non-genetic, genetic, and phenotypic features at baseline 
were individually compared between progressors and non-progressors, adjusted for age and 
sex (Table 2). 
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Non-genetic risk factors
There was no significant difference in follow-up time (P = 0.121) and sex distribution (P = 
0.446) between progressors and non-progressors, whereas the non-progressors tended to 
be younger (P = 0.056). History of smoking, hypertension, cardiovascular disease, allergy and 
increased BMI were not associated with progression to late AMD after five years of follow-up. 
Also, the C3d/C3 ratio and systemic serum lipid levels showed no association with progression 
to late AMD. 
Genetic risk factors
Among the 36 tested SNPs only three tended to be associated with progression to late AMD 
in univariable logistic regression analyses: CFH rs1061170 (Odds Ratio [OR] 2.41, P = 0.25x10-
3), CFH rs800292 (OR 0.37, P = 0.005), and CETP rs3764261 (OR 1.94, P = 0.008). In contrast, 
the ARMS2 rs10490924 risk allele showed no significant association with conversion to late 
AMD (OR 1.22, P = 0.431). Analysis of the ROC curve of the multivariable model that included 
the four SNPs with a P-value < 0.10 in the CFH, CETP and C3 genes revealed a fairly good 
ability to discriminate between progressors and non-progressors with an AUC of 0.763 (95% 
confidence interval [CI] 0.677-0.849).
Phenotypic risk factors
Presence of HF on SD-OCT were associated with a disproportionally high risk of progression to 
late AMD (OR 166.78, P = 0.05x10-4). Furthermore, presence of dPED (OR 35.43, P = 1.93x10-15), 
pigment abnormalities (OR 12.27, P = 2.30x10-10), and presence of RPD (OR 4.56, P = 0.004) 
at baseline increased the odds of progression to late stages of AMD.
A multivariable logistic regression model with all statistically significant phenotypic features 
(presence of HF, RPD, dPED, and pigment abnormalities) reached an AUC of 0.955 (95% CI 
0.926-0.984). 
Final multivariable prediction model 
In a next step, all parameters with a P-value < 0.10 from the univariable analyses were 
combined in a backward multivariable logistic regression procedure. This resulted in a final 
prediction model including age, CFH rs1061170, CFH rs800292, and presence of the following 
phenotypic risk factors: pigment abnormalities, dPED, RPD, and HF. Within the final model, 
the AUC increased to 0.978 (95% CI 0.961-0.996) and showed good calibration (Hosmer-
Lemeshow P = 0.712) (Table 3). 
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Table 2. Univariable Logistic Regression Analysis for Predictors for Conversion of Early/Intermediate to Late AMD 
after Five Years Follow‐up (adjusted for age and sex)
Baseline Progressors 
(n=52)
Non‐
Progressors 
(n=180)
Odds Ratio 95% CI P‐Value
Age, mean (SD), years 71.50 (8.34) 69.73 (5.35) 1.051 0.999-1.107 0.056 
Female sex, n (%) 31 (59.6) 101 (56.1) 1.283 0.676-2.437 0.446
Follow up period, mean (SD), years 6.10 (0.93) 5.90 (0.91) 1.301 0.933-1.815 0.121
Environmental Factors
Ever smoked, n (%) 33 (68.8) 109 (60.9) 1.620 0.783-3.355 0.194
Hypertension, n (%) 16 (33.3) 68 (37.8) 0.780 0.396-1.539 0.474
Cardiovascular diseases, n (%) 10 (20.8) 34 (18.9) 1.067 0.472-2.413 0.877
Allergy, n (%) 9 (18.8) 57 (31.7) 0.503 0.227-1.115 0.091
BMI ≥25, n (%) 26 (54.2) 91 (50.8) 1.236 0.644-2.372 0.524
Lab measurements
C3d/C3 Ratio, mean (SD) 1.51 (0.36) 1.46 (0.36) 1.568 0.544-4.522 0.406
Total cholesterol, mean (SD),mmol/l 5.61 (1.10) 5.83 (1.13) 0.855 0.625-1.169 0.327
HDL cholesterol, mean (SD), mmol/l 1.55 (0.37) 1.54 (0.38) 1.286 0.491-3.366 0.608
Triglyceride, mean (SD), mmol/l 1.61 (0.68) 1.63 (0.76) 0.953 0.606-1.498 0.834
ApoB, mean (SD), mg/l 945.6 (267.8) 961.4 (216.9) 1.000 0.998-1.001 0.746
ApoA1, mean (SD), mg/l 1723.0 (299.8) 1732.3 (310.9) 1.000 0.999-1.001 0.984
Lp(a), mean (SD), U/l 287.4 (381.4) 319.5 (374.8) 1.000 0.999-1.001 0.588
CRP, mean (SD), mg/l 5.91 (4.95) 5.27 (5.35) 1.023 0.969-1.081 0.405
Genetics*
ARMS2, rs10490924, T MAF 0.34 MAF 0.30 1.220 0.744-1.999 0.431
CFH, rs1061170, C MAF 0.64 MAF 0.41 2.405 1.503-3.847 0.25x10‐3
CFH, rs800292, A MAF 0.11 MAF 0.25 0.372 0.188-0.737 0.005 
CETP, rs3764261, A MAF 0.46 MAF 0.31 1.942 1.191-3.165 0.008 
C3, rs433594, T MAF 0.49 MAF 0.40 1.604 0.949-2.710 0.077
Imaging features 
Pigment abnormality, n (%) 41 (80.4) 46 (25.6) 12.268 5.651-26.630 2.30x10‐10
DPED, n (%) 42 (80.8) 23 (12.8) 35.434 14.697-85.430 1.93x10‐15
RPD, n (%) 10 (19.2) 8 (4.4) 4.562 1.622-12.827 0.004
HF≥10, n (%) 17 (37.8) 1 (0.6) 166.779 18.566-1498.175 0.05x10‐4
* Not all variables are shown here; variables not shown had P-values > 0.10 (Supplementary Table 1).
CI: Confidence Interval, SD: Standard Deviation, BMI: Body Mass Index, C3d/C3 ratio: Complement Activation Level 
as the ratio of C3d and C3 fragments, HDL: High-Density Lipoprotein, ApoB: Apolipoprotein B, ApoA1: Apolipoprotein 
A1, Lp(a): Lipoprotein a, CRP: C-reactive protein, DPED: Drusenoid Pigment Epithelial Detachment, RPD: Reticular 
Pseudodrusen, HF: Hyperreflective Foci 
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Table 3. Final model resulting from backward multivariable logistic regression analysis with risk factors for 
development of late AMD within follow‐up time of at least five years
Baseline Progressors
 (n=52)
Non‐Progressors 
(n=180)
Odds Ratio 95% CI P‐Value
Age, mean (SD), years 71.5 (8.3) 69.7 (5.4) 1.25 1.08-1.45 0.003
CFH, rs1061170, C MAF 0.64 MAF 0.41 7.02 2.08-23.65 0.002
CFH, rs800292, A MAF 0.11 MAF 0.25 0.07 0.01-0.64 0.019
Pigment abnormality, n (%) 41 (80.4) 46 (25.6) 11.61 2.35-57.39 0.003
DPED, n (%) 42 (80.8) 23 (12.8) 103.31 14.04-760.20 0.5x10-5
RPD, n (%) 10 (19.2) 8 (4.4) 14.68 1.06-202.92 0.045
HF ≥10, n (%) 17 (37.8) 1 (0.6) 85.1 4.002-1810.64 0.004
CI: Confidence Interval, SD: Standard Deviation, MAF: Minor Allele Frequency, DPED: Drusenoid Pigment Epithelial 
Detachment, RPD: Reticular Pseudodrusen, HF: Hyperreflective Foci
Subanalysis of patients with intermediate AMD at baseline
Since all progressors had intermediate AMD at baseline, we performed a subanalysis including 
only patients with intermediate AMD at baseline (age OR 1.26, P = 0.004; CFH rs1061170 OR 
6.12, P = 0.003; CFH rs800292 OR 0.06, P = 0.018; pigment abnormality OR 13.34, P = 0.004; 
dPED OR 56.05, P = 0.2x10-3; RPD OR 6.50, P = 0.171; presence of HF OR 61.25, P = 0.009; 
AUC=0.964 (95% CI 0.933-0.995)). Despite reduced statistical power, all features, except RPD, 
remained significantly associated with progression to advanced AMD thereby underlining 
these features have additive risk effects. 
DISCUSSION
This multicenter study comprehensively analyzed the effects of genetic, non-genetic and 
multiple phenotypic risk factors on the conversion of early to late AMD. 
In literature, progression rates of early to late AMD range from 0.5% to 76.5% (Supplementary 
Table 2).4,10,11,24-26 This vast spread can be explained by varying follow-up periods (2-15 years), 
differences in cohorts and study designs as well as definitions of progression. The most 
straightforward definition of progression is conversion to late AMD in one or both eyes: in 
our study 22.4% of patients with early or intermediate AMD at baseline progressed to CNV 
and/or GA after five years, and 37.1% with intermediate AMD at baseline converted to late 
AMD, which is similar to previously reported progression rates.10,27
To date, several studies have analyzed the combined effect of genetic, environmental, 
demographic and phenotypic factors. However, the grading of phenotypic features was 
solely based on FP.4,7-11 A multimodal approach allows for a better differentiation of specific 
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phenotypic features like HF22 and it increases the sensitivity for detection of other phenotypic 
features like RPD and atrophy.28,29 Recent studies included data from multimodal imaging or 
automatic grading systems based on SD-OCT, but in these cohorts no genetic information 
was available.12,13,15,16,24,30 To our knowledge, this is the first study to present a comprehensive 
prediction model which considers the distinctive phenotypic features based on multimodal 
imaging together with genetic, demographic and environmental risk factors on the conversion 
of early to late AMD stages. Here, a combination of both genetic and phenotypic risk factors 
showed superior performance, with an AUC of 0.978. Compared to other progression studies 
(Supplementary Table 2), this model has one of the highest AUCs. A similar AUC was provided 
by Perlee et al9 who also combined both genetic and phenotypic risk factors. The model 
based on only genetic factors in our cohort is inferior to the model including only phenotypic 
risk factors (AUC of 0.763 vs. 0.955). The high predictive value of phenotypic characteristics 
for AMD progression is in concordance with previous studies7,9 and could be very valuable in 
clinical routine.
Our final model included age, CFH rs1061170, CFH rs800292 and phenotypic risk factors (RPE 
abnormalities, dPED, RPD and HF), which are all involved in local inflammatory processes. 
Aging is a process that is associated with continuous subclinical inflammation,31 leading to 
gradual loss of RPE cells and photoreceptors.32 Age is considered as the major risk factor 
for onset and progression of AMD. Besides aging, genetic polymorphisms in genes encoding 
components of the complement system play an important role in the pathogenesis of AMD.3,33 
In concordance with previous studies, we found a strong association of CFH variants with 
disease progression.4,7,9,10 However, in contrast to previous studies,4,7,9,10 ARMS2 did not reach 
statistical significance in our study, which could be due to limited sample size or different study 
design. Likewise, systemic complement activation was not predictive for AMD progression. 
Previous work has shown that increased complement activation occurs in a subset of 
patients carrying genetic risk variants in complement-associated genes.34,35 However, due to 
our limited cohort size we were not able to perform such a subgroup analysis. Additionally, 
measuring complement activation in aqueous humor might be a more sensitive parameter.36
Chronic retinal inflammation is considered to play a major role in the formation of focal 
deposits known as drusen.37,38 Enlargement or confluence of drusen can be clinically identified 
as dPED,39 which is a known risk factor for AMD progression and presumably reflects the 
high degree of chronic retinal inflammation.16,39,40 Moreover, HF and RPD, which are highly 
associated with development of late AMD,15,16,18 are discussed as in vivo inflammation 
biomarkers of the disease.41-44 Although both RPD and HF are not pathognomonic for AMD45-
48 they are related to AMD-associated genetic variants.18,49 Given their dynamic nature, these 
features could serve as clinical marker for local inflammation.15,42,50 
Increasing AMD severity is known to be associated with higher risk of progression.4,9,11 
Nevertheless, the risk factors remained associated with conversion to late AMD when 
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applying the model performed only on patients with intermediate AMD at baseline, which 
underlines the additive risk effects of features such as HF and dPED.
It is known that several systemic markers are associated with both chronic inflammation and 
disease activity.51 However, in this study, no major influence of non-genetic risk factors on 
disease progression could be detected. Additional investigation of metabolites, proteins and 
epigenetics in future studies would be helpful to identify non-genetic risk factors for AMD 
progression.51,52
A high number of patients in this study was lost to follow-up due to nonresponse towards 
attempts to contact, other severe medical conditions or death. This is likely explained by the 
more advanced age of this group in comparison to included patients. As a consequence of 
the limited sample size of our study, we were unable to perform subanalyses for progression 
to either CNV or GA separately. Also, split-sample validation for our prediction model was not 
possible, and validation in another study is therefore a warranted next step. 
Strengths of our study include usage of multimodal imaging including FP, high-resolution 
SD-OCT and IR, providing a more detailed assessment of retinal pathologies that might be 
essential for prediction of AMD conversion. Furthermore, multimodal image analysis was 
based on a generally accepted clinical classification system and was performed by certified 
graders. Our findings have practical clinical value, as patients at high risk of progression could 
be monitored more frequently for optimal support and early detection of advanced disease 
leading to better treatment outcomes.53
In summary, we report a 5.9-year prospective follow-up study of patients with early forms 
of AMD and present a prediction model for conversion to late AMD based on multimodal 
imaging and genetics. All features in this model are considered to be involved in local 
inflammation processes, which might be the main trigger for progression to late AMD. In 
our model, patients of advanced age, carrying CFH-risk alleles, and presenting with RPE 
abnormalities, dPED, HF and RPD are highly likely to progress to late AMD. In clinical routine, 
these phenotypic features can easily be detected with non-invasive high-resolution retinal 
imaging. In cases at high risk of progression, an intensified monitoring may aid the early 
detection of conversion to late AMD.
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ABSTRACT
Importance: Rare variants in the complement factor H (CFH) gene and their association with 
age-related macular degeneration (AMD) have been described. However, there is limited 
literature on the phenotypes accompanying these rare variants. Phenotypical characteristics 
could help ophthalmologists select patients for additional genetic testing.
Objective: To describe the phenotypical characteristics of patients with AMD carrying a rare 
variant in the CFH gene.
Design, setting and participants: In this cross-sectional study, we searched the genetic 
database of the department of ophthalmology at the Radboudumc (tertiary ophthalmologic 
referral center) and the European Genetic Database for patients with AMD with a rare genetic 
variant in the CFH gene. Patient recruitment took place from March 30, 2006, to February 
18, 2013, and data were analyzed from November 30, 2015, to May 8, 2017. Phenotypical 
features on fundus photographs of both eyes of patients were graded by two independent 
reading center graders masked for carrier status.
Main Outcomes and Measures: Differences in phenotypical characteristics between rare 
variant carriers and noncarriers were analyzed using univariable generalized estimated 
equations logistic regression models accounting for intereye correlation. 
Results: Analyses included 100 eyes of 51 patients with AMD carrying a CFH variant (mean 
[SD] age, 66.7 [12.1] years; 64.7% female) and 204 eyes of 102 age-matched noncarriers 
(mean [SD] age, 67.1 [11.8] years; 54.9% female). Carrying a rare pathogenic CFH variant was 
associated with larger drusen area (odds ratio range, 6.98 [95% CI, 2.04-23.89] to 18.50 [95% 
CI, 2.19-155.99]; P = 0.002), presence of drusen with crystalline appearance (odds ratio, 3.24; 
95% CI, 1.24-8.50; P = 0.02), and drusen nasal to the optic disc (odds ratio range, 4.03 [95% 
CI, 1.70-9.56] to 7.42 [95% CI, 0.65-84.84]; P = 0.003).
Conclusions and Relevance: Identification of rare CFH variant carriers may be important 
for upcoming complement-inhibiting therapies. Patients with an extensive drusen area, 
drusen with crystalline appearance, and drusen nasal to the optic disc are more likely to 
have a rare variant in the CFH gene. However, it is not likely that carriers can be discriminated 
from noncarriers based solely on phenotypical characteristics from color fundus images. 
Therefore, ophthalmologists should consider genetic testing in patients with these phenotypic 
characteristics in combination with other patient characteristics, such as early onset, cuticular 
drusen on fluorescein angiography, and family history of AMD. 
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INTRODUCTION
Age-related macular degeneration (AMD) is a common multifactorial eye disease in 
Western countries,1 however the exact pathophysiology of the disease is not yet completely 
understood. Environmental factors, such as age and smoking,2,3 and both common and rare 
genetic variants have been identified as risk factors for AMD.4 A large number of these genetic 
variants are located in genes encoding components of the complement system. Additionally, 
higher local and systemic complement activity has been reported in patients with AMD 
compared with control individuals.5-7 Together, these findings implicate a pivotal role of the 
complement system in AMD.
Rare genetic variants located in the complement factor H (CFH) gene are among the variants 
that confer the highest risk for AMD.4,8,9 The CFH gene encodes factor H (FH), a regulator of the 
alternative pathway of the complement system. Factor H inhibits the C3-convertase (C3bBb) 
and also acts as cofactor for factor I-mediated inactivation of C3b,10 leading to decreased 
activity and thereby preventing overactivation of the complement system. Several studies 
showed lower systemic FH levels in patients carrying a rare CFH variant.10,11 Furthermore, 
functional studies have reported an altered function of FH in patients carrying a rare variant 
in CFH resulting in increased complement activation despite normal systemic FH levels.9,12,13 
While antivascular endothelial growth factor treatment is available for neovascular AMD, 
there is currently no effective treatment available for the early and atrophic stages of AMD. 
Because the complement system plays an important role in AMD pathogenesis, therapies 
targeting different components of the complement system are being developed. Currently, 
a number of phase 2/3 clinical trials are in progress, and so far two phase 2 trials have been 
completed with mixed results.9,14,15 The Complement Inhibition With Eculizumab for the 
Treatment of Non-Exudative Age-Related Macular Degeneration (COMPLETE) study did not 
show decreased atrophy progression after administration of eculizumab,16 while the MAHALO 
study showed beneficial effect of lampalizumab treatment on reducing atrophy progression.17 
With upcoming therapies targeting the complement system, it may be important to identify 
the patients who will most likely benefit from these therapies. Patients carrying a rare variant 
in the CFH gene seem to be a very suitable patient group for complement inhibiting therapies 
because of the associated functional consequences on complement activation.12 However, it 
is expensive to genetically screen every patient with AMD in a diagnostic setting; therefore, 
it is desirable to preselect cases for genotyping based on phenotype. Unfortunately, there is 
limited literature on the phenotypes accompanying these CFH variants. Previously, a higher 
burden of extramacular drusen was reported in families carrying rare CFH variants compared 
with unrelated AMD cases; however, other distinct phenotypical characteristics were not 
described.11 Another study described phenotypical characteristics in a more detailed manner, 
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but only included individuals carrying the rare p.Arg1210Cys variant in CFH.18 We hypothesize 
that all pathogenic CFH variants share phenotypical characteristics owing to their functional 
influences on FH. Detailed characterization of phenotypes caused by a broad spectrum of 
rare CFH variants is lacking. Therefore, we aim to describe the phenotypical characteristics of 
patients with AMD carrying a rare variant in the CFH gene. A distinct phenotype description 
of these CFH carriers will enable ophthalmologists to select patients for additional genetic 
testing and complement-inhibiting therapies more efficiently. 
METHODS
Study Population
In this retrospective cross-sectional study, we searched the genetic database of the 
department of ophthalmology at the Radboud university medical center, Nijmegen, the 
Netherlands (Radboudumc) and the European Genetic Database (EUGENDA), a multicenter 
database for clinical and molecular analysis of AMD, for individuals with a rare genetic variant 
in the CFH gene. Patient recruitment took place from March 30, 2006, to February 18, 2013. 
We selected AMD cases carrying protein-altering variants with a population frequency of 
less than 1%. We defined AMD as the presence of at least 10 small drusen (<63 μm) and 
pigmentary changes, intermediate or large drusen (≥63 μm), or late AMD, including subfoveal 
geographic atrophy (GA) and/or choroidal neovascularization (CNV) in at least one eye on 
color fundus images. Details of this classification are described elsewhere.19 In total, 51 
patients, with 33 different CFH variants, were identified and included in this study, hereafter 
referred to as carriers. Additionally, for each carrier, we selected from the European Genetic 
Database two similarly aged AMD cases (±2 years) without a rare genetic variant associated 
with AMD; these cases were defined as noncarriers (n = 102). For two carriers color fundus 
images of only one eye were available; therefore, final analyses included 100 eyes of 51 
carriers and 204 eyes of 102 noncarriers. All participants indicated to be of European descent. 
Written informed consent was provided by all participants. The study was approved by the 
local ethics committee on research involving human participants, Commissie Mensgebonden 
Onderzoek Regio Arnhem–Nijmegen, and the local committee of University Hospital Cologne 
and was performed in accordance with the tenets of the Declaration of Helsinki. 
Genotyping
Whole-exome sequencing (WES) and/or Sanger sequencing was previously performed. For 
both approaches, DNA was extracted from venous blood using standard procedures. 
Most CFH carriers (n = 42) were identified through WES. Preparation and sequencing of 
the DNA samples were done as previously described.12 In short, exome capture Nimblegen 
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SeqCap EZ V2 kit (Roche) paired-end sequencing was performed on an Illumina HiSeq2000 
sequencer using TruSeq V3 chemistry (Illumina) followed by downstream quality control and 
genotyping of the samples. For this study, WES data were filtered specifically for the CFH 
gene (HUGO Gene Nomenclature Committee ID: 4883; NM_000186). Additional filtering 
steps on the data were implemented to select genetic variants that result in a splice-site or 
protein change (non-synonymous) as these variants are more likely to be pathogenic. We 
focused on rare genetic variants only (minor allele frequency ≤ 1%) as based on the Exome 
Aggregation Consortium (ExAC) database, specifically the non-Finnish European population.20 
Individual variants were confirmed with Sanger sequencing using primers designed by 
Primer3 software.21 The remainder of CFH carriers (n = 9) was identified through conventional 
Sanger sequencing of the entire CFH gene as described in detail previously.22 We excluded 
rare CFH variants with a described protective effect in case-control analyses (c.2850G>T 
p.Gln950His) or a likely benign effect in functional studies (c.2669G>T p.Ser890Ile, c.2867C>T 
p.Thr956Met, c.3019G>T p.Val1007Leu).9 All CFH variants included in this study are described 
in Supplementary Table 1.
For all noncarriers, WES data were available and screened for rare genetic variants in the CFH, 
CFI, C3 and C9 genes associated with AMD. Only individuals without any rare variant in the 
CFH gene or a described pathogenic rare variant in the other AMD-associated genes9 were 
included in this study as noncarriers.
Image Assessment
Digital 35° or 40° field of view color fundus photographs centered on the fovea were performed 
with a Topcon TRC 50IX camera (Topcon Corporation) or Canon 60 UVi fundus camera 
(Canon), respectively. Color fundus photographs were analyzed for this study by two senior 
graders from an independent reading center (Moorfields Eye Hospital, London, England, UK) 
according to a standardized grading protocol. The following fundus features were assessed: 
predominant type of drusen, largest type of drusen in the central field, percentage of the 
area of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid covered with drusen, 
presence of extramacular drusen (defined as drusen outside the ETDRS grid), drusen nasal 
to the optic disc, reticular drusen, drusen with crystalline appearance, serogranular/serous 
drusen pigment epithelium detachment, pigmentary abnormalities, geographic atrophy, or 
signs of neovascularization. 
Statistical analysis
Data were analyzed from November 30, 2015 to May 8, 2017. Demographic characteristics 
of the two study groups were compared using one-way analysis of variance or the χ2 test. 
Phenotypical characteristics were individually assessed using binary logistic regression 
models. Generalized estimating equations procedures were used to correct for the fellow 
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eye. To compare the frequencies of late AMD subtypes between carriers and noncarriers, 
we performed a χ2 test based on the more severely affected eye of each patient. In case 
both geographic atrophy and choroidal neovascularization were present in an individual, it 
was classified as mixed late AMD. A phenotypic risk score for each eye was calculated as 
the sum of regression coefficients of all individual phenotypical characteristics resulting 
from univariable generalized estimating equations logistic regression analyses. A receiver 
operating characteristic curve was obtained and the area under the curve was measured for 
this risk score. Finally, symmetry between eyes was calculated as follows: number of equal 
phenotypical characteristics between right and left eye divided by the number of phenotypical 
characteristics graded times 100%. 
All statistical analyses were performed using SPSS statistics software (released 2013; IBM 
SPSS Statistics for Windows, Version 22.0; IBM Corp).
RESULTS
In total, 100 eyes of 51 carriers and 204 eyes of 102 noncarriers were included for analyses. 
Demographic and environmental characteristics were comparable between carriers and 
noncarriers (Table 1). The frequency of common genetic variants in CFH, ARMS2, and C3 
seems to be slightly higher in noncarriers compared with carriers. However, the minor allele 
frequencies of these common variants in noncarriers are comparable with the general AMD 
population.23 This may imply that carriers of rare CFH variants are less burdened by common 
AMD risk variants and that their AMD risk is rather attributable to the rare variants.
When comparing the fundus features by carrier status, the odds of carrying any rare CFH 
variant increases with increasing drusen area within the ETDRS grid (odds ratio [OR] up to 
6.85 when more than 50% of the ETDRS grid is covered with drusen, P = 0.004), and with 
the presence of serogranular/serous drusen pigment epithelium detachment (OR, 4.74; 95% 
CI, 1.30-17.31; P = 0.02). Additionally, drusen deposition in rare variant carriers is often not 
limited to the central retina; these carriers tend to have extramacular drusen (80.8%) and 
drusen nasal to the optic disc (43.8%) more frequently than noncarriers (73.4% and 35.1%, 
respectively), although these differences were not significant. The association of all assessed 
fundus features of carriers and noncarriers are shown in Table 2.
Because the carrier group contains both rare variants known to be associated with AMD and 
rare variants of unknown clinical significance, we repeated the analyses with stricter inclusion 
criteria comparing only cases carrying a known pathogenic variant (n = 25) with noncarriers 
(Table 3). Known pathogenic variants included rare CFH variants associated with AMD in case-
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Table 1. General Characteristics of the Study Groups
Characteristic Noncarriers (No. [%])
(n = 102; 204 eyes)
Carriers (No. [%])
(n = 51; 100 eyes)
Age at participation, mean (SD), y 67.1 (11.8) 66.7 (12.1)
Sex
Male 46 (45.1) 18 (35.3)
Female 56 (54.9) 33 (64.7)
Smoking status
Never 21 (22.3) 16 (39.0)
Past 53 (56.4) 17 (41.5)
Current 20 (21.3) 8 (19.5)
BMI, mean (SD) 26.1 (4.1) 26.5 (4.2)
Family history for AMD
Yes 52 (58.4) 27 (67.5)
No 37 (41.6) 13 (32.5)
Common genetic variants, 
No. of minor allels/total No. of alleles (MAF %)
ARMS2, rs10490923, T 75/176 (42.6) 17/74 (23.0)
CFH, rs1061170, C 99/176 (56.3) 29/76 (38.2)
C3, rs2230199, G 49/174 (28.2) 10/76 (13.2)
Abbreviations: ARMS2, age-related maculopathy susceptibility 2; BMI, body mass index (calculated as weight in 
kilograms divided by height in meters squared); C3, complement component 3; CFH, complement factor H; MAF, 
minor allele frequency.
control or segregation analyses or with a described functional effect. This subanalysis showed 
an even higher association between drusen area within the ETDRS grid and rare pathogenic 
CFH variant carriers (OR range, 6.98 [95% CI, 2.04-23.89] to 18.50 [95% CI, 2.19-155.99]; 
P = 0.002). Additionally, intermediate and large drusen located nasal to the optic disc (OR 
range, 4.03 [95% CI, 1.70-9.56] to 7.42 [95% CI, 0.65-84.84]; P = 0.003) and the presence 
drusen with crystalline appearance (OR, 3.24; 95% CI, 1.24-8.50; P = 0.02) were significantly 
associated with carrying a rare pathogenic CFH variant. Subanalysis of late AMD cases only 
(n = 71) showed a higher frequency of late atrophic AMD in rare pathogenic variant carriers 
(57.1%) compared with noncarriers (28.1%), although this was not significantly different (P 
= 0.12). Notably, the association between serogranular/serous drusen pigment epithelium 
detachment and carrier status did not remain significant but still tended to increase the odds 
of carrying a rare CFH variant. Examples of color fundus photographs of carriers of rare CFH 
variants with the associated fundus features are displayed in Figure 1.
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Table 2. Phenotypical Characteristics of Carriers and Noncarriers of Rare CFH Variants
Phenotypic characteristic
No. of Eyes (%)
Odds ratio 
(95% CI)a
P-valueNoncarrier 
(n = 204)
Carrier 
(n = 100)
Predominant drusen type within ETDRS grid
None or small drusen (<63 µm) 32 (15.7) 12 (12.0) Reference
0.31Intermediate drusen (63-125 µm) 107 (52.5) 45 (45.0) 1.12 (0.47-2.68)
Large drusen (>125 µm) 65 (31.9) 43 (43.0) 1.76 (0.71-4.38)
Largest drusen type within central field
None or small drusen (<63 µm) 106 (52.5) 44 (44.9) Reference
0.58Intermediate drusen (63-125 µm) 77 (38.1) 44 (44.9) 1.38 (0.75-2.52)
Large drusen (>125 µm) 19 (9.4) 10 (10.2) 1.27 (0.46-3.48)
Proportion of grid area covered by drusen, %
0-10 111 (54.4) 27 (27.3) Reference
0.004b
10-25 61 (29.9) 41 (41.4) 2.76 (1.36-5.63)
25-50 29 (14.2) 26 (26.3) 3.69 (1.58-8.58)
>50 3 (1.5) 5 (5.1) 6.85 (1.37-34.37)
Extramacular drusen
Absent 54 (26.6) 19 (19.2) Reference
0.27
Present 149 (73.4) 80 (80.8) 1.53 (0.72-3.24)
Drusen nasal to the optic disc
None or small drusen (<63 µm) 89 (65.0) 45 (56.3) Reference
0.47Intermediate drusen (63-125 µm) 46 (33.6) 32 (40.0) 1.38 (0.69-2.74)
Large drusen (>125 µm) 2 (1.5) 3 (3.8) 2.97 (0.30-29.51)
Reticular drusen
Absent 163 (86.7) 83 (93.3) Reference
0.14
Present 25 (13.3) 6 (6.7) 0.47 (0.18-1.27)
Drusen with crystalline appearance
Absent 178 (89.4) 76 (81.7) Reference
0.15
Present 21 (10.6) 17 (18.3) 1.90 (0.80-4.48)
SPED
Absent 199 (97.5) 84 (89.4) Reference
0.02
Present 5 (2.5) 10 (10.6) 4.74 (1.30-17.31)
RPE pigmentation
Absent 84 (45.4) 31 (32.3) Reference
0.08
Present 101 (54.6) 65 (67.7) 1.74 (0.93-3.27)
Geographic atrophy
Absent 154 (76.2) 65 (70.7) Reference
0.42
Present 48 (23.8) 27 (29.3) 1.33 (0.66-2.69)
Neovascular AMD
Absent 144 (72.4) 79 (82.3) Reference
0.12
Present 55 (27.6) 17 (17.7) 0.56 (0.28-1.15)
Abbreviations: AMD, age-related macular degeneration; CFH, complement factor H; ETDRS, Early Treatment Diabetic Retinopathy 
Study; RPE, retinal pigment epithelium; SPED, serogranular/serous drusen pigment epithelium detachment.
a The presented odds ratios result from univariable generalized estimating equations logistic regression analyses. 
b P-value remained significant after Bonferroni correction for multiple testing.
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Table 3. Associations of phenotypical characteristics with confirmed pathogenic rare CFH variants
No. of Eyes (%)
Phenotypic characteristic Noncarrier 
(n = 204)
Carrier 
(n = 48)
Odds ratio 
(95% CI)a
P-value
Predominant drusen type within ETDRS grid
None or small drusen (<63 µm) 32 (15.7) 4 (8.3) Reference
0.06Intermediate drusen (63-125 µm) 107 (52.5) 18 (37.5) 1.35 (0.34-5.38)
Large drusen (>125 µm) 65 (31.9) 26 (54.2) 3.20 (0.80-12.75)
Largest drusen type within central field
None or small drusen (<63 µm) 106 (52.5) 24 (50.0) Reference
0.97Intermediate drusen (63-125 µm) 77 (38.1) 19 (39.6) 1.16 (0.29-4.66)
Large drusen (>125 µm) 19 (9.4) 5 (10.4) 1.09 (0.50-2.39)
Proportion of grid area covered by drusen, %
0-10 111 (54.4) 6 (12.5) Reference
0.002b
10-25 61 (29.9) 23 (47.9) 6.98 (2.04-23.89)
25-50 29 (14.2) 16 (33.3) 10.21 (2.85-36.59)
>50 3 (1.5) 3 (6.3) 18.50 (2.19-155.99)
Extramacular drusen
Absent 54 (26.6) 6 (12.5) Reference
0.11
Present 149 (73.4) 42 (87.5) 2.54 (0.80-8.04)
Drusen nasal to the optic disc
None or small drusen (<63 µm) 89 (65.0) 12 (30.8) Reference
0.003bIntermediate drusen (63-125 µm) 46 (33.6) 25 (64.1) 4.03 (1.70-9.56)
Large drusen (>125 µm) 2 (1.5) 2 (5.1) 7.42 (0.65-84.84)
Reticular drusen
Absent 163 (86.7) 43 (93.5) Reference
0.23
Present 25 (13.3) 3 (6.5) 0.46 (0.13-1.64)
Drusen with crystalline appearance
Absent 178 (89.4) 34 (72.3) Reference
0.02
Present 21 (10.6) 13 (27.7) 3.24 (1.24-8.50)
SPED
Absent 199 (97.5) 43 (91.5) Reference
0.11
Present 5 (2.5) 4 (8.5) 3.70 (0.74-18.63)
RPE pigmentation
Absent 84 (45.4) 13 (28.3) Reference
0.10
Present 101 (54.6) 33 (71.7) 2.11 (0.87-5.14)
Geographic atrophy
Absent 154 (76.2) 28 (65.1) Reference
0.23
Present 48 (23.8) 15 (34.9) 1.72 (0.71-4.14)
Neovascular AMD
Absent 144 (72.4) 38 (82.6) Reference
0.23
Present 55 (27.6) 8 (17.4) 0.55 (0.21-1.47)
Abbreviations: AMD, age-related macular degeneration; CFH, complement factor H; ETDRS, Early Treatment Diabetic Retinopathy 
Study; RPE, retinal pigment epithelium; SPED, serogranular/serous drusen pigment epithelium detachment.
a The presented odds ratios result from univariable generalized estimating equations logistic regression analyses. 
b P-value remained significant after Bonferroni correction for multiple testing.
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Figure 1. Color fundus photographs of carriers of rare variants in the complement factor H (CFH) gene
A. A woman in her 50s (CFH c.2537A>G, p.Gln846Arg) with a symmetric appearance of extensive drusen deposition 
within the Early Treatment Diabetic Retinopathy Study grid extending beyond the inferior and superior retinal 
arcades and nasal to the optic disc in both eyes. B. A man in his 60s (CFH c.550delA, p.Ile184Leufs*33) with extensive 
bilateral drusen deposition inside and outside the Early Treatment Diabetic Retinopathy Study grid and nasal to 
the optic disc, presence of drusen with crystalline appearance, and hypopigmentations and hyperpigmentations. 
C. Woman in her 70s (CFH c.524G>A, p.Arg175Gln) with primary geographic atrophy surrounded by predominantly 
large drusen, some with crystalline appearance, beyond the retinal arcades and the optic disc. D. A man in his 
40s (CFH c.1198C>A, p.Gln400Lys) with hyperpigmentations and mainly centrally located large soft drusen but also 
extending to the peripheral retina.
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Overall, rare CFH variant carriers tend to have more and larger drusen, and drusen are 
more often located outside the ETDRS grid. However, not all of these analyzed phenotypical 
characteristics individually reach statistical significance. Based on the findings in Table 
3, we calculated a phenotypic risk score for each eye including all assessed phenotypical 
characteristics (Supplementary Figure 1). The mean (SD) phenotypic risk score in carriers 
(4.35 [2.0]) was significantly higher compared with noncarriers (2.32 [2.5]), although the 
ability to accurately discriminate between eyes of carriers of pathogenic CFH variants and 
noncarriers based on the phenotypic risk score was limited (area under the curve, 0.75; 95% 
CI, 0.65-0.85; Supplementary Figure 2). Similar results were obtained when including only the 
highest phenotypic risk score for each patient (area under the curve, 0.75; 95% CI, 0.61-0.88). 
Finally, for every patient, the grade of symmetry between eyes was determined based on 
the number of equal characteristics. Each study group showed a high grade of symmetry 
between the eyes (79.9% in noncarriers vs 79.1% in carriers of pathogenic variants) and the 
groups were not significantly different (P = 0.85).
DISCUSSION
In this study, we aimed to describe the phenotypical characteristics of patients with AMD 
carrying a rare variant in the CFH gene. Overall, rare CFH variant carriers have a more severe 
phenotype with more and larger drusen, often extending to the peripheral retina. Larger 
drusen area within the ETDRS grid and drusen located nasal to the optic disc were significantly 
associated with patients with AMD carrying a rare pathogenic CFH variant. These findings are 
in line with previous studies reporting extensive macular drusen accumulation and presence 
of extramacular drusen in patients with AMD carrying the CFH p.Arg1210Cys variant18 and 
other rare CFH variants.11 
In addition, we report an association between the presence of drusen with crystalline 
appearance and carrying a rare variant in CFH. Drusen with crystalline appearance, also 
known as refractile or calcified drusen, have a characteristic glistening appearance on color 
fundus imaging and have been associated with the development of geographic atrophy.24,25 
Thus, these patients might be at higher risk for developing geographic atrophy compared 
with noncarriers. In the current study, rare CFH variant carriers seem to develop geographic 
atrophy more often than choroidal neovascularization, as was already observed in rare variant 
carriers of other complement genes (CFI, C3, and C9).26 However, probably owing to the small 
number of patients with late AMD, this difference was not significant. 
From literature, it is known that CFH carriers usually have an earlier age at onset.8,11,13,22,26,27 
Owing to our study design a lower age at onset in rare variant carriers could not be analyzed. 
Our study was merely designed to analyze phenotypical differences between rare CFH carriers 
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and noncarriers; therefore, age-matched noncarriers were selected. As a consequence, no 
difference in age at onset could be observed. However, assessing the age at onset remains 
an important clue for ophthalmologists when considering (rare) genetic variants in a patient. 
Familial burden is also known to be associated with rare CFH variant carriers.11,13,18,26,28 
Although the number of carriers with a family history of AMD (64.7%) was not significantly 
different from noncarriers (53.9%), it must be emphasized that family history was obtained 
through interviewer-assisted questionnaires. From previous studies, it is known that CFH 
carriers often have asymptomatic family members29,30 and, therefore, it is plausible that the 
percentage of carriers with a family history of AMD is underestimated.
Assuming that rare protein-altering variants located in the CFH gene lead to similar phenotype, 
this study was not restricted to one or more specific CFH variants but included a wide variety 
of rare protein-altering CFH variants identified by WES or Sanger sequencing in our cohort. 
Therefore, our analyses also included some variants that were not described before in the 
literature. However, when limiting the analyses to confirmed pathogenic variants only, 
the associations between rare variant carriers and phenotypical characteristics become 
more pronounced. More information on pathogenicity of variants is therefore desirable. 
As prediction tools do not always correctly predict a genetic variant to be functionally 
impaired,31,32 other large sequencing or functional studies are needed to confirm the clinical 
significance of these variants. 
Limitations
Because of an overlap in phenotypical characteristics between carriers and noncarriers, even 
when including only confirmed pathogenic variants, the sample size of our study might be 
insufficient to detect small to moderate associations or associations with relatively infrequent 
features, such as serogranular/serous drusen pigment epithelium detachment and the 
presence of geographic atrophy. Additionally, when correcting for multiple comparisons, only 
drusen area remained significantly associated with rare variant carriers, which is most likely 
the result of our small sample size. 
Our study was also restricted by its retrospective design, therefore, for the analyses, we were 
limited to the images that were captured in the past. Peripheral fundus images and other 
image modalities were often lacking and therefore not taken into account in the current 
study. To assess to what extent drusen are located outside the central retina, imaging 
should preferably be extended to the peripheral retina. Additionally, certain phenotypical 
characteristics are better visualized with other imaging techniques (eg, cuticular drusen). 
Previously, CFH variants were identified in patients with the cuticular drusen subtype of 
AMD, and fluorescein angiography is considered the best modality to diagnose these type 
of drusen.22,29,30 Furthermore, optical coherence tomography enables detailed visualization 
of the different retinal layer structures that are not visible on color fundus images, and has 
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the advantage of three-dimensional image assessment. Future prospective studies could 
therefore benefit from assessing multiple image modalities and imaging of the peripheral 
retina. 
CONCLUSION 
Because patients with AMD carrying a rare CFH variant seem a very suitable group for 
upcoming complement-inhibiting therapies, identification of this subpopulation may be very 
important to direct choice of treatment. Our results indicate that patients with an extensive 
drusen area, drusen with crystalline appearance, and drusen nasal to the optic disc are more 
likely to have a rare genetic variant in the CFH gene. These phenotypical characteristics could 
aid ophthalmologists to select patients for genetic screening. However, it is unlikely that 
carriers can be discriminated from noncarriers based solely on phenotypical characteristics. 
Therefore, ophthalmologists should consider genetic testing in patients with extensive 
drusen deposition, drusen with crystalline appearance and/or drusen nasal to the optic disc 
in combination with other patient characteristics, such as an early age at onset, cuticular 
drusen on fluorescein angiography, and a positive family history for AMD. 
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Supplementary Figure 1. Distribution of Phenotypic Risk Scores in Eyes of Rare Pathogenic CFH Variant Carriers 
(green) and Noncarriers (blue)
The x-axis represents the phenotypic risk score and the y-axis frequency as percentages within each study group. 
Supplementary Figure 2. Receiver Operating Characteristic Curve of the Phenotypic Risk Score
The optimal cut-off for this phenotypic risk score is 3 with a sensitivity of 0.86 and specificity of 0.63. 
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ABSTRACT
Biomarkers can help unravel mechanisms of disease and identify new targets for therapy. 
They can also be useful in clinical practice for monitoring disease progression, evaluation of 
treatment efficacy and risk assessment in multifactorial diseases, such as age-related macular 
degeneration (AMD). AMD is a highly prevalent progressive retinal disorder for which 
multiple genetic and environmental risk factors have been described, but the exact etiology 
is not yet fully understood. Many compounds have been evaluated for their association with 
AMD. We performed an extensive literature review of all compounds measured in serum, 
plasma, vitreous, aqueous humor and urine of AMD patients. Over 3600 articles were 
screened resulting in more than 100 different compounds analyzed in AMD studies, involved 
in neovascularization, immunity, lipid metabolism, extracellular matrix, oxidative stress, diet, 
hormones, and comorbidities (such as kidney disease). For each compound we provide a short 
description of its function and discuss the results of the studies in relation to its usefulness 
as AMD biomarker. Additionally, biomarkers identified by hypothesis-free techniques, 
including metabolomics, proteomics and epigenomics, are covered. In summary, compounds 
belonging to the oxidative stress pathway, the complement system, and lipid metabolism are 
the most promising biomarker candidates for AMD. We hope that this comprehensive survey 
of the literature on systemic and ocular fluid compounds as potential biomarkers in AMD will 
provide a stepping stone for future research and possible implementation in clinical practice.
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1. INTRODUCTION
The term biomarker refers to an objective, measurable characteristic that is indicative of 
a biological process (normal, pathogenic, or in response to treatment).1 Biomarkers can 
help unravel mechanisms of disease and identify (new) targets for treatment. The potential 
benefit of biomarkers in drug development is to allow earlier, more robust drug safety 
and efficacy measurements.2 Additionally, biomarkers can be useful in clinical practice for 
detecting disease, monitoring disease progression, evaluation of treatment efficacy, and risk 
assessment. Biomarker testing is an important step towards personalized medicine in many 
diseases, such as cancer,3 but also in age-related macular degeneration (AMD). 
AMD is the leading cause of irreversible loss of vision among the elderly in the Western 
world, and the prevalence of AMD is expected to increase with population ageing.4 
The early stage of AMD is characterized by subretinal yellowish deposits, known as drusen, 
and changes in macular pigmentation.5,6 At this stage patients usually express little or no 
complaints. As AMD progresses, central vision becomes increasingly blurred, resulting in 
irreversible vision loss in the advanced stages of the disease. Two subtypes of advanced 
AMD can be distinguished: geographic atrophy (GA) and neovascular AMD (nAMD).5,6 The 
atrophic form of AMD is characterized by cell death of the retinal pigment epithelium (RPE) 
and photoreceptors causing gradual vision loss.7 Neovascular AMD, also referred to as “wet” 
or “exudative” AMD, is characterized by abnormal vessel growth into the retina from the 
choroid (choroidal neovascularization [CNV]). Leakage from these fragile neovascularizations 
can cause rapid loss of vision.8 In this review, we will use the following terms for the different 
AMD subgroups described in literature: any AMD, early AMD, advanced AMD (geographic 
atrophy/neovascular/any advanced), and dry AMD (For definitions of these terms, see Table 
1). 
AMD is a multifactorial disease, and many risk factors for the development of AMD have 
been described. The most commonly reported environmental risk factors include aging, 
smoking, family history, low dietary intake of antioxidants and omega-3 fatty acids, and 
reduced physical activity.9-11 Also, multiple genetic risk factors have been identified, consisting 
of genetic variants that are either common or rare in the population. A large risk effect has 
been reported for genetic variants located at the CFH and ARMS2/HTRA1 loci.12 Most genes 
associated with AMD can be clustered into five main pathways: the complement pathway, 
lipid transport, extracellular matrix remodeling, angiogenesis and cell survival.13 Despite 
considerable progress in understanding the genetic architecture of AMD, the exact disease 
etiology is not yet fully understood. 
In attempts to unravel the etiology of AMD, to improve patient stratification, to monitor 
disease progression and to discover new drug targets, many biomarker studies have been 
performed. In general, new analytical strategies have emerged, moving from single markers 
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towards complex biomarker signatures, increasing the chance for greater specificity and a 
higher diagnostic or predictive value. 
There has been no comprehensive overview of all potential biomarkers and their applicability 
in AMD. Here, we present a detailed summary of the current literature on molecular 
compounds reported as analysed in serum, plasma, aqueous humor, vitreous and urine of 
AMD patients. The scope of this review is limited to non-genetic chemical compounds. For 
all compounds, a short description of their function is provided and the results of the studies 
are summarized and discussed in relation to AMD. Currently, most of these markers are not 
yet established as routine clinical diagnostic tools and are discussed here in order to direct 
future research and eventually clinical implementation. A complete overview of the studies 
and references is provided in Supplementary Table 1.
Table 1. Explanation of terms used in this review to describe different types of AMD
Type of AMD Criteria
Any AMD No specific definition of AMD reported, or
Analyses were performed on all AMD stages together
Early AMD Analyses were performed on AMD cases in absence of advanced stage disease (GA 
or CNV) and can include early and/or intermediate AMD
Advanced: GA Geographic atrophy of the RPE secondary to AMD
Advanced: neovascular Choroidal neovascular lesion (active or occult) secondary to AMD, including serous 
and/or hemorrhagic RPE detachment, subretinal fibrovascular tissue and scarring
Any advanced AMD No specific definition of advanced AMD reported, or
Analyses were performed on both advanced AMD stages (GA and CNV) together
Dry AMD No specific definition of dry AMD reported, or 
Analyses were performed on AMD cases in absence of advanced neovascular AMD 
(can therefore include early AMD and/or advanced: GA)
2. NEOVASCULARIZATION AND HEMOSTASIS
Since choroidal neovascularization is one of the subtypes of advanced AMD, it is not 
surprising that factors involved in neovascularization and hemostasis have been extensively 
studied. The results of the studies describing these factors are described in section 2.1 and 
2.2, respectively.
2.1 Neovascularization
2.1.1 Vascular endothelial growth factor & Soluble VEGF receptor 1
Vascular endothelial growth factor (VEGF) is currently the most important target in the 
treatment of nAMD, and the expression profile of VEGF has been extensively investigated 
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in AMD patients. VEGF acts as a hypoxia-driven local signal to induce the formation of new 
blood vessels. Treatments inhibiting its function can partially restore and/or maintain vision 
in nAMD patients. 
Contrary to expectation, VEGF is not consistently upregulated in AMD patients across 
studies. One study showed that VEGF levels in the aqueous humor of 12 nAMD patients 
were highly elevated (668.9 pg/ml) compared to 10 controls (cataract patients; 108.3 pg/
ml).14 In a second study involving aqueous humor, however, significant higher VEGF levels 
could only be demonstrated in the most aggressive form of nAMD (type 3 neovascularization) 
compared to controls.15 A third study did not report a difference in VEGF levels in aqueous 
humor between nAMD and controls at all.16 Of note, a considerable range in VEGF levels in 
aqueous humor exists among these studies. In the study by Tong et al,14 the levels of VEGF in 
control individuals were around 100 pg/ml, whereas the VEGF levels in the two other studies 
were much lower in controls (39.5 pg/ml and 63.9 pg/ml respectively).15,16 These differences 
may be explained by the use of three different analytical systems, emphasizing the need 
for standardized assay systems for key marker compounds in eye fluids. Additionally, studies 
analyzing VEGF levels in vitreous samples did not detect differences between VEGF levels of 
nAMD cases and controls.17,18 
Even though the measurement of VEGF levels in vitreous or aqueous humor is expected to 
best reflect VEGF levels in the macula, the procedure is invasive and therefore not desirable in 
individuals with early or intermediate AMD. Thus, for purposes of a clinical tool for diagnosis 
and progression, measurement of VEGF levels in more accessible body fluids such as serum or 
plasma is preferable. Several studies did investigate VEGF levels in AMD patients and controls 
in serum or plasma, with mixed results. Four studies detected significantly upregulated levels 
of VEGF in serum or plasma,19-22 but these findings are contrasted with 10 other studies that 
reported no association.23-32 
VEGF signaling is mediated through a complex of receptors and co-receptors, of which the 
soluble form of VEGF receptor 1 (sVEGFR1) has been investigated in a number of studies. As in 
the case of VEGF, these studies do not offer a clear direction of effect. One study investigated 
the levels of sVEGFR1 in vitreous and found that levels were higher in nAMD patients.18 In 
contrast, two studies performed on serum could not corroborate these findings. One of the 
studies did not find any association,33 the other even reported lower levels of sVEGFR1 in 
nAMD.34 
2.1.2 Pigment epithelium derived factor 
Pigment epithelium derived factor (PEDF) is produced by RPE cells and has anti-angiogenic 
properties, opposing the effects of VEGF. It has been proposed as a target to inhibit 
choroidal neovascularization and its expression signature in model systems suggests that 
it is downregulated under hypoxic conditions.35 Two studies on vitreous support this by 
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demonstrating a marked reduction in PEDF levels in AMD patients versus controls.17,18 One 
study analyzing aqueous humor showed the opposite result, an increase of PEDF levels in AMD 
patients.14 These conflicting results are not readily explained. It is possible that in different 
fluids or in different parts of the eye (anterior/posterior) PEDF is regulated differently, but 
additional experiments are needed to determine the direction of the effect with certainty.
2.1.3 Transforming growth factor beta
Transforming growth factor beta (TGF-β) has been described to increase the expression 
of VEGF and is therefore also implicated in neovascularization.36 In vitreous samples of 
nAMD patients, TGF-β was significantly elevated when compared to controls (patients with 
idiopathic macular holes).36 An earlier study had already demonstrated that urinary TGF-β 
levels were increased in cases compared to controls, but only in early AMD the difference 
was significant.37 
2.2 Hemostatic system
2.2.1 Fibrinogen
Fibrinogen is a hemorheological factor involved in endothelial functioning.38 Abnormalities in 
this factor are linked to thrombogenesis and vascular disorders,39 hence fibrinogen has been 
examined for its potential involvement in AMD. Studies have yielded mixed results. A number 
showed that increased fibrinogen level is a significant risk factor,21,40-43 while others did not 
find evidence for an association.44-52 
2.2.2 Plasminogen activator inhibitor 1 (PAI-1)
Plasminogen activator inhibitor 1 (PAI-1) is another main component of the fibrinolytic 
system.53 Four studies have investigated whether a relation between PAI-1 and AMD 
exists, with some support for a positive association,52 while other studies did not find any 
association.48,51,54
2.2.3 Platelet count
Several studies have measured platelet count. Most did not find any association between 
platelet counts and AMD.21,45,55-57 Two larger studies did find lower platelet counts in AMD, but 
this minimally protective effect for platelets on the development of AMD was only significant 
in univariate analyses.58,59 
2.2.4 Von Willebrand factor
Von Willebrand factor (VWF) is a blood glycoprotein that is essential for normal hemostasis.60 
Since vascular pathology is hypothesized to be involved in the pathogenesis of AMD, VWF was 
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investigated as a possible risk factor. One study showed higher levels compared to controls 
(but in multivariate analysis no significant correlation was found),21 and three more studies 
found no association at all.48,51,52
In summary, many inconsistent results for factors involved in neovascularization have been 
reported and further work is required to determine whether these could be used as AMD 
biomarkers. Factors involved in hemostasis described in section 2.2 are unlikely to serve as 
biomarkers for AMD. 
3. OXIDATIVE STRESS
The human body is dependent on an aerobic environment for survival. This constant exposure 
to oxygen can lead to detrimental oxidative modifications of cell components and tissues. 
Usually, cells are equipped with sufficient antioxidative mechanisms to maintain oxidant 
homeostasis, but if this balance is disrupted, oxidative stress occurs.61 Oxidative stress in cells 
and tissues is characterized by an excess in molecules containing free radicals such as reactive 
oxygen species (ROS) and reactive nitrogen species (RNS). 
Polyunsaturated fatty acid (PUFA) molecules are present in lipids on the membranes of cells 
and are prone to oxidation due to the presence of susceptible double carbon bonds.61,62 
During the process of lipid peroxidation by ROS, the double carbon bond is oxidized, leading 
to the formation of unstable reactive carbonyl compounds (e.g. malondialdehyde).63-66 ROS 
can also oxidize proteins, resulting in 2-(ω-carboxyethyl) pyrrole (CEP) protein adducts67 and 
induce formation of advanced glycosylation end products (e.g. Nε-carboxymethyllysine).68,69
Increased oxidative stress is thought to be one of the underlying factors in the occurrence 
of AMD.61-63,70-72 The eye, and especially the macula, is susceptible to oxidative stress 
because of its high metabolic activity and the high PUFA content in the membranes of the 
photoreceptors.61 High oxygen pressure from the blood in the choroid and exposure to bright 
light also cause increased ROS levels in the retina.64,65,71 In addition, photoreceptors are 
subjected to constant shedding, and subsequent phagocytosis of the shed fragments leads to 
ROS generation.61,72 Environmental factors such as smoking and alcohol consumption can also 
increase ROS production.73 Therefore, factors related to oxidative stress could potentially be 
valuable biomarkers for the incidence and/or progression of AMD and are discussed in more 
detail in the sections 3.1 to 3.4. A schematic overview of these oxidative stress related factors 
is provided in figure 1 and a complete overview of the studies and references is provided in 
Supplementary Table 2.
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3.1 Oxidation products
3.1.1 Malondialdehyde (MDA)
Malondialdehyde (MDA) is one of the reactive carbonyl compounds originating from PUFA 
oxidation, and its presence is often used to measure lipid peroxidation levels in blood or 
serum samples.63,64,74 Increased systemic levels of MDA have been consistently observed 
in both wet and dry AMD.63-65,72-79 Additionally, an allele-dependent increase of MDA levels 
was measured in subjects carrying the A69S variant (rs10490924) in the ARMS2 gene that is 
associated with AMD. Patients heterozygous or homozygous for the risk allele showed higher 
MDA levels.65 
Figure 1. Networks of oxidative stress in age relatedmacular degeneration (AMD)
Spheres are colored to indicate levels in AMD patients compared to controls based on literature: upregulated (green), 
downregulated (blue), or inconsistent levels (gray). In this figure, studies reporting no association were not taken into 
account for the sake of readability. Abbreviations: Apo, apolipoprotein; CEP, 2-(u-carboxyethyl) carboxyethylpyrrole; 
DHA, docosahexaenoic acid; GSH, glutathione; GSHP, glutathione peroxidase; GSHR, glutathione reductase; HCTL, 
homocysteine thiolactone; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDA, malondialdehyde; MS, 
methionine synthase; Ox, oxidized; PON1, paraoxonase 1; PUFA, polyunsaturated fatty acid; RNS, reactive nitrogen 
species; ROS, reactive oxygen species; SOD, superoxide dismutase; Vit, vitamin.
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MDA is a highly reactive molecule that forms covalent bonds with the amino acids 
of endogenous proteins. This MDA modification can be recognized by factors of the 
innate immune system such as complement factor H (FH), immunoglobulin M (IgM) and 
macrophages.66,80,81 Binding of MDA by IgM or macrophages leads to a pro-inflammatory 
response by increasing the expression of the inflammation factor IL-8,81,82 whereas binding to 
FH attenuates inflammation.81 
3.1.2 2-(ω-Carboxyethyl) pyrrole (CEP) adducts and N(6)-carboxymethyllysine (CML) 
Docosahexaenoic acid (DHA) accounts for about 80% of all PUFAs in the photoreceptor outer 
segments, and is most prone to oxidation in human tissues.83 Upon oxidative stress DHA 
is oxidized forming specific CEP-adducts.67 Plasma CEP levels in AMD patients are elevated 
compared to controls.84-86 Moreover, elevated CEP levels combined with AMD risk alleles in 
ARMS2, HTRA1, CFH, or C3 increased the risk of AMD two- to threefold compared to genotype 
alone.84 
Furthermore, plasma of AMD patients contained more and a higher diversity of CEP 
autoantibodies compared to controls in two studies from the same group.67,84 Another 
independent study found no association between CEP autoantibodies and AMD.85
N(6)-carboxymethyllysine (CML) is an advanced glycation end product that originates from 
a protein lysine modification, is a major immunological epitope recognized by the immune 
system.68 Plasma CML levels were upregulated in AMD in one study,85 but no significant 
difference was found in another.69 
Both CEP adducts and CML are present on proteins. They are recognized by the immune 
system68,87 and can stimulate angiogenesis in vivo.88,89 Receptor-mediated binding of 
CEP adducts results in an angiogenic response of endothelial cells independent of VEGF 
signaling.87 Upregulation of CML and CEP levels in AMD might be implicated in the progression 
towards nAMD by promoting angiogenesis, but further studies are necessary to support this 
hypothesis. 
3.1.3 Protein Carbonyl Groups (PCG) and total oxidation status
Levels of protein carbonyl groups (PCG) are often used to assess the total protein oxidation 
status in subjects as they are easy to measure.90 Protein carbonyl groups consist of an 
oxygen molecule bound to a carbon atom with a double bond (-RC=O) resulting from protein 
oxidation and are therefore indicative of oxidative stress. Elevated levels of both PCG78,91 and 
total oxidation status78,92 were found in nAMD patients.
3.1.4. Oxidized low density lipoprotein (Ox-LDL)
Low-density lipoprotein (LDL) is abundantly present in and around cells and is an easy target 
for oxidation by ROS. LDL-cholesterol has been studied extensively in the context of AMD, 
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described in section 5.2; however, studies on its oxidized form (Ox-LDL) are more limited. 
Higher Ox-LDL levels were found systemically in AMD patients compared to controls,93-95 but 
a lack of association has also been reported.96
Increased Ox-LDL levels are known to activate various factors of the complement system 
such as C3b, C5b-9 and complement factor B.97 These factors are described in more detail 
in section 4.1. High Ox-LDL levels as observed in AMD might initiate apoptosis of RPE cells 
through disruption of the mitochondrial pro-(Bax) and anti-apoptotic (Bcl2) balance,98 leading 
to GA. Additionally, uptake of Ox-LDL molecules by macrophages contributes to the formation 
of foam cells, implicated in the development of atherosclerotic plaques.99
3.2 Nitric oxide
Nitric oxide (NO) is one of the most abundant free radicals in the human body and is able 
to react with other ROS resulting in cell dysfunction and apoptosis.75 It is synthesized by 
endothelial cells and is an important vasoactive agent affecting blood flow and other vascular 
functions.100 Involvement of NO in AMD is less clear. One study observed increased levels of 
NO in AMD patients,75 another study described downregulation of NO in nAMD,74 and a third 
study reported no association.22
3.3 Homocysteine
Homocysteine is an intermediate molecule in the conversion of the amino acid methionine 
to cysteine and glutathione, a process mediated by multiple enzymes.101,102 Homocysteine 
can auto-oxidize in plasma, leading to the formation of various reactive products such as 
homocysteine thiolactone (HCTL), which is also accompanied by ROS generation (Figure 1).103 
Dysregulation of the homocysteine balance has been associated with various diseases such 
as vascular dysfunction, autoimmune diseases and neurodegenerative disorders.102 Increased 
systemic levels of homocysteine were observed in both neovascular and dry forms of AMD 
compared to controls,63,94,95,103-111 and there were also higher levels in the vitreous of nAMD 
patients.108 Moreover, some studies found higher homocysteine levels in nAMD compared 
to dry AMD.104,105 However, other studies did not find an association between homocysteine 
levels and AMD.47,51,52,112-114 
3.4 Antioxidants
Antioxidants enhance ROS clearance and prevent ROS formation thereby averting damage 
in the aging eye and other tissues.71 Enzymes such as catalase, superoxide dismutase and 
paraoxonase prevent the accumulation of oxidized lipids by converting ROS before they 
can react, or by removing the oxidized products from the endogenous proteins.71 Several 
vitamins and trace elements act as co-factors for these enzymes, or react with ROS to prevent 
accumulation.66,72
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Multiple studies hypothesized that the antioxidant capacity in AMD patients might be impaired, 
and some showed a decreased overall antioxidant capacity in serum of patients.44,77,78,91,115,116 
In the next sections, we discuss levels of thiols (section 3.4.1), carotenoids (section and 3.4.2) 
and enzymes with antioxidant activity (section 3.4.3) in AMD patients.
3.4.1 Thiols and glutathione 
Thiols mediate an important part of the balance between proper oxidation versus antioxidants 
in tissues. Their main characteristic is a carbon-bonded sulfhydryl group (C-SH), which can 
form a disulfide bridge with other thiols via redox reactions (C-S-S-C). Thiols can neutralize 
ROS by providing an electron during the formation of the disulfide bridge.117 Although their 
normal function is to prevent oxidative stress, thiols can also promote oxidative stress in the 
presence of metal ions such as iron.94
Thiol content is either measured by focusing on the individual thiols or by evaluating total 
thiol (tSH) content of the blood. Glutathione (GSH) is one of the most important thiols in the 
body. GSH can be transformed into glutathione disulfide (GSSG) by the enzyme glutathione 
peroxidase (GSHP), thereby breaking down hydrogen peroxide (2 GSH + H
2
O
2 
 GS-SG + 2 
H
2
O).117 Glutathione reductase (GSHR) is able to transform the formed glutathione disulfide 
to its monomeric form (GS-SG + NADPH + H+  2 GSH + NADP+), making it available for 
conversion by GSHP again.117 This circular process (Figure 1) is of vital importance for proper 
ROS maintenance. 
Lower levels of GSH and tSH are thought to result in more ROS formation owing to absence of 
hydrogen peroxide clearance, resulting in subsequent oxidative damage.71,103 Lower levels of 
total thiol content92,94,103 and plasma GSH94,103 were found in patients with AMD compared to 
control subjects, and both were negatively correlated with homocysteine levels;103 however, 
multiple studies have found no association between systemic GSH levels and AMD.79,118-121
Plasma and serum GSHR levels were lowered in patients with AMD,44,91,122 although one 
study did not find this association in erythrocytes.123 Systemic GSHP levels were lowered in 
some studies73,116,124,125 and higher in one study,126 but in most studies no association was 
found.44,79,91,122,123
3.4.2 Carotenoids
Carotenoids are a group of natural red and yellow hued pigments (carotenes and xanthophylls) 
synthesized in most plants. The antioxidant capacity of carotenoids is based on their ability to 
absorb and process free electrons from ROS such as singlet oxygen (1O
2
) and peroxyl radicals 
(ROO•). After the uptake of an electron the carotenoid releases its energy in the form of heat, 
and can be used again. Humans are unable to synthesize carotenoids, and rely on dietary 
intake of vegetables.127,128 In AMD, total serum carotenoid levels were decreased in two 
studies by the same group,41,115 while two other studies described a lack of association.129,130
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Two main xanthophylls are located in the macula: lutein is concentrated in the peripheral 
macula and zeaxanthin in the fovea. Here they are able to attenuate blue-light wavelengths, 
preventing the light from reaching and damaging the underlying photoreceptors.131 In blood, 
lutein and zeaxanthin are transported by lipoproteins such as HDL and LDL. Zeaxanthin and 
lutein exert their antioxidant abilities by reacting with free radicals both in the macula and 
in blood.131 Levels of lutein and zeaxanthin were found to be decreased in AMD patients in 
several studies.115,132,133 One study described decreased levels of zeaxanthin but not lutein in 
AMD patients.134 Others found no association for either lutein or zeaxanthin.129,130,135-137
β-cryptoxanthin is a carotenoid most commonly found in citrus fruits. Besides its role as an 
antioxidant, in vitro experiments have shown that β-cryptoxanthin also stimulates DNA repair 
mechanisms.138 Levels of β-cryptoxanthin were decreased in patients with advanced AMD in 
some studies,115,130,133,136 while others did not find a significant association with AMD.129,132,135,137
A decrease of α-carotene was found in patients with nAMD,115,133 whereas higher levels of 
α-carotene were present in early AMD.133 Also β-carotene levels were decreased in advanced 
AMD in some studies;115,133,136 however, most studies did not find a significant association 
between AMD and α-carotene or β-carotene levels.129,130,132,135-137,139,140 Importantly, 
supplementation of β-carotene has been associated with an increased risk of lung cancer in 
smokers and former smokers, and therefore long-term use to inhibit AMD progression is not 
recommended.141,142
Finally, one of the most potent antioxidants present in blood is lycopene. The main dietary 
sources of this red pigment carotenoid are red fruits or vegetables, such as tomatoes.143 
Levels of lycopene were either decreased in AMD patients129,130,133 or not associated with 
AMD.115,132,135-137
In summary, when studies reported a significant association between carotenoids and AMD, 
the vast majority described decreased carotenoid levels in patients. This probably reflects a 
difference in dietary intake of these carotenoids between AMD patients and controls. Several 
reported that a higher intake of carotenoids is associated with a reduced risk of AMD.144-146 
Additionally, a beneficial effect was shown for supplementation with lutein and zeaxantin on 
progression to advanced AMD.147-149 
3.4.3 Enzymes
Superoxide dismutase (SOD)
Superoxide dismutase (SOD) is an important antioxidant that catalyzes the conversion of 
superoxide (O
2
•-) into oxygen and hydrogen peroxide (H
2
O
2
).71 Two families of SOD exist based 
on their metal ion cofactor: SOD1 (CuZnSOD), which is localized to the cytoplasm and SOD2 
(MnSOD), found in mitochondria.71 Absence of SOD1 or SOD2 has been associated with early 
retinal cell degeneration in mice,150,151 suggesting an important role for SOD in the eye. 
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With regard to AMD, several reports show elevated systemic SOD activity in AMD patients 
compared to controls,76,77,152,153 others found lowered SOD activity levels,73,75,79,91,125 and still 
others measured no significant association.44,116,122,123,126 One study showed a significant 
difference in SOD activity between late and early AMD, with a lower SOD activity in late AMD 
patients.75
The association of both low and high SOD serum activity levels with AMD might be explained 
by the damaging effects of both high and low levels of SOD. High levels of SOD lead to higher 
H
2
O
2
 production, whereas low SOD activity leads to the continuing presence of O
2
•- molecules. 
The detrimental effects of both low SOD and high SOD activity on ROS production suggest 
that imbalance of the enzyme activity leads to pathological conditions and that proper SOD 
balance is important to maintain homeostasis.
Paraoxonase 1 (PON1)
Paraoxonase 1 (PON1) is bound to high-density lipoprotein (HDL). PON1 hydrolyzes 
organophosphates and lipid peroxides, and inhibits the oxidation of LDL.63,95 Additionally, 
PON1 is able to detoxify HCTL, one of the highly reactive metabolites of homocysteine.95 
Active PON1 interacts with oxidized proteins or lipids, leading to its own inactivation.63 The 
low serum PON1 activity levels observed in AMD patients63,64,92 could be due to inactivation 
of PON1 after reacting with oxidized proteins. 
Catalase
Catalases are important in ROS clearance by converting hydrogen peroxide (H
2
O
2
) to oxygen 
and water.154 In AMD, three studies reported downregulated systemic catalase activity 
levels,72,73,125 while three others reported no difference in catalase activity levels between 
AMD patients and controls.75,116,123
Taken together, dysregulation of the oxidative stress pathway and the manner in which 
oxidative stress is managed by the body seems to play an important role in AMD. A large 
number of investigators have reported decreased levels of antioxidants and elevated oxidized 
protein or lipid levels (Figure 1). The most promising biomarker candidates in the oxidative 
stress pathway are MDA and homocysteine, which were consistently reported to be increased 
in AMD patients. For other factors, however, the reported associations were less clear and 
with mixed results. This could indicate that an imbalance of the entire oxidative stress system 
may play a role, rather than levels of individual factors of this system specifically. 
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4. IMMUNITY
The involvement of the immune system in the pathology of AMD is widely accepted, and 
some suggest reframing AMD as an auto-immune disease.155 The activity of the immune 
system in AMD, both innate and adaptive, has been implicated at several levels. Immune cell 
infiltrates have been shown in the retinas of AMD patients examined post-mortem,156 with 
evidence of cytokine/chemokine expression at the affected site, as described in more detail 
in section 4.2. 
Strong evidence for the involvement of the immune system in AMD also comes several 
GWAS studies (described in section 1).12,157 In particular, the role of the complement system is 
apparent. In the next sections, we discuss immunity-related compounds, including systemic 
markers of the complement system (section 4.1), and elements of adaptive and innate 
immunity (sections 4.2-4.4). A complete overview of the studies and references is provided 
in Supplementary Table 3.
4.1 The complement system
The complement system is an integral part of innate immunity with essential roles in protection 
against foreign intruders via tissue inflammation, cell opsonization, and cytolysis. It is also 
involved in monitoring and maintaining host tissues by clearing cellular debris, maintaining 
cellular integrity, tissue homeostasis, and modifying the adaptive immune responses.158 
Ever since histopathological studies demonstrated the presence of complement components 
in drusen,159,160 the involvement of the complement system in AMD has been studied 
extensively and genetic evidence showing strong links between components of the alternative 
pathway of the complement system and AMD followed.12,161 Although the complement system 
acts locally, its components can also be detected systemically in serum or plasma. A number 
of studies have investigated the expression levels of complement regulators, complement 
components and activation products in AMD patients versus controls. An overview of the 
alternative pathway of the complement system is provided in Figure 2. 
The central molecule of the complement system is complement component 3 (C3). Enzymatic 
cleavage of C3 results in the generation of its active fragments C3a (a potent proinflammatory 
molecule) and C3b that, via several digestion steps, leads to C3d.162 A number of studies 
measured systemic C3 levels but did not find an association with AMD,163-166 whereas higher 
systemic levels of its active fragments, C3a and C3d, were detected in AMD patients.163,164,166,167 
These findings suggest that the processing of C3, i.e. its activation, may be associated with 
AMD and a number of studies have investigated this. Complement activation was measured 
as the ratio of C3 and its degradation product C3d (C3d/C3),166,168,169 or as a cleaved form of 
C3a (C3a-desArg) in blood170 and urine.37 Out of the five studies that investigated complement 
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Figure 2. Overview of the alternative pathway of the complement system
Spheres are colored to indicate levels in AMD patients compared with controls based on literature: upregulated 
(green), upregulated/no difference (dark green), upregulated/downregulated (gray), and no difference (yellow). 
(1) Complement component 3 (C3) splits into C3a and C3b by spontaneous hydrolyzation or by the C3-convertase 
(C4bC2) resulting from activation of the classical or lection pathway. (2) Factor B (FB) can bind C3b to form C3bB. 
(3) The bound factor B is then cleaved by factor D (FD) which results in the formation of the C3-convertase: C3bBb 
(4). This C3-convertase can cleave C3 which leads to more C3b and in turn increased formation of the C3-convertase 
(known as the C3 amplification loop). The C3-convertase can also bind another C3b molecule to form C3bBb3b, 
which is a C5-convertase (5). This C5-convertase can convert C5 into C5a and C5b. (6) C5b then sequentially binds 
C6, C7, C8, and multiple C9 molecules to form the terminal complement complex (SC5b-9), also known as membrane 
attack complex. * The C3-convertase is inhibited by several complement regulators, among which decay accelerating 
factor (DAF) and factor H (FH). ** Factor I (FI) can breakdown C3b via several digestion steps to C3c and finally C3d, 
this protease activity, however, requires a cofactor, such as FH.
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activation in AMD, four found higher complement activation levels in AMD patients.166,168-170 
An association of C3a-desArg in urine with AMD was not established.37 A recent study suggests 
that complement activation levels may decrease at more advanced stages of the disease, but 
this finding needs to be confirmed in prospective AMD cohorts.171
Besides C3, complement component 5 (C5) is also essential in the activation cascade because 
it serves as the entry point for the formation of the terminal complement complex (SC5b-
9).162 The activation product of C5, C5a, is a potent anaphylatoxin. Increased levels of C5a 
were detected in most, but not all,167 studies examining the role of C5a in AMD.163,164,166 
These same studies also tested whether SC5b-9 is associated with AMD. Higher SC5b-9 levels 
were detected in AMD in one study,164 but the other two studies found no evidence for an 
association.163,166
The activity of the complement system is tightly controlled by regulatory factors that ensure 
appropriate, but not excessive, generation of terminal complexes. Among others, they 
include complement factor H (FH, encoded by the CFH gene), factor I (FI, encoded by CFI), 
factor B (FB, encoded by CFB), factor D (FD, encoded by CFD), and decay accelerating factor 
(DAF/CD55, encoded by CD55).162
Genetic association studies showed strong evidence of an association between the CFH gene 
and AMD.12 Systemic levels of FH have been investigated with mixed results, however. Four 
studies report lower FH levels in AMD,153,163,172,173 one study detected higher levels of FH in 
AMD,174 and another four studies did not find an association with AMD.164-166,175
Similar to FH, FI also inhibits the activity of the complement system through inactivation of 
C3b. Genetic evidence for factor I involvement in AMD has been shown previously, but no 
conclusive evidence links FI levels to AMD in general. One study reports increased FI levels in 
AMD,165 another reports decreased levels but only in patients carrying a rare genetic variant 
in CFI,176 and two did not find any association.163,166
The findings for FB and FD levels in AMD are also inconsistent. Three studies reported 
higher FB levels in AMD patients,164,166,167 while two others did not detect an association with 
AMD.163,165 Similar results were described for FD, where three studies reported higher FD 
levels,164,167,177 one study reported lower levels in AMD,165 and another found no association 
with AMD.163 Finally, two studies that examined the role of CD55 did not find evidence for an 
association with AMD.178,179
In summary, not only genetic studies but also studies measuring complement components 
provide evidence that link complement activation to AMD (Table 2). Some factors, however, 
should be taken into account when considering the use of systemic complement activation 
levels as a biomarker for AMD in individual patients. Often antibody based tests do not 
discriminate between the total amount of a specific complement factor and its processed 
activated part, as cleavage of the pro-form to the active mature form cannot be distinguished by 
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the reagent. Moreover, complement activation levels are subject to high variability, and other 
causes of increased complement activity should be excluded since increased complement 
activation may reflect immune system activity that is not necessarily connected to disease 
progression. Linking exacerbated complement activation in an individual patient to his or her 
genetic blueprint is potentially more useful. For example, haplotypes and combinations of 
genotypes in several complement genes have been associated with increased complement 
activation levels.167,180 In addition, several investigations have now demonstrated that FI 
Table 2. Overview of studies measuring complement components in AMD patients compared to controls 
Component Upregulation No difference Downregulation
C3 Scholl et al. 2008164
Reynolds et al. 2009163
Silva et al. 2012165
Smailhodzic et al. 2012166
C3a Scholl et al. 2008164
Reynolds et al. 2009163
C3d Scholl et al. 2008164
Hecker et al. 2010167
Smailhodzic et al. 2012166
C3a des Arg Sivaprasad et al. 2007170 Guymer et al. 201137
C3d/C3 Smailhodzic et al. 2012166
Ristau et al. 2014168
Ristau et al. 2014169
C5a Scholl et al. 2008164
Reynolds et al. 2009163
Smailhodzic et al. 2012166
Hecker et al. 2010167
SC5b-9 Scholl et al. 2008164 Reynolds et al. 2009163
Smailhodzic et al. 2012166
FH Hakobyan et al. 2008174 Scholl et al. 2008164
Silva et al. 2012165
Smailhodzic et al. 2012166
Guymer et al. 2015175
Reynolds et al. 2009163
Ansari et al. 2013172
Sharma et al. 2013173
Sharma et al 2013153
FI Silva et al. 2012165 Reynolds et al. 2009163
Smailhodzic et al. 2012166
Van de Ven et al. 2013*176
FB Scholl et al. 2008164
Hecker et al. 2010167
Smailhodzic et al. 2012166
Reynolds et al. 2009163
Silva et al. 2012165
FD Scholl et al. 2008164
Hecker et al. 2010167
Stanton et al. 2011177
Reynolds et al. 2009163 Silva et al. 2012165
DAF/CD55 Haas et al. 2011178
Singh et al. 2012179
*Significant downregulation of FI was described in a subgroup of patients with a rare variant in the CFI gene.
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levels are lower in AMD patients carrying rare genetic variants in the CFI gene.176,181,182 For 
FH levels, there were similar associations with genotype. Some but not all rare variants in 
the CFH gene were associated with reduced FH levels.183-185 Thus, patients carrying rare 
variants in complement genes tend to have higher complement activation levels than AMD 
patients in general.186 These insights may benefit ongoing clinical trials on the effectiveness 
of complement inhibitors and could prioritize patients who carry rare variants in these genes. 
4.2 Cytokines
4.2.1 Interleukins
Cytokines are a large family of small proteins that play a pivotal role in cell signaling. An 
important group of cytokines are interleukins. Interleukins play a key signaling role in the 
inflammatory response. Interleukin 6 (IL-6) is a cytokine with many described functions,187,188 
and its relationship to AMD has been investigated. A number of studies reported increased 
levels of IL-6 in AMD patients,19,189,190 but the majority found no association with AMD in 
general.16,29,44,47,51,52,191-193 Notably, a number of these studies did find an association in 
subgroup analyses. For instance, an association with AMD was reported only in patients with 
high IL-6 levels44 or the association with IL-6 was established only for GA patients.47 Also, only 
the highest tertile of IL-6 levels was associated with progression of AMD in a prospective 
cohort study.194
Other interleukins have also been studied in relation to AMD, though to a lesser extent. 
In most studies these interleukins were measured in a multiplex analysis of inflammatory 
markers. Two studies measured multiple interleukins in serum.29,193 In one study, there were 
higher serum levels of IL-1β, IL-4, IL-5, IL-10 and IL-13 in patients with nAMD,193 but these 
factors were not associated with early, atrophic, or neovascular AMD in another study.29 
Higher serum levels of IL-1α and IL-17 in nAMD patients were only reported in the first study. 
Additionally no association was found for IL-2, IL-12 and IL-15.193 Other studies also detected 
no association between IL-2,47 IL-15195 and AMD. For IL-8, although no association was 
present in two studies,196,197 a third larger study described higher IL-8 levels in AMD patients, 
in particular in dry AMD.19 Higher IL-18 levels were reported in dry, but not nAMD, in one 
study.198 A second study did not find different levels between different types of AMD and 
controls.195
Although most studies focused on systemic levels of interleukins, a small number performed 
measurements in aqueous humor16 and vitreous.199 Higher IL-1β levels were found in the 
vitreous of nAMD patients.199 In aqueous humor, IL-1α and IL-15 were upregulated and IL-
13 was downregulated, while for IL-2, IL-4, IL-8, IL-10, IL-12 and IL-17 no differences were 
detected.16 
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4.2.2 Chemokines and chemokine receptors
Chemokines (chemotactic cytokines) have the ability to direct movement of cells through 
receptor-mediated chemotaxis. Evidence from post-mortem material as well as animal 
models have implicated infiltrating immune cells in pathological eye tissues, suggestive of 
the involvement of chemokines in these environments.156,200-202 
Chemokine Ligand 2 (CCL2; or monocyte chemoattractant protein 1 [MCP-1]) attracts C-C 
Chemokine Receptor type 2 (CCR2)-expressing monocytes into tissues and is one of the 
most studied chemokines in AMD. Five relatively small, case-control studies did not find an 
association between levels of CCL2 and AMD,16,29,175,203,204 but several larger studies did see 
an association with increased levels of CCL2.153,205,206 This effect was also reported in a cross-
sectional study linking higher levels of urinary CCL2 to early AMD.37 Overall, these findings 
support the notion that CCL2 is involved in AMD. Interestingly, CCR2-expressing cells can also 
be detected systemically, and both decreased and increased levels have been associated with 
AMD.20,205 Two other studies did not find any association.207,208
Another receptor involved in the recruitment of monocytes, CX3C Receptor 1 (CX3CR1), 
was measured in two AMD studies.203,204 Only the more recent study reported CX3CR1 to be 
upregulated in both early and neovascular AMD.203 
Eotaxin (eosinophil chemotactic protein/CCL11) and closely related Eotaxin-2 (CCL24) 
attract eosinophils. These are interesting molecules for AMD pathogenesis since CCL11 and 
CCL24 and their receptor CCR3 are implicated in choroidal neovascularization.209,210 CCR3 is 
expressed on choroidal neovascular endothelial cells and signaling through this receptor leads 
to endothelial proliferation, even without the involvement of eosinophils or other immune 
cells. Blocking CCR3 signaling in animals led to a potent inhibition of neovascularization, even 
stronger than blocking VEGFA signaling.202 Levels of CCL11 were investigated in two studies, 
one reporting increased levels in AMD,29 and the other finding no differences.209 Supportive 
of the findings above, two studies of the same group reported CCL24 to be upregulated 
in AMD.153,210 Despite these overall promising results, systemic elevations of CCR3 on 
immune cells have not yet been reported. The only study investigating CCR3 on granulocytes 
reported no association, although there was a trend towards higher expression of CCR3 in 
nAMD.209 Taken together, the CCL11/CCL24-CCR3 axis is potentially involved in human AMD 
pathology, but it is not yet clear whether this is mostly a local signaling, mediated through 
CCR3 expression on endothelial cells, or whether systemic CCR3-expressing cells could also 
be involved.
The chemokine ligand CXCL10, also known as interferon gamma-induced protein 10 (IP-
10), attracts a range of cell types and is an inhibitor of angiogenesis.211 Two studies showed 
no association with CXCL10 in serum or plasma and AMD,204,212 and only one study showed 
elevated serum CXCL10 levels in AMD patients.29 Of interest is a recent publication, showing 
upregulation of CXCL10 in aqueous humor of AMD patients compared to controls undergoing 
cataract surgery,16 suggesting that the effect of this chemokine might be local.
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The receptor for CXCL10 is CXCR3 which is expressed on a variety of cell types. Only one study 
investigated numbers of CXCR3-expressing cells peripherally and detected reduced presence 
of CD8+ T-cells expressing CXCR3 in AMD,212 but additional research is warranted before 
concluding whether the CXCL10-CXCR3 axis can be reliably used as a biomarker for AMD.
It has been suggested that stem cell progenitor cells are involved in the disease etiology of 
AMD. Chemokine ligand CXCL12, also known as stromal cell-derived factor 1 (SDF-1), plays 
a role in the movement of these stem cell progenitor cells throughout the body. Four small 
case-control studies have investigated the plasma levels of SDF-1 in AMD patients with mixed 
results. Two, by the same group, report significantly lower levels of SDF-1 in patients with 
nAMD,28,213 whereas another study showed the inverse effect30 and the fourth did not report 
any differences between nAMD and control individuals.20
4.2.3 Other cytokines
Tumor necrosis factor alpha (TNF-α) 
Tumor necrosis factor alpha (TNF-α), an important marker for systemic inflammation, has 
been investigated as such in several studies; however, no significant associations between 
AMD cases and controls were reported in serum or plasma.29,32,47,175,189,192,193 Increased levels 
of soluble TNF-α receptor 2 were reported in a case-control study in early and neovascular 
AMD,195 which in a large population-based study did not reach statistical significance but 
there was a trend towards upregulation in early AMD patients.190
Interferon gamma (IFN-γ) 
Interferon gamma (IFN- γ) is an important cytokine in both innate and adaptive immunity as 
it induces cellular response to infections.214 Three studies measured IFN-γ in AMD cases and 
controls, but none found an association with AMD.29,193,195
4.3 Other immune factors 
4.3.1 C-reactive protein
C-reactive protein (CRP) is a marker of inflammation and a so-called acute phase protein 
because its levels change quickly upon disturbances of homeostasis. Evidence regarding the 
possible relation of this protein with AMD is inconclusive, with a roughly equal number of 
studies reporting higher CRP levels in AMD patients16,19,69,111,208,215-224 or no clear evidence for 
an association.40,44,46,59,165,175,225-231 Those that employed a more precise measurement of CRP 
(high-sensitivity CRP [hsCRP]) were also not able to provide conclusive results: five studies 
detected higher levels of hsCRP in AMD patients,49,189,190,232,233 compared to five that did not 
show an association with AMD.47,51,52,191,192
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4.3.2 (Soluble) Intercellular adhesion molecule and vascular cell adhesion molecule
Intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) are 
immunoglobulins that are usually upregulated on cell surfaces after immune signaling has 
taken place.234 They form a sticky surface to which immune cells that express integrins can 
adhere. These molecules and their soluble counterparts are rarely investigated alone, but 
usually as part of a panel that measures inflammatory activity. For ICAM, one study reported 
higher levels to be associated with the incidence of AMD in women,49 whereas six others did 
not find any association.51,52,175,190,192,227 In the case of VCAM, one study measured higher levels 
in AMD patients,190 while two studies did not find any association with AMD.175,227 Additionally, 
no association with AMD progression and either ICAM or VCAM was reported.194
4.3.3 White blood cell count
As mentioned before in section 4, a clear link with inflammation and inflammatory processes 
and AMD has been established, and several immune-competent cells have been implicated 
in the disease etiology. As a result of local stress or inflammation, the body may respond 
by cellular proliferation of immune cells and recruitment of these cells to the affected site. 
From this perspective, white blood cell count (WBC) is an interesting parameter to measure 
in AMD. A relatively large number of studies have investigated WBC in AMD and some did 
detect increased white blood cell numbers.56,190,224,235-237 This contrasts with the majority of 
studies that did not find any association.21,45,46,51,52,55,56,58,59,106,192,230,238,239 Nevertheless, WBC 
may still be considered as a potential biomarker for AMD if the analysis is performed in the 
context of a different theoretical framework. It is conceivable that it is not the total number 
of cells that change, but rather the ratio between different cell types. Supporting this notion, 
a higher neutrophil/lymphocyte ratio has been associated to AMD and AMD subtypes.240 A 
more in-depth analysis of the different cellular subtypes, such as the relative expression of 
cytokine/chemokine receptors, would offer more insights. 
4.3.4 Pentraxin-3 (PTX3)
Pentraxin-3 (PTX3), like CRP, belongs to the pentraxin superfamily. Upon inflammation, 
PTX3 is produced locally by the RPE,241 and can interact with complement component C1q 
and enhances activation of the classical and lectin pathways of the complement system. 
Additionally, PTX3 attracts complement FH, thereby inhibiting the amplification loop and 
preventing excessive activation of the alternative pathway.241,242 Although one case-control 
study reported higher plasma PTX3 levels in nAMD,219 a more recent study (including also 
early AMD and GA patients) could not replicate these findings.241 The latter study did however 
describe an increased expression of the PTX3 gene with age and inflammation-induced apical 
PTX3 secretion of the RPE.241 Taken together, this suggests a more local expression of PTX3 
in AMD; however, measurements of PTX3 locally in vitreous samples have not yet been 
performed and would therefore be a target of further research. 
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4.4 Antibodies
4.4.1 Anti-retinal autoantibodies
The formation of antibodies against foreign epitopes is a key element of immunity. When 
endogenous epitopes become the trigger for mounting an immune response, auto-immunity 
ensues.243 Antibodies against epitopes found in retinal material of AMD patients have been 
investigated in various studies. Several studies demonstrated upregulation of circulating anti-
retinal autoantibodies (ARAs) in the serum of AMD patients.244-247 Although one study showed 
similar levels of ARAs in cases and controls, it did show a difference in types of antibodies 
specific for each disease stage.248 Additionally, higher concentrations of circulating ARAs were 
detected in treatment-naïve nAMD patients compared to controls.249,250 These levels also 
correlated to lesion size.250 After the loading phase of anti-VEGF treatment, autoantibody levels 
decreased.249,250 Moreover, correlations were reported between ARA levels and improvement 
of visual acuity, fluid reduction on Optical Coherence Tomography, and decreased leakage on 
fluorescein angiography after three months.250
Furthermore, other studies attempted to identify specific circulating ARAs associated with 
AMD.251-253 Surprisingly, one study showed not only upregulation of antibodies, but also 
downregulation of a specific ARA in AMD. Lower antibody concentrations were reported for 
α-crystallin, while α-enolase and glial fibrillary acidic protein (GFAP) antibodies were both 
significantly higher in serum of AMD patients.252 The latter finding is supported by results from 
a previous study which showed different staining patterns in serum of AMD patients, with the 
most frequent pattern observed being almost identical to that using anti-GFAP antibodies.247 
In addition, using an untargeted approach, one study identified four novel retinal antigens in 
serum of AMD patients: retinol binding protein 3 (Rbp3), aldolase C (ALDOC), pyruvate kinase 
isoform M2 (PKM2), and retinaldehyde binding protein 1 (RLBP1).253 Because Rbp3 and 
RLBP1 were previously reported in other ocular diseases, this study focused on ALDOC and 
PKM2. A significant higher reactivity to ALDOC in nAMD, but not in early AMD, was reported. 
Because reactivity to PKM2 was higher in both AMD groups compared to controls, this could 
potentially be a biomarker for the development of AMD.253 A more recent study with a similar 
approach also identified ARAs with higher reactivity in AMD; heat shock 70 kDa protein 8 and 
9, α-crystallin A chain, annexin A5, and protein S100-A9.251
4.4.2 Other autoantibodies 
Serum autoantibodies have been extensively investigated by Morohoshi and colleagues using 
a antigen microarray analysis containing 85 autoantigens. Serum of AMD patients and controls 
showed a different IgG and IgM autoantibody profile, and multiple autoantibodies were 
significantly higher in AMD. Additionally, they calculated IgG/IgM ratios for the antibodies 
and evaluated whether this ratio correlated to disease severity. Anti-phosphatidylserine (PS) 
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IgG/IgM was significantly elevated in AMD and correlated best with AMD stage. Moreover, 
reactivity to PS was highly increased in retina of AMD patients compared to controls.254
Other investigators focused specifically on antiphospholipid antibodies, which are reported to 
be found in aging people and diseases associated with aging.255 In this study, anti-cardiolipin 
IgG levels were associated with AMD, supported by the findings of Morohoshi et al. which 
showed higher expression of anti-cardiolipin antibodies in nAMD compared to controls.254,255
As described in section 3.1, anti-CEP antibodies have also been investigated in association 
with AMD.67,84,85
4.4.3 Antibodies against pathogens
Infection by pathogens leads to increased antibody titers of the foreign pathogen. Several 
infectious agents have been implicated in AMD and we detail the antibodies against these 
pathogens in this section.
Chlamydia pneumoniae is an intracellular bacterial species that has been linked to 
atherosclerosis.256 Since AMD involves inflammatory processes similar to atherosclerosis, the 
association of Chlamydia pneumoniae with AMD was explored. One small case-control study 
found support for this with increased antibody levels in AMD patients,257 while four larger 
studies did not find evidence for a relation between anti-Chlamydia pneumoniae antibodies 
and AMD.47,192,258,259
The cytomegalovirus (CMV) is another infectious agent that has been hypothesized to be 
associated with the pathogenesis of AMD, based on the relation between inflammatory 
processes induced by infection and the resulting vasculopathy.258 Only two studies investigated 
this association. One found no evidence for an association,260 while the other described 
higher levels of antibodies against CMV in nAMD compared to controls and dry AMD.258
Another infectious agent possibly involved in the pathogenesis of AMD is Helicobacter pylori. 
Two studies have tested an association between antibodies against Helicobacter pylori and 
AMD, but found no evidence for this, even when distinguishing between dry and neovascular 
AMD.47,258
To summarize the most important findings regarding immune related factors, involvement 
of the complement system in AMD is evident and complement activation products seem 
to be good biomarker candidates. Increased levels of inflammatory factors, such as CCL2 or 
CRP, have been frequently reported and support the notion that inflammatory processes 
underlie AMD. Yet, these are not specifically related to AMD and may therefore not be the 
best biomarker for clinical implementation. The use of multiplex assays for the simultaneous 
detection of multiple inflammatory markers (cytokines, chemokines) holds great promise, but 
additional data are required to determine their usefulness as AMD biomarkers. Additionally, 
ARAs are also associated with AMD, but at present it is unclear whether these autoantibodies 
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play a direct role in the etiology of the disease or rather are the result of retinal damage. 
Further research is therefore necessary to determine if (specific) ARAs could be used as a 
biomarker for AMD. 
5. LIPID METABOLISM/HOMEOSTASIS
Lipid metabolism is one of the major pathways involved in the pathogenesis of AMD as 
evidenced by genetic associations of lipid-linked genes CETP, LIPC, ABCA1 and APOE.12,157 
Moreover, drusen, the major hallmark of AMD, consist of at least 40% lipids.261,262 Also, as 
mentioned in section 4.4, there are similarities in the pathogenesis of atherosclerosis and 
AMD.263 Since lipids are important risk factors for atherosclerosis and CVD,264 these might also 
be associated with AMD. Numerous studies have measured lipid levels in serum or plasma, 
and the results of these studies are summarized in sections 5.1 to 5.4. We focus on studies 
that reported associations with AMD and results from large population-based studies. A 
complete overview of all studies and references is provided in Supplementary table 4. 
5.1 Lipids
Cholesterol has multiple functions. It is required for building and maintaining cell membranes, 
it is involved in cell signaling processes, and it is a precursor molecule for synthesis of steroid 
hormones, bile acids, and vitamin D.265
The population-based Cardiovascular Health Study reported lower levels of total cholesterol 
in AMD patients, of which the majority had early AMD.46,229 Also in the Beaver Dam Eye Study 
lower cholesterol levels were associated with development of early AMD in women,236 and 
there was a trend for lower levels of cholesterol in nAMD;57 a more recent analysis of the Beaver 
Dam Eye Study data, however, did not show an association between AMD and cholesterol 
levels.192 Additionally, two case-control studies described lower levels of cholesterol in 
AMD patients.266,267 In contrast, higher cholesterol was associated with AMD in ten studies, 
though these were all case-control studies, and only half studied nAMD.41,94,216,223,227,268-
272 The vast majority of studies (Supplementary Table 4), however, did not demonstrate a 
difference in cholesterol levels between AMD patients and controls, including a meta-
analysis of three large population-based studies,273 and several large population-based 
studies.43,50,52,58,69,96,198,225,226,228,238,274-286
Triglycerides are molecules that have a glycerol backbone, connected to three fatty acids 
of variable length. Most studies did not report differences in triglyceride levels between 
AMD cases and controls (Supplementary Table 4). Lower triglyceride levels were reported in 
early AMD,185, 371 in nAMD219 and in any AMD.59,69,225,280,287 In contrast, three studies reported a 
higher level of triglycerides to be associated with AMD,197,269,272 of these, one study included 
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only women,62 and one study found the association in women only.197
Phospholipids are another class of lipids, and are an important component of cell membranes. 
In three studies, no association was found between phospholipids and AMD.129,137,288 
5.2 Lipoproteins
Because of the insoluble nature of lipid molecules, lipoproteins are needed for transportation 
of lipids through the circulation. Five different lipoproteins exist, differing in their density 
and size: chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein 
(IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL).289 Both HDL and LDL 
carry cholesterol between the liver and periphery.265,287,290 The association between these two 
lipoproteins and AMD has been extensively studied. 
For AMD, higher levels of LDL-cholesterol (LDL-C) were found in several studies. Half of these 
studies found this association when comparing controls to nAMD,94,223,271,291,292 others found 
an association in early AMD,120 any AMD,216,269 and in women with dry AMD.272 Almost all 
other studies, including multiple large population-based studies,50,58,69,96,225,274,276,285,286,293 
did not report an association between AMD and LDL-C (Supplementary table 4). Only the 
Cardiovascular Health Study associated lower LDL-C levels with early AMD patients46 and 
reported a trend towards lower levels in patients with any AMD.229 Differences in results 
regarding LDL-C levels can be partly due to different measurement methods across studies, as 
it can either be measured directly, but often it is estimated using the Friedewald equation.294 
Since HDL-cholesterol (HDL-C) is inversely associated with CVD, one may have expected 
to also find this inverse association with AMD. Surprisingly, lower HDL-C levels were only 
described in a few studies in varying AMD stages; in late AMD,50,292 in women with dry 
AMD,272 and in early AMD.55 Increased HDL-C levels in AMD patients were present in multiple 
studies.57,58,69,96,191,208,224,226,228,236,266,276,277,284,287,295 It must be noted that most of these studies 
only found a weak association in a subgroup of AMD patients. The majority of the studies did 
not describe significant differences in HDL-C levels (Supplementary Table 4). 
Three studies evaluated non-HDL-C, which is calculated by subtracting HDL-C from total 
cholesterol. Two studies, including a large meta-analysis of three population-based studies, 
reported no association with AMD,273,287 while the third study found higher non-HDL-C to be 
associated with any AMD.216
Lipoprotein (a), Lp(a), is an LDL-like particle, which consists of apolipoprotein-B100 and 
apoliprotein-A. Its precise function is unclear, but higher levels of Lp(a) have been repeatedly 
associated with CVD.296,297 Contrarily, no association of Lp(a) levels with AMD or progression 
of AMD has been described so far.46,194,207,216,272,288,298
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5.3 Apolipoproteins
Apolipoproteins bind lipids to form lipoproteins that are responsible for lipid transport. 
They also function as enzyme cofactors and receptor ligands.288 There are several classes of 
apolipoproteins. The overview presented in this section is restricted to apolipoprotein A1 
(ApoA1), the major component of HDL-C, apolipoprotein B (ApoB), mostly found in LDL-C, 
and apolipoprotein E (ApoE), found in IDL-C and chylomicrons. Several investigations found 
an association between apolipoproteins and AMD or features of AMD.207,272,277,287,288 The 
Pathologies Oculaires Liées à l’Age (POLA) study described ApoA1 to be associated with an 
increased risk of soft drusen,277 and also in the European Genetic Database (EUGENDA) cohort 
higher levels of ApoA1 were associated with AMD, even after adjustment for genetic variants 
that influence lipid levels.287 In contrast, one study reported a lower ApoA1 concentration 
in women with dry AMD.272 This study also described a higher concentration of ApoB in dry 
AMD cases, which is in concordance with another study.207 Higher ApoE levels were reported 
in advanced AMD compared to early AMD and control individuals; this difference could be 
due to a higher allelic burden of the APOE gene in these patients.288 Other studies did not 
describe an association between ApoA1, ApoB or ApoE and AMD.46,216,298,299 
5.4 Fatty acids
There are different types of fatty acids. Polyunsaturated fatty acids (PUFAs) usually derive 
from phospholipids or triglycerides.62,300 The most commonly studied PUFAs in AMD are the 
omega-3 fatty acids DHA and eicosapentaenoic acid (EPA). Fish and other seafood are the 
main source of these omega-3 PUFAs.301,302 Animal and epidemiological studies have shown 
a lower risk for AMD in subjects with high dietary intake of omega-3 fatty acids.303,304 Also 
two interventional studies with omega-3 fatty acid supplementation have been performed; 
the Age-related Eye Disease Study (AREDS)2 showed no beneficial effect for omega-3 fatty 
acid supplementation,147 while the Nutritional AMD Treatment 2 (NAT2) study showed a 
protective effect for DHA supplementation only in patient homozygous for the major allele 
(T) of the Y402H variant in the CFH gene.305 
Considering omega-3 fatty acids as potential biomarkers, a number of studies investigated 
plasma or serum levels of these factors. In the Antioxydants, Lipides Essentiels, Nutrition et 
maladies Oculaires (ALIENOR), a population-based study, advanced AMD cases had lower 
plasma levels of α-linoleic acid (ALA) and DHA compared to no or early AMD. In addition, lower 
plasma levels of EPA were associated with GA.302 This is in line with baseline measurements 
performed in the NAT2 study, that showed that nAMD cases had lower EPA and DHA levels 
in red blood cell membranes and lower serum EPA.301 On the contrary, smaller case-controls 
studies reported no effect or opposite effects for DHA, EPA and ALA.137,300,306,307 For plasma 
or serum levels of docosapentaenoic acid (DPA), another omega-3 fatty acid, no significant 
associations were described.137,302,306
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Omega-6 fatty acids arachidonic acid (AA) and linoleic acid (LA), and omega-9 fatty acid oleic 
acid (OA) have also been measured. A small case-control study found lower levels of LA and 
OA, and higher levels of AA in the membranes of erythrocytes of AMD patients.300 In line 
with these findings, a recent study reported higher serum AA in nAMD.307 Two larger case-
control studies, however, did not show different levels of these omega-6 and omega-9 fatty 
acids.137,306
Regarding saturated fatty acids (which are single-bonded), lower levels of palmitic acid in 
erythrocytes of AMD patients were reported in a small, case-control study,300 though systemic 
levels were not different between cases and controls.300,306 Also for stearic acid, no association 
with AMD was detected.300,306
Evidence for the involvement of lipids in AMD comes from epidemiologic, molecular, and 
genetic studies, but the exact role of systemic lipid levels is not yet clear. These studies are 
complicated by high variability of lipid and fatty acid levels in general and are potentially 
further confounded by the use of medication and/ or dietary intake, including supplements. 
Although a combination of factors could constitute a risk profile that may be linked to the 
development and progression of AMD, it is unlikely that these factors individually could act 
as proper biomarkers for the disease. 
6. EXTRACELLULAR MATRIX
Remodeling of the extracellular matrix (ECM) plays a role in the pathogenesis of AMD.308,309 
Drusen development, as well as alterations of Bruch membrane310,311 and infiltration 
of immune cells, relate to a balance between structural tightness or looseness of the 
extracellular environment. The constant remodeling of the ECM is carefully regulated by 
matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs).312 
Dysregulation of MMPs and/or TIMPs could lead to ECM changes seen in AMD and therefore, 
these are potentially useful biomarkers for AMD. 
Genetic variations in several ECM-related genes are associated with AMD;157,313 however, 
only few studies have measured plasma or serum levels of MMPs and TIMPs.47,175,314-316 An 
overview of the studies and references is provided in Supplementary Table 5. Upregulation of 
MMP9 in plasma was associated with AMD in one study;314 however, two other studies could 
not replicate these findings.175,316 No association was found for serum MMP1 levels175,316 or 
MMP2 in serum or plasma.175,314,316
All three studies were limited because of small samples sizes and the measurement 
techniques used. Moreover, in these studies both the proenzyme and active forms were 
measured together. Increased immunoactivity of MMPs does not necessarily mean an 
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increase in enzymatic activity. Other measurement techniques are required to measure MMP 
activity more reliably, and larger future studies are needed to elucidate the potency of MMPs 
as biomarkers for AMD. 
One of the main constituent of the ECM in Bruch membrane is elastin.309 Elastin, in 
combination with other proteins of the ECM,317 provides strong and long lasting elasticity to 
the Bruch’s membrane. The elastin layer degrades with age, however, and elastin metabolism 
may contribute to AMD where there is frequently thinning and fragmentation of the elastic 
layer,310 especially in relationship to choroidal neovascularization.235,318 There is also evidence 
for abnormal systemic elastin metabolism in AMD. Patients with nAMD had significantly 
increased susceptibility to elastolysis in the skin.235 Patients with nAMD had significantly 
higher levels of serum elastin-derived peptide levels,319 probably due to the above mentioned 
elevated levels of MMPs in serum.314 Apart from elevated elastin peptide fragment levels, 
sera from patients with AMD contain specific autoantibodies against elastin and it has been 
suggested that the IgG/IgM ratio for elastin, and other, autoantibodies might allow monitoring 
the progression of AMD.254 Therefore, analyzing elastin degradation product or autoantibody 
levels or ratios might be a useful tools as biomarkers, at least for, nAMD.
7. DIETARY FACTORS
Known risk factors for AMD include dietary factors, such as low intake of antioxidants. 
Some vitamins are antioxidants, whereas others act as co-factors for enzymes involved in 
ROS clearance,71 as detailed in section 7.1. Trace elements have also been hypothesized to 
be involved in the pathogenesis of AMD and are described in section 7.2. Another marker 
influenced by diet is serum albumin, this is considered to be an indicator of nutritional status 
and inflammation and is discussed in section 7.3. Additionally, diet is also an important source 
for fatty acids and carotenoids both related to AMD. These are described in section 5.4 and 
section 3.4.2, respectively. A complete overview of the studies and references is provided in 
Supplementary Table 6.
7.1 Vitamins
Vitamin C can act as a ROS scavenger and it mediates reactivation of vitamin E.71 When vitamin 
C hydrolyzes and reactivates vitamin E the molecule itself is inactivated, and hydrolysis by 
GSH can reactivate vitamin C (Fig. 1).320 Lowered levels of vitamin C result in less vitamin E 
conversion to its active form. Additionally, vitamin C itself cannot fulfill its antioxidant function, 
and as a consequence ROS production will rise.320 Vitamin C levels were found to be lower in 
AMD patients compared to controls,77 and lower in advanced versus early AMD,130 however 
most studies do not report an association between vitamin C and AMD.41,79,115,119,140,235
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Vitamin E is anchored in the plasma membrane and prevents lipid peroxidation.71 Lower 
levels of serum vitamin E in AMD patients were reported.130,135,140,321 However, associations 
with vitamin E were not conclusive, since no difference in vitamin E levels have been found in 
several studies.41,77,115,119,129,136,137,139,235,322
One study reported lower levels of vitamin A in patients with nAMD.133 However, the 
majority of studies did not find a significant association between vitamin A levels and 
AMD.41,119,130,136,137,140,235
B vitamins are essential molecules in homocysteine metabolism and synthesis of methionine. 
Both vitamin B9 (folate) and B12 (cobalamin) act as cofactors to convert homocysteine into 
methionine.102 In AMD patients, lower serum levels of vitamin B12 were detected compared 
to controls.106,107,109 These results were not consistently replicated, as equal levels of serum 
vitamin B12 in patients and controls have also been described.113,114 Folate levels were similar 
between controls and AMD patients in all studies.106,107,109,113,114,192
Vitamin D can be produced in the dermis upon sunlight exposure or can be obtained through 
diet. For its activity the molecule has to be converted into its active form in the liver and 
kidney before it can regulate uptake of nutrients such as iron, calcium, magnesium and 
zinc.323 There are inconsistent results for vitamin D levels in AMD patients. They have been 
described to be higher,280 lower,324,325 or not associated with the disease.58,282,326-330 
7.2 Trace Elements
Trace elements are required by the human body in very low concentrations for proper 
physiological functioning; however, deficiency or excess amounts may be harmful.331 
Iron is essential for retinal functioning, as phototransduction is dependent on iron-containing 
enzymes. Accumulation of iron, however, can be harmful. Iron can convert hydrogen peroxide 
(H
2
O
2
) into highly reactive ROS and thereby enhance oxidative stress.332 Cadmium can also 
increase ROS formation,333 and mercury can decrease oxidant defense mechanisms,334 both 
leading to increased oxidative stress. In contrast, manganese, copper and zinc contribute 
to antioxidant activity as they are co-factors for the antioxidant enzyme SOD.71,335 GSHP is 
dependent on the presence of the essential heavy metal selenium.336 Additionally, copper 
and zinc are able to stabilize proteins, reducing their vulnerability to oxidation,335 but can 
also lead to pathological aggregation or even precipitation of proteins.337-339 Both zinc and 
manganese can reduce uptake or accumulation of toxic cadmium.340
Several studies reported elevated cadmium levels in blood,58,279,341,342 aqueous humor343 and 
urine of AMD patients.342 Measurement of cadmium levels in blood might represent only 
recent cadmium exposure, while urinary cadmium reflects long-term exposure to cadmium 
and might therefore be a more accurate biomarker. A study comparing both blood and urinary 
cadmium levels did not show an association with AMD in the total study group; however, when 
stratified for smoking status, increased urinary cadmium levels were associated with AMD in 
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smoking individuals, suggesting a smoke-related association of cadmium with AMD.344 Lead 
levels were elevated in serum and urine of both early and advanced AMD,58,341,342 and one 
study reported an association between lead and AMD only for women.198 Levels of mercury 
were only elevated in patients with advanced AMD.58,341
Selenium was in general not associated with AMD.41,115,343 One study found a borderline 
significant association with AMD,322 and another measured significantly lower levels of 
selenium in nAMD patients.345 Conflicting results are reported for levels of iron,235,343,346 
copper,129,343 manganese,341,343 and zinc.41,130,321,341,343
7.3 Albumin
Albumin is essential for maintenance of plasma colloid oncotic pressure, acts as a plasma 
binding protein, and also has antioxidant activity.347 Additionally, albumin is one of the most 
common proteins found in drusen.348 A few studies measured serum albumin in AMD patients 
and controls. Two case-control studies did not show a significant association between serum 
albumin and AMD.41,235 The population-based Cardiovascular Health Study and Beaver Dam 
Eye Study did report significantly lower serum albumin levels in early and neovascular AMD, 
respectively.46,239 A more recent nested case-control study within the Beaver Dam population 
further analyzing these data could not confirm decreased albumin levels in AMD.192
Taken together, because of the highly variable diet between subjects, and varying levels of 
dietary factors within subjects based on fasting state, assessment of the role of these dietary 
factors as biomarkers in AMD remains difficult. Dietary intake and/or supplementation of 
antioxidants and vitamins, however, have therapeutic benefit. The AREDS trial, one of the 
largest investigations into vitamin supplementation in AMD, focused on daily supplementation 
with vitamin E, vitamin C, β-carotene and zinc, and demonstrated a lower chance of advanced 
AMD development in subjects taking these supplements.149 In the AREDS2 study, an improved 
formula was evaluated and β-carotene was replaced by lutein/zeaxanthin because of the 
increased risk of lung cancer in smokers.147,148
Regarding trace elements, toxic heavy metals (such as lead, mercury and cadmium) are mainly 
associated with an increased risk of AMD, while essential heavy metals (e.g. zinc, manganese) 
seem to protect against the development of AMD. For most trace elements there are only 
a limited number of studies available in the public domain to date, and further research is 
required to assess their potential role as a biomarker or as protective supplement.
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8. HORMONES
In this section we discuss the few hormones that have been investigated in relation to AMD: 
leptin, melatonin and dehydroepiandrosterone sulfate (DHEAS). A complete overview of the 
studies and references is provided in Supplementary Table 7.
8.1 Leptin
Since AMD is a multifactorial disease in which dietary factors and body-mass-index also play 
a role in the disease mechanism, it has been suggested that the principal hormone involved 
in food intake behavior, leptin, may be associated with AMD. Two studies support this theory; 
both showed a reduction in serum leptin levels in AMD patients compared to controls.124,283 
After controlling for potential confounders, including smoking, body mass index, blood 
pressure, and HDL-C, the association remained significant, which suggests that mechanisms 
other than body fat underlie the relationship between leptin levels and AMD.283 A third study 
did not observe a difference in leptin levels in patients versus control individuals.189
8.2 Melatonin
Melatonin has strong antioxidative capacities, is expressed in the retina, and expression 
levels decrease during aging.349-351 Two studies investigated levels of melatonin in AMD. One 
showed elevated blood levels of daytime melatonin in pseudophakic AMD patients.352 The 
second study analyzed the major metabolite of melatonin in urine, 6-sulfatoxymelatonin, 
and described lower levels in AMD.353 Comparing the two studies is difficult because of the 
differences in methodology and fluid matrix analyzed, so additional experiments linking 
melatonin and AMD are necessary.
8.3 Dehydroepiandrosterone sulfate (DHEAS)
DHEAS is a sulfate ester of dehydroepiandrosterone (DHEA), which is an endogenous steroid 
hormone synthesized from cholesterol in the adrenal glands and serves as precursor molecule 
for sex steroids androgen and estrogen.354 It has been suggested that DHEAS has antioxidant 
effects.223,354,355 Also, the DHEAS level in blood decreases with age.354-356 Since both oxidative 
stress and aging are important risk factors for AMD,311 the question arises whether DHEAS 
and AMD could be correlated. Three studies investigated the association between AMD and 
DHEAS, all with different outcomes; higher levels of DHEAS were reported in women with 
early AMD,357 another study described low DHEAS in both dry and neovascular AMD cases,355 
and a third study did not find an association between nAMD and controls.223 
In summary, only a limited amount of studies assessing hormones in AMD have been 
performed with inconclusive results and do not seem to be reliable biomarkers for AMD at 
this point in time.
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9. FACTORS RELATED TO COMORBIDITIES
AMD has been suggested to share risk factors or coexist with other diseases, such as kidney 
disease, diabetes mellitus and Alzheimer disease. Factors related to these comorbidities are 
discussed in section 9.1 to 9.3, respectively. Although AMD has not been associated with 
liver disease before, some studies investigated factors related to liver function and these are 
described in section 9.4. A complete overview of the studies and references is provided in 
Supplementary Table 8.
9.1 Kidney disease
Several studies have suggested overlapping risk factors between AMD and kidney 
diseases.224,358-360 A number of large, often population-based, studies have investigated 
kidney function, like glomerular filtration rate, but also markers that can be measured in 
serum/plasma like creatinine and cystatin-C. In the Beaver Dam Eye Study, serum cystatin-C 
was associated to the incidence of early AMD and nAMD.359 In the Multi-Ethnic Study of 
Atherosclerosis (MESA) this association was only found when the highest deciles of cystatin-C 
were compared to other deciles with prevalence of early AMD.361 In the Hatoyama study no 
association between cystatin-C and AMD was found.191 
Several large studies investigated creatinine in patients, but no clear association between 
serum creatinine and AMD was found. Two reports from the Korean National Health and 
Nutrition Examination Survey (KNHANES) describe a significant difference between AMD 
patients and controls, but after adjustment for other variables no significant association was 
found.58,282 The remainder of the studies, including large population-based studies such as 
the MESA and the Singapore Malay Eye Study, did not find any association between serum 
creatinine and AMD.94,95,114,225,235,274,324
Another indicator of renal health is blood nitrogen urea (BUN), but also for this factor no link 
was established with AMD.58,235,282,359 
9.2 Diabetes Mellitus 
While some cardiovascular risk factors, such as smoking, have been consistently related to 
AMD, there are conflicting results for an association between diabetes mellitus and AMD.9 
Several studies, mostly population-based, measured glycated hemoglobin (HbA1c) and 
glucose as indicators for the presence of diabetes mellitus. Only one study found lower levels 
of glucose in advanced AMD,281 but none of the other studies described an association of 
either markers with AMD.41,43,94,95,198,225,235,274,277-279,286,293 Several studies, all reports from the 
KNHANES, reported lower HbA1c levels in AMD,58,198,279-281 however, studies from other 
cohorts detected no difference.32,223,225,274,278 
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9.3 Alzheimer disease
Similar to AMD, the prevalence of Alzheimer disease increases with age. This neurological 
disorder is characterized by amyloid plaques in the brain, with the main component being 
amyloid beta (Aβ).362 In AMD, two studies identified Aβ as a component of drusen.363,364 Also, 
Aβ might trigger activation of the complement cascade in AMD.365 Several isoforms of Aβ 
with different amino acid lengths exist; in this section we discuss the most common isoforms: 
Aβ1-40 and Aβ1-42. 
A small, case-control study did not show different levels of Aβ1-42 between controls and 
either dry or neovascular AMD;114 however, two more recent case-control studies showed 
significantly higher Aβ1-42 peptide levels in AMD patients.175,189 Also after correction for age, 
Aβ1-42 was significantly associated with AMD, and there was a trend towards increasing 
levels of Aβ with increasing disease severity.175 An association of AMD with Aβ1-40 in these 
studies was less clear. A significant upregulation was described in one study in nAMD only,175 
while the other study did not report a difference between nAMD patients and controls.189
9.4 Liver function
So far, to our knowledge, no study has focused specifically on liver function and AMD. In a few 
studies indicators of liver function have been reported as part of a routine blood examination 
with no associations between lactate dehydrogenase, aspartate transaminase, or alanine 
transaminase and AMD.58,59,235
For hepatitis B surface antigen (HBsAg) on the other hand, an association was described in 
several Korean studies, a country where hepatitis B is still endemic.58,59,282 In these studies 
HBsAg carrier status was positively associated with AMD. HBsAg has been detected in 
subretinal fluid, and it is hypothesized these individuals are therefore at increased risk for 
uveoretinal pathology, such as AMD.59,282 
In conclusion, despite coexistence and overlapping risk factors with AMD, biomarkers for 
kidney disease, diabetes mellitus and liver disease discussed here do not seem good biomarker 
candidates for AMD. As an exception, Αβ could potentially be a marker of disease progression, 
however, larger prospective studies are required to confirm these findings. Additionally, also 
in terms of a potential new drug target, further evaluation of this biomarker in AMD seems 
worthwhile, as promising anti-Aβ therapies are being developed for Alzheimer’s disease.362 
10. HYPOTHESIS‐FREE TECHNIQUES
In the past decade many advanced high-throughput omic technologies have been 
developed. These technologies enable us to analyze large numbers of markers at the same 
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time in an untargeted and unbiased manner. Here, we discuss several omic technologies in 
association with AMD (Figure 3): proteomics (section 10.1), metabolomics (section 10.2), and 
epigenomics (section 10.3). Expression of circulating microRNAs can also be measured using 
high-throughput techniques, these are described in section 10.4. 
10.1 Proteomics
The field of proteomic research uses mass spectrometry, or variations to this technique, to 
determine the nature of peptides or proteins in various tissues or other biological samples. The 
advantage of proteomic research is that it delivers results that are unbiased by preconceived 
notions or hypotheses. Within the field of AMD, proteomics has been employed in a number 
of investigations, and several have been successful in showing particular proteomic signatures 
in plasma, vitreous, and aqueous humor from AMD patients when compared to controls.
A small study by Kim et al, identified 154 proteins in aqueous humor of 9 nAMD patients 
and 8 cataract controls.366 In this study seven potential biomarker candidates were selected 
for further analysis: ceruloplasmin, PEDF, plasma protease C1 inhibitor, TGF-β1, clusterin, 
cathepsin D and cystatin D. The relative abundances of TGF-β1, plasma protease C1 
inhibitor, ceruloplasmin and PEDF were shown to be significantly higher in AMD samples 
compared to controls. Another small study, collecting and profiling aqueous humor of 6 
nAMD patients and 6 cataract controls, found 68 proteins to be differentially expressed.367 
Only 9 proteins were identified in both studies, among which were some that were related 
to AMD previously (CCL24 and complement FI), lipocalin-1 and several members of the 
crystallin family. These crystallins, known for their chaperone function, may also be involved 
Figure 3. Omics in age‐related macular degeneration
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in protein-protein interaction, prevention of apoptosis, and inhibition of inflammation among 
others.368 Lipocalin-1 concentrations were quantified using enzyme-linked immunosorbent 
assay (ELISA) and levels were significantly elevated in the aqueous humor of nAMD patients.
A third small study performed a focused proteomic analysis on protein members of the 
ubiquitin pathway.369 Difference in expression of six proteins in aqueous humor of two 
AMD patients compared to two controls was reported. This included the 26S proteasome 
non-ATPase regulatory subunit 1 (Rpn2), a protein that is also present in plasma. Rpn2 was 
therefore selected as potential AMD biomarker and liquid chromatography-multiple reaction 
monitoring (LC-MRM) mass spectrometry of another 15 aqueous humor samples showed a 
relative increase of Rpn2 in nAMD patients.
Kang et al analyzed aqueous humor samples of 26 treatment-naive patients with nAMD and 
18 controls.370 By comparing expression profiles in exosomes of aqueous humor and cultured 
RPE cells, six candidate proteins were selected for verification in an independent sample 
set by LC-MRM mass spectrometry: actin, myosin-9, heat shock protein 70, cathepsin D, 
cytokeratin 8, cytokeratin 14. Of these, cytokeratin 8 showed the highest area under the 
curve value (0.929), suggesting that it is a strong predictor for AMD. Although cytokeratins 
were not previously reported in other proteomic analyses in AMD, and might be valuable 
markers to further investigate, it is disputable whether they could qualify as manageable 
biomarkers. Cytokeratins are abundant contaminants in laboratories,371 so careful replication 
of these findings in other laboratories is warranted. 
One other study investigated in a targeted manner the involvement of Wnt modulators in 
aqueous humor and found that WNT inhibitory factor 1 (WIF-1) and Dickkopf-related protein 
3 (DKK-3) were upregulated in nAMD.372
In a study of 73 nAMD patients and 15 controls, a large set of proteins were detected in vitreous 
humor, of which 19 were upregulated in nAMD patients.373 Bioinformatic analyses suggested 
enrichment of the complement and coagulation cascades, as well as markers involved in 
arachidonic acid metabolism. Of the 19 proteins, five were randomly selected for Western 
blot validation; alpha-1-antitrypsin reached statistical significance, while apolipoprotein A1 
and transthyretin showed a non-significant increase in AMD. These findings need validation 
in a larger sample set. 
Nobl et al investigated vitreous samples of 108 nAMD patients and 24 controls, distributed 
over a discovery and validation set, and discovered 101 different proteins.374 Using a closed 
testing procedure, they focused on four differentially expressed proteins as candidate AMD 
biomarkers: clusterin, opticin, PEDF and PH2D, which were increased in nAMD compared to 
controls, except for opticin, which was reduced. Upregulation of PEDF and PH2D in nAMD 
was described previously.366,373 Clusterin and PEDF remained significantly increased in nAMD 
after validation and correction for multiple testing in an independent sample set using ELISA. 
There have been limited plasma proteomic studies. Xu et al found 28 clinically relevant proteins 
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to be altered in AMD patients (n=24) compared to healthy volunteers (n=6),375 but further 
investigation of these plasma proteins is necessary to validate these findings. Additionally, 
two studies using proteomic profiling of the same dataset identified three potential AMD 
biomarkers: vinculin, phospolipid transfer protein and mannan-binding lectin protease-1.376,377 
In general, proteomics of plasma or serum is a great analytical challenge due to the dominant 
fraction of highly abundant proteins, which have effectively prevented the discovery of 
novel proteomic biomarkers in these fluids in the past. Therefore improved technologies are 
needed. Fortunately, some progress has been made using quantitative shot-gun proteomics, 
recently.378
10.2 Metabolomics
Metabolomic studies use mass spectrometric technologies or nuclear magnetic resonance 
spectroscopy to measure derivatives of metabolism. The technique offers a snapshot of the 
physiological state of an organism at the level of body fluids (urine, tears, serum, plasma), 
cells or even tissues. Metabolomic analysis of AMD has great potential to uncover novel 
pathways in the disease that are reflective of the interaction between the genetic blueprint of 
an individual and environmental factors that influence the metabolites (for example diet and 
smoking). To date, only one metabolome-wide study was conducted in plasma samples of 26 
nAMD patients and 19 controls. Pathway analysis pointed towards involvement of tyrosine 
metabolism, urea metabolism as well as vitamin-D related metabolism.379
10.3 Epigenomics
Whereas it is clear that both genetic components as well as environmental elements 
contribute to the risk of developing AMD, it is less clear how these two systems interact. 
This interaction is the domain of epigenetics, induced changes in the expression levels of 
genes controlled by outside influences. Epigenetics is a broad term, encompassing many 
possible regulatory mechanisms of gene expression. One type of epigenetic mark that has 
been explored in a number of studies is the difference in DNA methylation patterns between 
cases and controls. 
Epigenetic changes can be observed in peripheral blood leukocytes, which are relatively easy 
to obtain. One study showed a decrease in methylation near the IL17RC promotor region, 
suggesting that this could serve as a potential biomarker for AMD.380 However the finding 
could not be validated by an independent study with a sufficiently powered study design.381
Based on these results, and also because epigenetic mechanisms are likely to be tissue-
specific, the relationship between DNA methylation patterns in peripheral blood and retinal 
tissue was investigated in a recent study.382 Although no epigenome-wide association peak 
was observed, the study did report consistent methylation changes across multiple samples 
near the ARMS2 locus and near the protease serine 50 (PRSS50) gene. 
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Despite a limited sample size, the results provided some evidence that methylation patterns 
in blood leukocytes could serve as proxies for retinal changes, implying that such studies 
could deliver additional biomarkers for AMD.382
10.4 Circulating microRNAs
A microRNA (miRNA) is a small non-coding RNA molecule that regulates gene expression 
after transcription, thereby influencing biological processes. These miRNAs are present in 
circulation and could potentially serve as biomarkers.196 Because we focus on compounds 
found in body fluids, only the studies that investigate circulating miRNAs (cmiRNAs) in serum 
or plasma are described here. 
In a small study by Ertekin, plasma samples of 33 nAMD patients and 31 controls were 
analyzed for the expression of 384 miRNAs.383 They found 16 miRNAs to be differentially 
expressed between the two groups and additionally discovered 10 miRNAs to be only 
expressed in nAMD patients. 
Grassmann and colleagues identified 203 cmiRNAs in serum, of which three (hsa-mir-301-
3p, hsa-mir-361-5p, hsa-mir-424-5p) were significantly altered in nAMD patients (n=129) 
compared to control individuals (n=147).384 No significant association was found in GA 
patients (n=59), suggesting different mechanisms for advanced AMD subtypes. Pathway 
analysis of the genes that are likely regulated by the altered cmiRNAs implicated the mTOR 
and TGF-β pathways in nAMD and knockdown of these cmiRNAs in vitro resulted in increased 
angiogenesis, but only significantly for hsa-mir-361-5p. 
Szemraj et al also reported significant differences in cmiRNA profiles between dry and 
neovascular AMD patients.385 In this study, serum expression levels of 377 miRNA genes in 300 
AMD patients (150 nAMD/150 dry AMD patients) and 200 control individuals were analyzed. 
This study identified 31 differentially expressed miRNAs between patients and controls, 
including two of the three previously associated384 cmiRNAs (hsa-mir-301-5p and hsa-mir-
424-5p). Of the differentially expressed miRNAs in this study, five were significantly different 
between patients with dry and neovascular AMD. Additionally, the correlation between these 
miRNAs and expression of VEGF and VEGFR2 was assessed, and it was suggested that miRNA 
Let-7 is implicated in the neoangiogenesis in nAMD. 
So far, limited studies on miRNA profiling in AMD have been performed and results need 
to be replicated in larger studies, however, these initial findings emphasize the potential of 
cmiRNAs as biomarkers in AMD. 
In general, studies using hypothesis-free techniques demonstrate proof of concept that 
omic analyses are able to identify novel biomarkers for AMD; however, more are needed to 
validate results and to confirm the clinical utility of these biomarkers. 
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11. CONCLUSION AND FUTURE DIRECTIONS
In summary, numerous compounds have been analyzed in relation to AMD. However, only a 
few of these have potential as AMD biomarkers. The most promising biomarker candidates 
belong to the oxidative stress pathway, the complement system, and to a lesser extent, lipid 
metabolism. Finally, the use of hypothesis-free techniques in biomarker detection holds 
great promise. For summarized findings regarding factors belonging to the other biological 
pathways described in this review, we refer to the closing paragraphs of the respective 
chapters. As of yet, none of the biomarkers that we have reviewed here are used clinically. 
Many studies reported decreased antioxidant levels and elevated levels of oxidized proteins or 
lipids indicating oxidative stress in AMD. MDA is often used as a marker for lipid peroxidation 
and increased levels of MDA have been very consistently observed in both wet and dry 
AMD (11 out of 11 studies, section 3.1). Additionally, most studies reported higher levels of 
homocysteine, an intermediate in the oxidative stress pathway, in AMD (12 out of 18 studies, 
section 3.3). Besides dysregulation of the oxidative stress pathway, many studies indicate 
the involvement of the complement system in AMD. Products of complement activation and 
levels of complement activation – described by the ratio of C3 and its degradation product 
C3d (C3d/C3) – were repeatedly associated with AMD (section 4.1). In addition, there is 
clear involvement of lipids in AMD from genetic and molecular studies. However, the role 
of systemic lipids in AMD is not fully elucidated and therefore they are not yet applicable as 
robust biomarkers for the disease. 
In general, many inconsistencies exist between studies evaluating biomarkers and their 
association with AMD. The contradicting results are difficult to interpret due to a variety of 
differences between studies, including methodological differences (fasting versus nonfasting 
blood), different populations (Caucasian/Asian/Mediterranean) with different dietary habits, 
different study designs, different analytical methods and correction factors, but also types 
of AMD included in the studies. It must be noted that compiling and comparison of data 
deriving from different sources represent a major limitation. Therefore, large well-conducted 
prospective studies are needed to further clarify these results.
Although AMD represents a phenotype restricted to the eye, many studies have investigated 
systemic markers in relation to AMD. However, because of the presence of the blood-retinal 
barrier, biomarkers might be only locally dysregulated inside the eye without a measurable 
systemic effect. Additionally, some compounds are differently expressed between tissues, 
leading to different results when analyzing different matrices. One might therefore argue to 
measure markers only locally, however because of the invasive character and accompanying 
ethical issues systemic markers are preferred for implementation as clinical biomarkers. 
Until now, most studies have targeted specific single biomarkers in a candidate-driven 
approach. Omic studies with an unbiased view are heavily outnumbered. Future biomarker 
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research should therefore combine hypothesis-free as well as candidate-driven approaches. 
Quantitative analytical approaches applied in an untargeted as well as targeted fashion, such 
as metabolomic or proteomic studies, are necessary to identify novel biomarker candidates. 
Once validated as robust and reliable markers, they can offer more insights into the etiology 
and pathogenesis of AMD, and support prediction, diagnosis, stratification, monitoring of 
treatment, and drug development for AMD. 
Other biomarker types in AMD, such as genetic factors, imaging biomarkers or visual function 
measurements, are currently of key importance for proper clinical diagnosis, stratification 
and treatment of AMD. In the future, these established clinical examinations and diagnostic 
tests may well be applied in combination with molecular biomarkers, an area which is still in 
a nascent stage.
12. METHODS OF LITERATURE SEARCH
A review of literature was performed through a thorough PubMed search in November 
2015. We used the following keywords and their synonyms in various combinations: age-
related macular degeneration, serum, plasma, blood, urine, tear, aqueous, and vitreous. 
No limitations were set for the time range covered by our search, and therefore all articles 
published until our search were included.
Figure 4. Flow diagram of literature search
The screening and selection process of studies included for this review is depicted in the flow diagram.
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All abstracts were screened for relevance and full texts of the selected articles were studied. 
We included only papers written in English. Articles cited in the reference lists of articles 
obtained through this search were also included whenever relevant. Animal, ex vivo and in 
vitro studies were excluded. To include the most recent developments before submission, the 
search was repeated in June 2016. An overview of our selection process is detailed in figure 4. 
After the final article selection, all described compounds in these studies were grouped based 
on their common biological function or pathway and results were discussed accordingly. Of 
note, compounds that were only described once in literature were not mentioned in this 
review to reduce the effect of selective reporting.
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ABSTRACT
Age-related macular degeneration (AMD) is a common, progressive multifactorial vision-
threatening disease and many genetic and environmental risk factors have been identified. 
The risk of AMD is influenced by lifestyle and diet, which may be reflected by an altered 
metabolic profile. Therefore, measurements of metabolites could identify biomarkers for 
AMD, and could aid in identifying high-risk individuals. Hypothesis-free technologies such as 
metabolomics have a great potential to uncover biomarkers or pathways that contribute to 
disease pathophysiology. To date, only a limited number of metabolomic studies have been 
performed in AMD. Here, we aim to contribute to the discovery of novel biomarkers and 
metabolic pathways for AMD using a targeted metabolomics approach of 188 metabolites. 
This study focuses on non-advanced AMD, since there is a need for biomarkers for the 
early stages of disease before severe visual loss has occurred. Targeted metabolomics was 
performed in 72 patients with early or intermediate AMD and 72 control individuals, and 
metabolites predictive for AMD were identified by a sparse partial least squares discriminant 
analysis. In our cohort, we identified four metabolite variables that were most predictive for 
early and intermediate stages of AMD. Increased glutamine and phosphatidylcholine diacyl 
C28:1 levels were detected in non-advanced AMD cases compared to controls, while the 
rate of glutaminolysis and the glutamine to glutamate ratio were reduced in non-advanced 
AMD. The association of glutamine with non-advanced AMD corroborates a recent report 
demonstrating an elevated glutamine level in early AMD using a different metabolomics 
technique. In conclusion, this study indicates that metabolomics is a suitable method for the 
discovery of biomarker candidates for AMD. In the future, larger metabolomics studies could 
add to the discovery of novel biomarkers in yet unknown AMD pathways and expand our 
insights in AMD pathophysiology.
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INTRODUCTION
Age-related macular degeneration (AMD) is a common vision-threatening disease affecting 
the elderly.1-3 Visual loss in AMD occurs as a result of progressive degenerative events at the 
centre of the retina, known as the macula. Early AMD is characterized by the accumulation 
of waste products (drusen) in the macula. Usually, patients experience no or only mild 
complaints at this stage. As AMD progresses, visual loss occurs and two advanced subtypes 
of AMD are distinguished: geographic atrophy and choroidal neovascularization, also referred 
to as wet AMD. Targeting vascular endothelial growth factor, which is central to the disease 
process of wet AMD, has proven to be a highly effective treatment.4 However, for the early, 
intermediate and atrophic stages of AMD, constituting over 80% of AMD patients, no effective 
treatment exists.
Many environmental and genetic risk factors for AMD have been discovered, including age, 
smoking, dietary factors (plasma lipids and anti-oxidant levels) and both common and rare 
genetic variants.3,5-9 However, not all individuals with a high genetic risk develop AMD, while 
some low-risk individuals do develop AMD. Potentially, the disease risk in these AMD patients 
could be influenced by lifestyle and diet, which may be reflected by their metabolic profile. 
It has been described that metabolite levels can be influenced by many factors, including 
age, body-mass index (BMI) and nutrition,10 factors that are also associated with AMD. 
Therefore, measurements of metabolites could identify biomarkers for AMD, which could aid 
in identifying high-risk individuals. 
Metabolomics is an hypothesis-free approach that enables simultaneous analysis of large 
numbers of metabolites, and has the potential to uncover physiological pathways that differ 
between patients and controls.11 To date, only a limited number of metabolomic studies 
have been performed in AMD.12-17 Two small case-control studies involving a total of 45 and 
40 individuals, respectively, showed that individual metabolites and metabolic pathways 
relevant for AMD pathogenesis can be identified using metabolomics.13,15 Another larger 
study in 396 individuals concluded that, although metabolite changes related to AMD are of 
low magnitude, they seem to be specific to AMD and further studies are warranted.12 More 
recently, a study in 120 individuals indicated that the most significant metabolites belong to 
the glycerophospholipid pathway.16 
Here, we aim to contribute to the discovery of novel biomarkers for AMD and uncover 
clinically relevant metabolic pathways using a targeted metabolomics approach. Ideally, future 
AMD treatment should be initiated in early stages of the disease to prevent progression to 
advanced AMD with accompanying visual loss. To identify biomarkers for early stages of the 
disease, this study focuses on non-advanced AMD. 
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MATERIALS AND METHODS
Study design and study population
Individuals were selected from the European Genetic Database (EUGENDA), a large multicenter 
database for clinical and molecular analysis of AMD. Disease status was determined based on 
classification of color fundus photographs, and if available spectral domain optical coherence 
tomograms and fluorescein angiography by certified graders as described previously.18 In 
this study, we included cases with non-advanced AMD defined as presence of at least 10 
small drusen (<63µm) and pigmentary changes in at least one eye, and absence of central 
geographic atrophy or choroidal neovascularization in both eyes. Individuals having only 
pigmentary changes, less than 10 small drusen or without macular abnormalities were 
classified as control individuals. 
Individuals were matched for age, sex, smoking status, body mass index (BMI), number or risk 
alleles of two prominent common genetic variants in CFH (p.Y402H; rs1061170) and ARMS2 
(p.A69S; rs10490924), and complement activation levels (measured as C3d/C3 ratio19) 
to minimize potential confounding effects. Interviewer-assisted questionnaires provided 
information on lifestyle, dietary habits and other environmental factors. For metabolomic 
analyses in this study, 72 AMD cases and 72 controls were selected (total n=144). 
This study was approved by the local ethical committees at both sites of patient recruitment, 
the Radboud university medical center and the University Hospital of Cologne, and was 
performed in accordance with the tenets of the Declaration of Helsinki. Written informed 
consent was provided by all individuals. 
Serum collection and genotyping
Venous blood samples were collected from all individuals in a non-fasting state at time 
of enrolment in EUGENDA. Serum was obtained using standardized coagulation and 
centrifugation procedures, and subsequently stored at -80oC within one hour after collection 
until analysis. 
Genomic DNA was extracted from peripheral blood leukocytes, and genotyping of single 
nucleotide polymorphisms (SNPs) in the CFH (rs1061170) and ARMS2 (rs10490924) genes 
was performed using competitive allele-specific PCR assays (KASPar SNP Genotyping System, 
KBiosciences).
Targeted metabolomics 
Targeted identification and quantification of 188 metabolites (Supplementary Table 1) was 
achieved by executing the mass spectrometric acquisition methods as provided by the 
AbsoluteIDQ p180 kit (Biocrates Life Sciences, Innsbruck, Austria) with some modifications. 
Instead of using a conventional HPLC-MS system the analyses were performed on an Eksigent 
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200 microLC chromatography system (ABSciex, Darmstadt, Germany) coupled to a 6500 
QTRAP (ABSciex, Darmstadt, Germany). To detect amino acids and biogenic amines, 50 µL 
of the metabolite extract were diluted in 350 µL of 50% methanol. Chromatography was 
performed using two running solvents (A: water, 0.2% formic acid; B: acetonitrile, 0.2% 
formic acid). Two µL of the diluted metabolite extracts were resolved on an Acquity UPLC 
BEH C18, 1.0 x 50 mm (120 A) reverse phase column (Waters, Eschborn, Germany) using a 
linear gradient from 2% B to 40% B in 3.5 minutes, from 40 % B to 80 % B in 1.5 minutes, and 
to 100% B in 0.1 min at 30 µL/min.
To determine the content of glycerophospholipids, hexoses and acylcarnitines, 50 µL of the 
metabolite extract were diluted with 450 µL methanol. Five µL of this dilution were analyzed 
in the mass spectrometer by direct infusion using the acquisition parameters as given by the 
manufacturer’s manual. Two injections were done to acquire data in positive and negative 
mode separately. 
Quality control
Technical quality control steps were undertaken before statistical analyses. Individual 
analytical batches were normalized to at least 3 replicates of the identical plasma quality 
control provided by the kit manufacturer to account for plate-to-plate variability. All 
metabolites that exhibited concentration values below limit of detection (as defined by the 
analytical specifications) in more than 50% of the measurements were omitted from the 
dataset (Supplementary Table 1).
Statistical analyses
To compare demographic characteristics of the two groups, one-way ANOVA and chi-squared 
tests were performed. After quality control 153 metabolites remained available for statistical 
analyses (Supplementary Table 1). Additionally, various derivative variables were created 
based on the metabolite levels (n=57; Supplementary Table 2). Due to the large number 
of variables to be evaluated, we used a sparse partial least squares discriminant analysis 
(sPLSda) to perform variable selection while taking into account the correlations between 
the variables. This approach aims at combining variable selection and dimension reduction 
in a one-step procedure.20 We considered one latent dimension since we are predicting a 
univariate binary outcome and to facilitate interpretation of the model.20 The optimal tuning 
parameters (i.e., number of selected predictors) were estimated using a leave one out cross-
validation strategy. Thereafter, a logistic regression was performed on the selected predictors 
resulting from the sPLSda to reduce the bias induced by shrinkage.21 We performed these 
analyses on the entire dataset (including the created variables) and on the crude metabolites 
only. Statistical tests were performed using R statistical software (R Core Team (2016). R: A 
language and environment for statistical computing. R Foundation for Statistical Computing, 
Chapter 3
228
Vienna, Austria. URL https://www.R-project.org/). We used the cran R package “mixOmics” 
to train and to test the sPLSda.
RESULTS
Serum samples of 72 cases and 72 control individuals were selected for metabolomic 
analyses. Demographic characteristics and other potential confounding factors in our cohort 
are provided in Table 1. No significant differences between the groups were detected for sex, 
age, smoking status, BMI, diabetic status, diet and complement activation levels. 
Next, we performed sPLSda to select the most predictive variables from our dataset, including 
all 153 measured metabolites and 57 derivative variables. This approach selected four relevant 
predictors for non-advanced AMD: glutamine, glutamate:glutamine ratio, glutaminolysis, and 
phosphatidylcholine diacyl C28:1 (PC aa C28.1) (Table 2; Fig 1). Two of these predictors are 
derivative variables that were created from measured metabolite levels, which both involved 
glutamine: the rate of glutaminolysis was expressed by the ratio of the sum of the potential 
glutamine conversion products (aspartate, alanine, glutamate) to glutamine (Fig 2), and 
another measure of glutamine metabolism was defined as the ratio between glutamine and 
glutamate (Glu:Gln ratio). 
The distributions of these variables in non-advanced AMD cases and control individuals are 
illustrated in Figure 1. A higher mean glutamine level was detected in non-advanced AMD 
cases (746.33 µM) compared to controls (695.0 µM). The mean rate of glutaminolysis and 
the Glu:Gln ratio were reduced in non-advanced AMD cases (0.73 and 0.08, respectively) 
compared to controls (0.80 and 0.10, respectively). The mean level of phosphatidylcholine 
diacyl C28:1 was elevated in non-advanced AMD cases (3.35 µM) compared to controls (3.04 
µM). 
When performing sPLSda on the measured metabolites only (excluding the derivative 
variables), glutamine levels were the most predictive for non-advanced AMD (OR 1.005). 
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Table 1. Patient characteristics of AMD cases and control individuals
  AMD cases
(n=72)
Control individuals (n=72) P-value
Sex Male 26 (36.1%) 28 (38.9%)
 Female 46 (63.9%) 44 (61.1%) 0.73
  
Age (mean years ±SD)  72.65±7.30 70.64±5.27 0.06
  
Smoking status Never 34 (47.2%) 37 (51.4%)
 Past 38 (52.8%) 35 (48.6%)
 Current 0 (0%) 0 (0%) 0.62
  
BMI (kg/m2) <20 3 (4.2%) 3 (4.2%)
 20-25 35 (48.6%) 29 (40.3%)
 25-30 28 (38.9%) 33 (45.8%)
 >30 6 (8.3%) 7 (9.7%) 0.79
  
Diabetes Mellitus* Present 64 (90.1%) 64 (91.4%)
 Absent 7 (9.9%) 6 (8.6%) 0.79
  
Diet Regular diet 65 (94.2%) 66 (95.7%)
 Vegetarian diet** 4 (5.8%) 3 (4.3%) 0.70
  
Complement activation 
(mean±SD***)
C3d/C3 ratio 1.54±0.40 1.47±0.44 0.37
*Self-reported diagnosis
**Vegetarian diet when participant indicated to (almost) never eat fish and red meat
***For the purpose of analyses data was transformed to the natural logarithm
Abbreviations: SD, standard deviation; BMI, body mass index.
Table 2. Metabolite predictors for non‐advanced AMD from sPLSda
Estimate Odds ratio
Glutamine (µM) 0.0037 1.004
Glu:Gln ratio -2.79 0.061
Glutaminolysis -1.73 0.177
PC.aa.C28.1 (µM) 0.62 1.858
Chapter 3
230
Figure 1. Boxplots of the four metabolite predictors for non‐advanced AMD from sPLSda
All metabolites were measured in µM.
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DISCUSSION
In the present study, we investigated potential differences of the metabolome between non-
advanced AMD patients and control individuals using a targeted metabolomics approach. 
Four variables were identified by sPLSda as the most predictive features to discriminate 
between non-advanced AMD patients and control individuals, including glutamine, 
glutamine-related variables and a glycerophospholipid (PC aa C28.1). These results are in 
line with previous studies describing metabolic differences between AMD patients and 
controls.12,13,15 Of particular interest is the slightly increased glutamine level in AMD patients, 
which independently corroborates a recent report demonstrating an elevated glutamine level 
in early AMD using a different metabolomics technique.12 Also, other measures of glutamine 
metabolism in our study were indicative of a possible association between glutamine and 
AMD. In AMD patients, both glutaminolysis (the ratio of glutamate, aspartate and alanine to 
glutamine) as well as the Glu:Gln ratio were decreased, although these effects were driven 
mainly by elevated levels of glutamine. Glutamine is a nonessential amino acid necessary 
to sustain immune competence,23 and immunological processes are at the heart of AMD 
pathology.24,25 It remains to be investigated whether increased glutamine in serum is a 
Fig 2. Metabolic conversion of glutamine
Glutaminolysis, the metabolic conversion of glutamine to glutamate, aspartate and alanine, represents an alternative 
pathway to supply the mitochondrial citric acid cycle with a surplus of α-ketoglutarate. As this pathway is preferentially 
used by proliferating tissue, glutaminolysis measured as (c
Ala
+c
Asp
+c
Glu
)/c
Gln
 is increased in tumor tissue.22 Metabolites 
determined in this study are marked in grey.
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physiological response to a higher demand from the immune system or a result of increased 
protein catabolism, decreased clearance of glutamine, increased dietary intake of glutamine, 
or other mechanisms. 
The observed association between a glycerophospholipid (PC aa C28.1) and non-advanced 
AMD is interesting because alterations in concentrations of these species have been 
implicated in a variety of metabolic diseases and pathomechanisms.26-28 Glycerophospholipids 
and sphingomyelin are constituents of cell membranes and myelin sheaths, and 
phosphatidylcholines are the main constituents of lipoproteins,29 which have been described 
to be relevant for AMD pathology.30,31 Although literature is not entirely consistent, multiple 
studies have associated higher high-density lipoprotein cholesterol levels with increased risk 
of AMD.8,25,31-34 Furthermore, it is conceivable that not only levels of lipoprotein classes, but 
also their molecular composition in terms of glycerophospholipid species could be potential 
biomarkers for AMD development, as has been reported for other conditions, such as arterial 
hypertension.35 Therefore in-depth lipidomics studies that cover a wider range of lipoprotein 
subclasses and their molecular constituents are required to corroborate our findings and to 
further explore the relationship between lipids, lipoprotein dynamics and AMD pathology.
It must be noted that the effect sizes of the identified AMD-associated metabolites are small, 
consistent with slightly altered metabolic profiles of AMD patients compared to controls. Due 
to the limited sample size of the current study, we might have been unable to detect smaller 
associations and therefore larger studies are warranted. A strength of our study is that the 
study groups were carefully selected and matched on potential confounders including age, 
sex, smoking status and BMI. Due to this strict patient stratification, differences in metabolites 
likely reflect true differences in metabolic profiles between AMD cases and controls. 
Additionally, our study included patients with non-advanced AMD only, which allows for the 
identification of potentially relevant biomarkers already in an early stage of the disease. 
Of note, the samples used for this study were collected at time of enrolment in EUGENDA 
and were not specifically collected for the current study. Because of possible influences of 
diet on the metabolome, the use of non-fasting samples in this study might not be ideal. 
However, although the reproducibility of metabolite levels over time was previously reported 
to be lower using non-fasting samples compared to fasting samples, in general the reliability 
of metabolites was not significantly different when comparing fasting versus non-fasting 
samples.36 
In summary, the findings of this study indicate that metabolomics is a suitable method for 
the discovery of biomarkers in AMD. Using a targeted approach, several metabolites were 
identified as candidate biomarkers for AMD with glutamine being the most promising, which 
may serve as potential targets for future interventions. Larger metabolomic studies are 
needed to further elucidate the metabolic profile of AMD patients. Additionally, untargeted 
metabolomic studies could provide novel biomarkers in yet unknown AMD pathways and 
expand our insights in AMD pathophysiology. 
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SUPPLEMENTARY MATERIAL
Supplementary Table 1. List of metabolites
Metabolite name Abbreviation Passed QC?
Aminoacids (n=21)
Alanine Ala Yes 
Arginine Arg Yes
Asparagine Asn Yes
Aspartate Asp Yes
Citrulline Cit Yes 
Glutamine Gln Yes
Glutamate Glu Yes
Glycine Gly Yes
Histidine His Yes 
Isoleucine Ile Yes
Leucine Leu Yes
Lysine Lys Yes
Methionine Met Yes 
Ornithine Orn Yes
Phenylalanine Phe Yes
Proline Pro Yes
Serine Ser Yes 
Threonine Thr Yes
Tryptophan Trp Yes 
Tyrosine Tyr Yes
Valine Val Yes
Biogenic amines (n=21)
Acetylornithine Ac-Orn < LOD
Asymmetric dimethylarginine ADMA Yes
alpha-Aminoadipic acid alpha-AAA < LOD
cis-4-Hydroxyproline c4-OH-Pro < LOD
Carnosine Carnosine < LOD
Creatinine Creatinine Yes 
DOPA DOPA < LOD
Dopamine Dopamine < LOD
Histamine Histamine < LOD
Kynurenine Kynurenine Yes
Methioninesulfoxide Met-SO < LOD
Nitrotyrosine Nitro-Tyr < LOD
Phenylethylamine PEA < LOD
Putrescine Putrescine Yes
Sarcosine Sarcosine Yes
Serotonin Serotonin Yes 
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Metabolite name Abbreviation Passed QC?
Spermidine Spermidine < LOD
Spermine Spermine < LOD
trans-OH-Pro t4-OH-Pro < LOD
Taurine Taurine Yes
Symmetric dimethylarginine SDMA Yes
Acylcarnitines (n=40)
Carnitine C0 Yes
Acetylcarnitine C2 Yes
Propionylcarnitine C3 Yes 
Propenoylcarnitine C3:1 < LOD
Hydroxypropionylcarnitine C3-OH < LOD
Butyrylcarnitine C4 Yes
Butenylcarnitine C4:1 Yes
Hydroxybutyrylcarnitine C4-OH (C3-DC) Yes
Valerylcarnitine C5 Yes
Tiglylcarnitine C5:1 Yes
Glutaconylcarnitine C5:1-DC Yes
Glutarylcarnitine (Hydroxyhexanoylcarnitine) C5-DC (C6-OH) Yes 
Methylglutarylcarnitine C5-M-DC < LOD
Hydroxyvalerylcarnitine
(Methylmalonylcarnitine)
C5-OH (C3-DC-M) < LOD
Hexanoylcarnitine
(Fumarylcarnitine)
C6 (C4:1-DC) Yes 
Hexenoylcarnitine C6:1 < LOD
Pimelylcarnitine C7-DC < LOD
Octanoylcarnitine C8 Yes
Nonaylcarnitine C9 Yes
Decanoylcarnitine C10 Yes 
Decenoylcarnitine C10:1 Yes
Decadienylcarnitine C10:2 < LOD
Dodecanoylcarnitine C12 Yes
Dodecenoylcarnitine C12:1 Yes
Dodecanedioylcarnitine C12-DC < LOD
Tetradecanoylcarnitine C14 Yes 
Tetradecenoylcarnitine C14:1 Yes
Hydroxytetradecenoylcarnitine C14:1-OH < LOD
Tetradecadienylcarnitine C14:2 Yes
Hydroxytetradecadienylcarnitine C14:2-OH < LOD
Hexadecanoylcarnitine C16 Yes
Hexadecenoylcarnitine C16:1 < LOD
Hydroxyhexadecenoylcarnitine C16:1-OH < LOD
Hexadecadienylcarnitine C16:2 < LOD
Hydroxyhexadecadienylcarnitine C16:2-OH < LOD
Hydroxyhexadecanoylcarnitine C16-OH < LOD
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Metabolite name Abbreviation Passed QC?
Octadecanoylcarnitine C18 Yes 
Octadecenoylcarnitine C18:1 Yes
Hydroxyoctadecenoylcarnitine C18:1-OH < LOD
Octadecadienylcarnitine C18:2 Yes
Glycerophospholipids (n=90)
lysophosphatidylcholine acyl C14:0 lysoPC a C14:0 < LOD
lysophosphatidylcholine acyl C16:0 lysoPC a C16:0 Yes
lysophosphatidylcholine acyl C16:1 lysoPC a C16:1 Yes 
lysophosphatidylcholine acyl C17:0 lysoPC a C17:0 Yes
lysophosphatidylcholine acyl C18:0 lysoPC a C18:0 Yes
lysophosphatidylcholine acyl C18:1 lysoPC a C18:1 Yes
lysophosphatidylcholine acyl C18:2 lysoPC a C18:2 Yes 
lysophosphatidylcholine acyl C20:3 lysoPC a C20:3 Yes
lysophosphatidylcholine acyl C20:4 lysoPC a C20:4 Yes
lysophosphatidylcholine acyl C24:0 lysoPC a C24:0 Yes
lysophosphatidylcholine acyl C26:0 lysoPC a C26:0 Yes 
lysophosphatidylcholine acyl C26:1 lysoPC a C26:1 Yes
lysophosphatidylcholine acyl C28:0 lysoPC a C28:0 Yes
lysophosphatidylcholine acyl C28:1 lysoPC a C28:1 Yes
Phosphatidylcholine diacyl C24:0 PC aa C24:0 Yes 
Phosphatidylcholine diacyl C26:0 PC aa C26:0 < LOD
Phosphatidylcholine diacyl C28:1 PC aa C28:1 Yes
Phosphatidylcholine diacyl C30:0 PC aa C30:0 Yes
Phosphatidylcholine diacyl C30:2 PC aa C30:2 < LOD
Phosphatidylcholine diacyl C32:0 PC aa C32:0 Yes
Phosphatidylcholine diacyl C32:1 PC aa C32:1 Yes 
Phosphatidylcholine diacyl C32:2 PC aa C32:2 Yes
Phosphatidylcholine diacyl C32:3 PC aa C32:3 Yes
Phosphatidylcholine diacyl C34:1 PC aa C34:1 Yes
Phosphatidylcholine diacyl C34:2 PC aa C34:2 Yes 
Phosphatidylcholine diacyl C34:3 PC aa C34:3 Yes
Phosphatidylcholine diacyl C34:4 PC aa C34:4 Yes
Phosphatidylcholine diacyl C36:0 PC aa C36:0 Yes
Phosphatidylcholine diacyl C36:1 PC aa C36:1 Yes 
Phosphatidylcholine diacyl C36:2 PC aa C36:2 Yes
Phosphatidylcholine diacyl C36:3 PC aa C36:3 Yes
Phosphatidylcholine diacyl C36:4 PC aa C36:4 Yes
Phosphatidylcholine diacyl C36:5 PC aa C36:5 Yes 
Phosphatidylcholine diacyl C36:6 PC aa C36:6 Yes
Phosphatidylcholine diacyl C38:0 PC aa C38:0 Yes
Phosphatidylcholine diacyl C38:1 PC aa C38:1 Yes
Phosphatidylcholine diacyl C38:3 PC aa C38:3 Yes 
Phosphatidylcholine diacyl C38:4 PC aa C38:4 Yes
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Metabolite name Abbreviation Passed QC?
Phosphatidylcholine diacyl C38:5 PC aa C38:5 Yes
Phosphatidylcholine diacyl C38:6 PC aa C38:6 Yes
Phosphatidylcholine diacyl C40:1 PC aa C40:1 < LOD
Phosphatidylcholine diacyl C40:2 PC aa C40:2 Yes 
Phosphatidylcholine diacyl C40:3 PC aa C40:3 Yes
Phosphatidylcholine diacyl C40:4 PC aa C40:4 Yes
Phosphatidylcholine diacyl C40:5 PC aa C40:5 Yes
Phosphatidylcholine diacyl C40:6 PC aa C40:6 Yes 
Phosphatidylcholine diacyl C42:0 PC aa C42:0 Yes
Phosphatidylcholine diacyl C42:1 PC aa C42:1 Yes
Phosphatidylcholine diacyl C42:2 PC aa C42:2 Yes
Phosphatidylcholine diacyl C42:4 PC aa C42:4 Yes 
Phosphatidylcholine diacyl C42:5 PC aa C42:5 Yes
Phosphatidylcholine diacyl C42:6 PC aa C42:6 Yes
Phosphatidylcholine acyl-alkyl C30:0 PC ae C30:0 Yes
Phosphatidylcholine acyl-alkyl C30:1 PC ae C30:1 Yes 
Phosphatidylcholine acyl-alkyl C30:2 PC ae C30:2 Yes
Phosphatidylcholine acyl-alkyl C32:1 PC ae C32:1 Yes
Phosphatidylcholine acyl-alkyl C32:2 PC ae C32:2 Yes
Phosphatidylcholine acyl-alkyl C34:0 PC ae C34:0 Yes 
Phosphatidylcholine acyl-alkyl C34:1 PC ae C34:1 Yes
Phosphatidylcholine acyl-alkyl C34:2 PC ae C34:2 Yes
Phosphatidylcholine acyl-alkyl C34:3 PC ae C34:3 Yes
Phosphatidylcholine acyl-alkyl C36:0 PC ae C36:0 Yes 
Phosphatidylcholine acyl-alkyl C36:1 PC ae C36:1 Yes
Phosphatidylcholine acyl-alkyl C36:2 PC ae C36:2 Yes
Phosphatidylcholine acyl-alkyl C36:3 PC ae C36:3 Yes
Phosphatidylcholine acyl-alkyl C36:4 PC ae C36:4 Yes 
Phosphatidylcholine acyl-alkyl C36:5 PC ae C36:5 Yes
Phosphatidylcholine acyl-alkyl C38:0 PC ae C38:0 Yes
Phosphatidylcholine acyl-alkyl C38:1 PC ae C38:1 Yes
Phosphatidylcholine acyl-alkyl C38:2 PC ae C38:2 Yes 
Phosphatidylcholine acyl-alkyl C38:3 PC ae C38:3 Yes
Phosphatidylcholine acyl-alkyl C38:4 PC ae C38:4 Yes
Phosphatidylcholine acyl-alkyl C38:5 PC ae C38:5 Yes
Phosphatidylcholine acyl-alkyl C38:6 PC ae C38:6 Yes 
Phosphatidylcholine acyl-alkyl C40:1 PC ae C40:1 Yes
Phosphatidylcholine acyl-alkyl C40:2 PC ae C40:2 Yes
Phosphatidylcholine acyl-alkyl C40:3 PC ae C40:3 Yes
Phosphatidylcholine acyl-alkyl C40:4 PC ae C40:4 Yes 
Phosphatidylcholine acyl-alkyl C40:5 PC ae C40:5 Yes
Phosphatidylcholine acyl-alkyl C40:6 PC ae C40:6 Yes
Phosphatidylcholine acyl-alkyl C42:0 PC ae C42:0 < LOD
Phosphatidylcholine acyl-alkyl C42:1 PC ae C42:1 Yes
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Metabolite name Abbreviation Passed QC?
Phosphatidylcholine acyl-alkyl C42:2 PC ae C42:2 Yes 
Phosphatidylcholine acyl-alkyl C42:3 PC ae C42:3 Yes
Phosphatidylcholine acyl-alkyl C42:4 PC ae C42:4 Yes
Phosphatidylcholine acyl-alkyl C42:5 PC ae C42:5 Yes
Phosphatidylcholine acyl-alkyl C44:3 PC ae C44:3 Yes 
Phosphatidylcholine acyl-alkyl C44:4 PC ae C44:4 Yes
Phosphatidylcholine acyl-alkyl C44:5 PC ae C44:5 Yes
Phosphatidylcholine acyl-alkyl C44:6 PC ae C44:6 Yes
Sphingolipids (n=15)
Hydroxysphingomyelin C14:1 SM (OH) C14:1 Yes 
Hydroxysphingomyelin C16:1 SM (OH) C16:1 Yes
Hydroxysphingomyelin C22:1 SM (OH) C22:1 Yes
Hydroxysphingomyelin C22:2 SM (OH) C22:2 Yes
Hydroxysphingomyelin C24:1 SM (OH) C24:1 Yes 
Sphingomyelin C16:0 SM C16:0 Yes
Sphingomyelin C16:1 SM C16:1 Yes
Sphingomyelin C18:0 SM C18:0 Yes
Sphingomyelin C18:1 SM C18:1 Yes 
Sphingomyelin C20:2 SM C20:2 Yes
Sphingomyelin C22:3 SM C22:3 < LOD
Sphingomyelin C24:0 SM C24:0 Yes
Sphingomyelin C24:1 SM C24:1 Yes
Sphingomyelin C26:0 SM C26:0 Yes 
Sphingomyelin C26:1 SM C26:1 Yes
Monosaccharides (n=1)
Sum of hexoses H1 Yes
Abbreviations: LOD = limit of detection.
*Notation of fatty acid chains take the form “C x:y,” where “x” is the number of carbon atoms and “y” the number 
of double bonds in the fatty acid. 
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Supplementary Table 2. List of custom metabolic indicator variables
Custom metabolic indicator Calculation
AAA Sum of aromatic amino acids (Phe, Tyr, Trp)
ADMA/Arg Ratio of Asymmetric dimethylarginine to Arginine
Arg/(Arg+Orn) Ratio of Arginine to (Arginine+Ornithine)
BCAA Sum of branched chain amino acids (Val, Leu, Ile)
Cit/Arg Ratio of Citrulline to Arginine
Cit/Orn Ratio of Citrulline to Ornithine
Essential AA Total of essential aminoacids
Fisher ratio Ratio of BCAA to AAA
Glu/Gln Ratio of Glutamate to Glutamine
Glucogenic AA Sum of selected amino acids (Ala, Gly, Ser)
Glutaminolysis Ratio of (Asparagine+Alanine+Glutamate) to Glutamine 
Gly/Arg Ratio of Glycine to Arginine
Gly/Gln Ratio of Glycine to Glutamine
Gly/His Ratio of Glycine to Histidine
Gly/Ser Ratio of Glycine to Serine
Glycolysis Sum of selected amino acids (Ala, Gly, Ser)
Kynurenine/Trp Ratio of Kynurenine to Tryptophan
Non essential AA Total of non essential aminoacids
Orn/Arg Ratio of Ornithine to Arginine
Orn/Ser Ratio of Ornithine to Serine
Putrescine/Orn Ratio of Putrescine to Ornithine
SDMA/Arg Ratio of Symmetric dimethylarginine to Arginine
Serotonin/Trp Ratio of Serotonin to Tryptophan
Thr/Ser Ratio of Threonine to Serine
Total AA Total of aminoacids
Total DMA/Arg Ratio of (SDMA+ADMA) to Arginine
Tyr/Phe Ratio of Tyrosine to Phenylalanine
(C2+C3)/C0 Ratio of (Acetylcarnitine+Propionylcarnitine) to Carnitine
C18/C18:1 Ratio of Octadecanoylcarnitine to Octadecenoylcarnitine
C2/C0 Ratio of Acetylcarnitine to Carnitine
C3/C4 Ratio of Propionylcarnitine to Butyrylcarnitine
C4/C0 Ratio of Butyrylcarnitine to Carnitine
C4/C5 Ratio of Butyrylcarnitine to Valerylcarnitine
CPT-I ratio Ratio of (Hexadecanoylcarnitine+Octadecanoylcarnitine) to Carnitine
lysoPC a C16:0/lysoPC a C16:1 Ratio of lysophosphatidylcholine acyl C16:0 to lysophosphatidylcholine acyl 
C16:1
lysoPC a C20:4/lysoPC a C20:3 Ratio of lysophosphatidylcholine acyl C20:4 to lysophosphatidylcholine acyl 
C20:3
MUFA (PC) Sum of mono-unsaturated glycerophosphocholins
MUFA (PC)/SFA (PC) Ratio of MUFA (PC) to SFA (PC)
PUFA (PC) Sum of poly-unsaturated glycerophosphocholins
PUFA (PC)/MUFA (PC) Ratio of PUFA (PC) to MUFA (PC)
PUFA (PC)/SFA (PC) PUFA (PC)/SFA (PC)
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Custom metabolic indicator Calculation
SFA (PC) Sum of saturated glycerophosphocholins
Total (PC+SM) Sum of choline-containing phospholipids
Total AC/C0 Ratio of esterified to free carnitine
Total AC-DC/Total AC Fraction of dicarboxyacylcarnitines of the total acylcarnitines
Total AC-OH/Total AC Fraction of hydroxylated acylcarnitines of the total acylcarnitines
Total lysoPC Sum of lysoglycerosphosphocholines
Total lysoPC/Total PC Ratio of lysoglycerosphosphocholines to glycerosphosphocholines
Total PC Sum of glycerosphosphocholines
Total PC aa Sum of diacyl-glycerosphosphocholines
Total PC ae Sum of glycerosphosphocholines plasmalogens
Total SM Sum of ceramide phosphocholines (sphingomyelins)
Total SM/Total (SM+PC) Fraction of ceramide phosphocholines (sphingomyelins) of total 
phospholipid pool
Total SM/Total PC Ratio of ceramide phosphocholines (sphingomyelins) to total 
glycerophosphocholines
Total SM-non OH Sum of non-hydroxylated ceramide phosphocholines (sphingomyelins)
Total SM-OH Sum of hydroxylated ceramide phosphocholines (sphingomyelins)
Total SM-OH/Total SM-non OH Ratio of hydroxylated to non-hydroxylated ceramide phosphocholines 
(sphingomyelins)
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ABSTRACT
Purpose: A recent genome-wide association study by the International Age-related Macular 
Degeneration Genomics Consortium (IAMDGC) identified seven rare variants that are 
individually associated with age-related macular degeneration (AMD), the most common 
cause of vision loss in elderly. In literature, several of these rare variants have been reported 
with different frequencies and odds ratios across populations of Europe and North America. 
Here, we aim to describe the representation of these seven AMD-associated rare variants in 
different geographical regions based on 24 AMD studies. 
Methods: We explored the occurrence of seven rare variants independently associated 
with AMD, namely (CFH rs121913059 (p.Arg1210Cys), CFI rs141853578 (p.Gly119Arg), C3 
rs147859257 (p.Lys155Gln), and C9 rs34882957 (p.Pro167Ser) and three non-coding variants 
in or near the CFH gene (rs148553336, rs35292876, rs191281603), in 24 AMD case-control 
studies. We studied the difference in distribution, interaction and effect size for each of the 
rare variants based on the minor allele frequency within the different geographical regions.
Results: We demonstrate that two rare AMD-associated variants in the CFH gene (rs121913059 
[p.Arg1210Cys] and rs35292876) deviate in frequency among different geographical regions 
(p=0.004 and p=0.001, respectively). The risk estimates of each of the seven rare variants 
were comparable across the geographical regions.
Conclusion: Our results emphasize the importance of identifying population-specific rare 
variants, for example by performing sequencing studies in case-control studies of various 
populations, because their identification may have implications for diagnostic screening and 
personalized treatment.
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INTRODUCTION
Genetic diversity is observed among populations of different ancestries. Allele frequencies 
can exhibit large diversity among populations due to forces like genetic drift and natural 
selection. While most common variants are shared worldwide, rare variants (minor allele 
frequency [MAF] <1%) have the tendency to cluster in specific populations. Particularly 
population-specific rare variants tend to have a strong functional effect.1 
In age-related macular degeneration (AMD), large variability in rare variant frequency has been 
reported in case-control studies of various populations, for instance for variant rs121913059 
(p.Arg1210Cys) in complement factor H (CFH). CFH rs121913059 was first reported in a 
case-control study from the United States.2 While some studies could replicate the finding,3-5 
other Caucasian studies6-9 and Asian studies10,11 were unable to replicate its strong association 
(Table 1). Another example, variant rs141853578 (p.Gly119Arg) in complement factor I (CFI) 
first reported in a European cohort,7 was screened both in a British12 and American13 cohort 
(OR = 22.2; 8.5 and 2.6, respectively). However, while the variant was associated with AMD, 
its risk effect size was much weaker when compared to the first report. 
Table 1. Minor allele frequencies of the CFH rs121913059 (p.Arg1210Cys) variant among 
different geographical regions reported in literature
Source Carriers 
(n)
Total 
Cases (n)
Total 
Controls 
(n)
MAF 
Cases 
(%)‡
MAF  
Controls 
(%)‡ 
Odds‐
Ratio
P-value
World Fritsche2016 3 108 16144 17832 0.319 0.014 20.3 8.9 x 10-24
Eastern USA Raychaudhuri2011 2# 34 2414 1120 0.684 0.045 NA 8.0 × 10-5
Zhan2013 5 24 2268 2268 0.507 0.022 23.1 2.9 × 10-6
European Helgason2013 8 0 1143 51435 0.000 0.000 NA NA
Saksens2016 9* 0 1589 1386 0.000 0.000 NA NA
Recalde2016 4 5 259 330 0.965 0.000 NA NA
Asian Shen2012 11 0 258 426 0.000 0.000 NA NA
Miyake2015 10 1 1364 1208 0.037 0.000 NA NA
Additional publications from: the Boston study#13,14 and EUGENDA study*6,7. ‡ major allele C, minor allele T. NA = Not 
available or not reported.
In a recent genome-wide association study of the International Age-related Macular 
Degeneration Genomics Consortium (IAMDGC)3 seven rare variants were observed to 
independently confer risk for AMD. All seven rare variants are localized in or near genes 
encoding components of the complement system, namely CFH, CFI, and complement 
components 3 and 9 (C3 and C9).
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The difference in association for rare variants among different AMD case-control studies may 
reflect the difference in distribution of such rare alleles across geographical regions. This 
observation raises the question if these variants identified by the IAMDGC are represented 
in all case-control studies or whether the association is driven by one or more studies from 
a specific geographical region. Therefore, we sought to evaluate the representation of these 
seven AMD-associated rare variants in 24 AMD case-control studies of different geographical 
regions. 
MATERIALS AND METHODS
Data for this study were provided by the IAMDGC. The genotypes are in part available via 
dbGaP under accession number phs001039.v1.p1. The original dataset contained data from 
40,633 individuals of European ancestry as described by Fritsche et al.3 For analyses of the 
current study, participants from the Utah case-control study were excluded due to their 
mixed regions of origin. Also, the Jerusalem case-control study was excluded due to its small 
sample size compared to the other geographical regions. Final analyses were performed on 
39,582 participants deriving from 24 of 26 studies.3 The included studies were grouped in 
five geographical regions: eastern USA, western Europe, Britain, western USA and Australia 
(Supplementary Table 1). Data were collected by all study groups in accordance with the 
tenets of the Declaration of Helsinki; participants provided informed consent and study 
protocols were approved by local ethical committees.3 
The MAF in each region was calculated and compared independently of AMD status. For 
comparison of effect sizes and interaction analyses, individuals were assigned “AMD” when 
exhibiting signs of (1) advanced AMD defined as geographic atrophy and/or choroidal 
neovascularization in at least one eye, or (2) non-advanced AMD defined as pigmentary 
changes in the macula and/or more than five macular drusen with a diameter ≥63 μm. 
Individuals without any reported signs of AMD were assigned “No AMD”. 
Genotype data of seven rare genetic variants were selected from array based data generated 
by the IAMDGC.3 Fritsche et al.3 showed these seven rare variants to be independently 
associated with AMD: CFH rs121913059 (p.Arg1210Cys), CFI rs141853578 (p.Gly119Arg), C3 
rs147859257 (p.Lys155Gln), and C9 rs34882957 (p.Pro167Ser) and three non-coding variants 
in or near CFH (rs148553336, rs35292876, rs191281603). 
The software package SAS, (Statistical Analysis System Institute, V9.2) was used to compare 
MAFs between the different geographical regions in a logistic regression analysis with Firth 
correction.15 Furthermore, we estimated the mean allele frequency of each rare genetic 
variant in each of the geographical regions including a 95% confidence interval. To study a 
potential difference in effect size of each variant between the geographical regions, interaction 
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analyses were performed using binary logistic regression models with SPSS statistics software 
(IBM SPSS Statistics, V22.0). 
RESULTS 
Demographic characteristics for each of the five geographical regions are shown in 
Supplementary Table 1. The characteristics of participants from the different regions were 
comparable, although the British study samples were slightly younger than the others, and 
Figure 1. The two rare variants in CFH that are differently distributed variants among different geographical 
regions
Minor allele frequencies (in percentage) for CFH rs121913059 (A) and CFH rs35292876 (B). Variants mapped to 
geographical location (from left to right): western USA, eastern USA, Britain, western Europe, and Australia.
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the western European study samples included relatively more female participants compared 
to the remainder . These differences were comparable in both cases and controls. 
We analyzed the difference in distribution of the seven rare variants among case-control 
studies from eastern USA, western Europe, Britain, western USA and Australia using logistic 
regression analysis with Firth correction (Table 2; Figure 1), and observed a difference in 
distribution of variants CFH rs121913059 (p.Arg1210Cys, p=0.004) and CFH rs35292876 
(p=0.001) across the different geographical regions. CFH rs121913059 was found at a higher 
frequency in eastern USA, especially compared to Britain and Australia (p=0.011 and p=0.003, 
respectively). CFH rs35292876 was found at a higher frequency in western Europe, compared 
to all other regions (ranging from p<0.001 in Britain to p=0.012 in Eastern USA). The other 
five variants were found to have similar allele frequencies among all geographical regions. 
The difference in distribution is also reflected by the estimated MAFs of each variant in 
the different geographical regions (Supplementary Table 2). The allele frequency of CFH 
rs121913059 is nearly three times higher in eastern USA than in Britain and Australia. 
Noteworthy is the near absence of this risk variant in control individuals without AMD, 
indicating that the difference in distribution appears to be driven solely by AMD individuals 
(Supplementary Table 3). 
To determine if the effect size was influenced by geographical region we performed interaction 
analyses for each variant. We observed that the risk associated with each specific rare variant 
is independent of geographical region (Table 2). Overall effect sizes of the rare variants are 
comparable to the effect sizes reported in the IAMDGC study.3
Table 2. Distribution and interaction analysis of seven rare AMD‐associated genetic variants across five 
geographical regions 
 Difference in 
distribution between 
geographical regions#
Interaction Analysis* Overall effect size‡
p-value p-value OR (95%CI)
CFH rs121913059 (p.Arg1210Cys) 0.004 0.665 24.2 (8.9-65.6)
CFI rs141853578 (p.Gly119Arg) 0.707 0.563 3.7 (2.5-5.7)
C3 rs147859257 (p.Lys155Gln) 0.665 0.680 2.8 (2.3-3.4)
C9 rs34882957 (p.Pro167Ser) 0.315 0.572 1.7 (1.5-2.0)
CFH rs148553336 0.053 0.015 0.5 (0.4-0.6)
CFH rs35292876 0.001 0.709 2.3 (2.0-2.6)
CFH rs191281603 0.735 0.980 0.9 (0.7-1.1)
#Logistic Regression with Firth correction. Individual Wald Chi-Square from likelihood ratio test for each of the 
variants across the geographical regions. 
*Interaction Analysis: Effect sizes in entire study and interaction analysis to study potential differences in effect size 
between cohorts. 
‡Overall effect size adjusted for geographical region. 
Bold values: p-value considered significant after Bonferroni correction (p<0.007).
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DISCUSSION
The distribution of rare CFH variants rs121913059 (p.Arg1210Cys) and rs35292876 was 
significantly different between several of the studied geographical regions. This confirms 
differences reported in previous studies for the CFH rs121913059 variant (Table 1).2-11,13,14 CFH 
rs121913059 was first associated with AMD in study from the USA,2 however the association 
was not consistently replicated in Dutch/German,7 Icelandic,8 Japanese10 and Chinese11 
studies. In this study we confirmed the hypothesis that rare variants can be differently 
distributed among geographical regions but, as expected, the risk estimates are comparable 
across the geographical regions.
In AMD, a difference in geographical distribution has already been described for common risk 
haplotypes of CFH and ARMS2 genes, which are the most prominent common genetic AMD 
risk factors.3 While Asian populations report a lower frequency of CFH risk haplotypes, the 
opposite holds true for the ARMS2/HTRA1 risk haplotype which is more prevalent in Asians 
compared to Caucasian populations.16,17 These patient and population specific variations have 
implications for genetic counseling and carrier screening in both diagnostic and research 
settings. 
Besides single variant associations, a significant burden of rare variants in the CFH and CFI 
genes has been reported for AMD.3,14 The disease burden in these genes is attributed to the 
cumulative effect of rare coding variants, some of which are identified in multiple studies, 
while others are restricted to a single population or even a single patient.18 Carriers of 
specific rare genetic variants in the complement genes that increase complement activation 
may benefit more from complement inhibiting therapy than those who do not carry such 
variants.18 Personalized treatment aiming at complement activating rare variants in clinical 
trials may only be applicable to specific populations where these variants are sufficiently 
common.
It is likely that additional rare variants, other than CFH Arg1210Cys and rs35292876, fluctuate in 
frequency among geographical regions. To identify these variants, additional large sequencing 
studies will need to be performed in populations originating from diverse geographic regions. 
Up to now, large sequencing initiatives are predominantly of North American or European 
origin, and sample sizes for non-European-descent population are limited.3,19 Recruiting case-
control studies from other geographical regions and ancestries could allow for identification 
of novel highly penetrant rare variants implicated in AMD pathogenesis. These variants may 
be located in known AMD pathways, such as the complement system, or novel pathways.20 
In conclusion, we demonstrated that rare AMD-associated variants CFH rs121913059 and 
rs35292876 are differently distributed among different geographical regions. These results 
emphasize the importance of identifying population-specific rare variants in AMD.
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SUPPLEMENTARY INFORMATION
Supplementary Table 1. Demographic characteristics of AMD cohorts grouped in five geographical regions 
Eastern USA1 Western Europe2Britain3 Western USA4 Australia5
Participants (n) 18454 6590 4329 4226 5983
Mean Age 
(years ± SD)
74.0 ± 9.2 74.1 ± 8.2 69.6 ± 10.4 74.8 ± 10.0 74.3 ± 9.7
Gender Male (%) 7934 (43.0%) 2512 (38.1%) 1743 (40.3%) 1875 (44.4%) 2531 (42.3%)
Female (%) 10520 (57.0%) 4078 (61.9%) 2586 (59.7%) 2351 (55.6%) 3452 (57.7%)
AMD status AMD (%) 11564 (62.7%) 3865 (58.6%) 2125 (49.1%) 2061 (48.8%) 2449 (40.9%)
No AMD (%) 6890 (37.3%) 2725 (41.4%) 2204 (50.9%) 2165 (51.2%) 3534 (59.1%)
1)Eastern USA: AREDS, BDES, CWRU, Marshfield, Vanderbilt, Miami, Michigan, Pittsburgh, Pennsylvania, Baltimore. 2)Western 
Europe: Regensburg, Rotterdam, Creteil, Paris, Bonn, Cologne, UMCN. 3)Britain: Cambridge, Southampton, NHS_HPF, 
Edinburgh. 4)Western USA: University California, UCSD, Oregon. 5)Australia: Westmead, UWA/LEI/ Flinders and Melbourne.
Supplementary Table 2. Overall estimated mean MAF of seven rare AMD‐associated genetic variants across five 
geographical regions 
 Eastern USA Western Europe Britain Western USA Australia
CFH rs121913059 0.229 (0.185-0.283) 0.178 (0.119-0.267) 0.087 (0.042-0.177) 0.136 (0.076-0.242) 0.088 (0.048-0.161)
CFI rs141853578 0.197 (0.156-0.247) 0.163 (0.107-0.249) 0.249 (0.163-0.379) 0.184 (0.112-0.302) 0.213 (0.145-0.314)
C3 rs147859257 0.803 (0.717-0.900) 0.907 (0.758-1.084) 0.918 (0.738-1.143) 0.917 (0.734-1.144) 0.840 (0.691-1.020)
C9 rs34882957 1.196 (1.090-1.312) 1.286 (1.107-1.493) 1.276 (1.060-1.536) 1.366 (1.140-1.637) 1.065 (0.896-1.266)
CFH rs148553336 0.630 (0.554-0.716) 0.573 (0.457-0.717) 0.815 (0.645-1.027) 0.503 (0.373-0.679) 0.740 (0.601-0.910)
CFH rs35292876 1.535 (1.414-1.665) 1.840 (1.624-2.084) 1.230 (1.018-1.485) 1.331 (1.107-1.599) 1.350 (1.158-1.573)
CFH rs191281603 0.321 (0.268-0.384) 0.391 (0.297-0.513) 0.295 (0.200-0.434) 0.337 (0.234-0.486) 0.313 (0.228-0.431)
Calculated by SAS for each variant in percentage separated by geographical region including 95% confidence interval
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Supplementary Table 3. Minor allele frequencies (%) of seven rare AMD‐associated genetic variants across five 
geographical regions stratified by AMD status
  Eastern USA Western 
Europe
Britain Western USA Australia
CFH rs121913059 AMD 0.359 0.272 0.165 0.243 0.204
No AMD 0.007 0.037 0.000 0.023 0.000
CFI rs141853578 AMD 0.259 0.259 0.353 0.291 0.388
No AMD 0.087 0.018 0.136 0.069 0.085
C3 rs147859257 AMD 1.020 1.216 1.365 1.431 1.450
No AMD 0.435 0.459 0.476 0.416 0.410
C9 rs34882957 AMD 1.397 1.630 1.647 1.698 1.307
No AMD 0.856 0.789 0.907 1.039 0.891
C3 rs147859257 AMD 1.020 1.216 1.365 1.431 1.450
No AMD 0.435 0.459 0.476 0.416 0.410
CFH rs148553336 AMD 0.519 0.349 0.376 0.291 0.286
No AMD 0.813 0.881 1.225 0.693 1.047
CFH rs35292876 AMD 1.889 2.393 1.765 1.868 2.103
No AMD 0.936 1.046 0.703 0.808 0.821
CFH rs191281603 AMD 0.307 0.336 0.259 0.315 0.286
No AMD 0.341 0.459 0.318 0.346 0.325
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Abstract
It can be clinically challenging to distinguish dry age-related macular degeneration (AMD) 
from AMD-mimicking dystrophies, and sometimes misdiagnosis occurs. With upcoming 
therapies for dry AMD it is important to exclude patients with a different retinal disease from 
clinical trials. 
In this study we evaluated the occurrence of AMD-mimicking dystrophies in an AMD cohort. 
Whole-exome sequencing (WES) was performed in 218 patients with intermediate AMD or 
geographic atrophy secondary to AMD and 133 control individuals. WES data was analyzed for 
rare variants in nineteen genes associated with autosomal dominant and recessive macular 
dystrophies mimicking AMD.
In three (1.4%) of 218 cases we identified a pathogenic heterozygous variant (PRPH2 
c.424C>T; p.R142W) causal for autosomal dominant central areolar choroidal dystrophy 
(CACD). Phenotypically, these patients all presented with geographic atrophy. In twelve 
(5.5%) of 218 cases we identified a heterozygous variant of unknown clinical significance, but 
predicted to be highly deleterious, in genes previously associated with autosomal dominant 
macular dystrophies. 
The distinction between AMD and AMD-mimicking dystrophies, such as CACD, can be 
challenging based on fundus examination alone. Genetic screening for genes associated with 
macular dystrophies, especially PRPH2, can be beneficial to help identify AMD-mimicking 
dystrophies. 
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INTRODUCTION
Age-related macular degeneration (AMD) is a common progressive retinal disorder affecting 
the elderly.1 The early stages of AMD are characterized by drusen accumulation in the macula, 
and as disease progresses two types of advanced AMD can be distinguished: geographic 
atrophy (GA) and choroidal neovascularization (CNV).2 Currently, no curative treatment exists 
for the early and atrophic stages of AMD, which affect the majority of patients (80-90%). 
However, therapies targeting AMD disease pathways are currently being evaluated in clinical 
trials.3,4 
In order for clinical trials to be successful, it is crucial to select patients that will most likely 
benefit from the treatment. However, sometimes it is clinically challenging to distinguish 
AMD from inherited macular dystrophies.5-7 Especially when a patient presents at older age 
and GA has already developed, it can be challenging to distinguish AMD from GA secondary 
to other macular diseases and potentially patients might be misdiagnosed. Before inclusion 
of patients in clinical trials for dry AMD, it may therefore be useful to perform genetic testing 
to exclude AMD-mimicking dystrophies. In this study, we evaluated the occurrence of rare 
genetic variants associated with autosomal dominant or autosomal recessive AMD-mimicking 
dystrophies in 218 cases diagnosed with dry AMD.
METHODS
Study population
For this study we selected patients with intermediate AMD (n=126) or advanced atrophic 
AMD (n=92) from the European Genetic Database (EUGENDA). For 33 cases one of more 
family members were included. In total 62 family members were included, of which 40 were 
diagnosed with AMD, and 22 did not have signs of AMD. Additionally, 133 control individuals 
aged 65 years and older without signs of AMD were included in this study. Color fundus 
photographs of both eyes, and if available spectral domain optical coherence tomograms 
and fluorescein angiograms, were evaluated by two independent reading center graders 
according to the Cologne Image Reading Center and Laboratory (CIRCL) classification 
protocol.8 All individuals provided written informed consent for enrollment in EUGENDA. This 
research was approved by the local ethical committees at the Radboud university medical 
center and the University Hospital of Cologne and the study adhered to the tenets of the 
Declaration of Helsinki. 
Chapter 3
256
Whole‐exome sequencing
Whole-exome sequencing (WES) was performed as previously described.9 WES data were 
analyzed for rare variants in nineteen genes associated previously with autosomal dominant 
and recessive macular dystrophies mimicking AMD as described by Saksens et al.5 and RetNet, 
the Retinal Information Network (Supplementary Table 1). Filtering of the data was performed 
to select protein-altering, nonsense, frameshift or splice-site variants with a minor allele 
frequency (MAF) ≤1% in European and Dutch population reference panels.10,11 Additional 
filter criteria included coverage depth of >=20 reads, >=10 variant reads and >=20% variation 
of reads. A variation of reads between 20% and 80% was defined as heterozygous, and all 
variants with a variation of reads ≥90% were named homozygous. Individual variants that 
were seen on less than 25 variant reads were confirmed by Sanger sequencing. Literature and 
public archives (ClinVar12 and LOVD13) were consulted to determine if a variant is described 
to be pathogenic or is of unknown clinical significance (including variants with conflicting 
interpretations of pathogenicity). We explored the deleteriousness of nonsynonymous 
missense variants of unknown clinical significance using scaled Combined Annotation 
Dependent Depletion (CADD phred) prediction scores.14 
RESULTS AND DISCUSSION
Variants in genes associated with autosomal dominant macular dystrophies
We identified a heterozygous variant in the PRPH2 gene (c.424C>T, p.Arg142Trp) in three 
(1.4%) of 218 patients. All three cases presented with geographic atrophy which could 
be secondary to AMD(Table 1, Figure 1), although the area of atrophy in two patients is 
somewhat larger than would be expected in a typical AMD patient. This variant causes a 
central cone dystrophy phenotype associated with autosomal dominant central areolar 
choroidal dystrophy (CACD), and represents a founder mutation in the southeast of the 
Netherlands.15,16 CACD and atrophic AMD have strong phenotypic similarities and their age 
of onset overlaps.6,15-17 CACD can be misdiagnosed with AMD based on ophthalmological 
examination alone, especially in families with incomplete penetrance, which may mask 
the autosomal dominant inheritance of CACD. Additional imaging, such as spectral-domain 
optical coherence tomography and fundus autofluorescence imaging, or genetic analyses 
could help distinguish these two diseases.6 
In additional, 28 rare variants of unknown clinical significance were identified in other genes 
associated with autosomal dominant macular dystrophies, while they were not identified 
in 133 control individuals (Supplementary Table 2). Because of their uncertain significance 
further evaluation included only those variants leading to a premature nonsense codon or 
a frameshift, affecting the invariable splice donor or acceptor sites, and nonsynonymous 
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missense variants predicted to be the 1% most deleterious variants in the human genome 
(CADD score ≥ 20). We identified sixteen variants of unknown clinical significance predicted 
to be highly deleterious. In four cases, the variants of unknown clinical significance (CTNNA1 
c.536C>T; p.A179V, FSCN2 c.1025G>A; p.R342Q, OTX2 c.425C>G; p.P142R, PROM1 c.2450A>G; 
p.K817R) did not segregate with the disease in available family members, and were therefore 
not considered to be pathogenic. The twelve remaining cases carried a variant of unknown 
clinical significance in the BEST1, ELOVL4, FSCN2, IMPG1, OTX2, PRDM13, PROM1 or RP1L1 
gene (Table 1). All twelve cases had typical characteristics of intermediate AMD or GA with 
drusen (Table 1, Supplementary Figure 1; available online). We cannot rule out the possibility 
that these variants might be disease-causing. Therefore, one might consider to exclude 
patients carrying variants in genes associated with autosomal dominant macular dystrophies 
from clinical trials, in particular if the disease phenotype matches previously reported disease 
characteristics of these dystrophies. 
Variants in genes associated with autosomal recessive retinal dystrophies
None of our cases carried homozygous or two heterozygous deleterious variants in genes 
associated with autosomal recessive macular dystrophies. However, thirteen (6.0%) out 
of 218 cases carried a single heterozygous variant, previously described to be pathogenic 
in literature or in public archives, in the ABCA4, ABCC6, MFSD8 or PROM1 gene (Table 2, 
Supplementary Figure 2; available online). Eight variants showed comparable MAFs with 
population reference panels, while seven variants were not detected in the 133 control 
individuals. 
It has been suggested that carriers of a single ABCA4 variant are at increased risk of 
developing AMD compared to noncarriers,18,19 although a more recent study described that 
monoallelic ABCA4 carriers do not result in retinal changes.20 In this study, we identified seven 
(3.2%) of 218 cases that carried a heterozygous ABCA4 variant previously reported to be 
pathogenic, compared to only one (0.8%) of 133 control individuals carrying a heterozygous 
pathogenic ABCA4 variant. Larger studies are needed to evaluate the hypothesis that carriers 
of heterozygous variants associated with autosomal recessive macular dystrophies might 
be at increased risk for AMD development. The frequency of ABCA4 variants in our control 
individuals is, however, lower than expected based on population frequencies, and could also 
be coincidentally low.
Clinical implications 
It is increasingly important to correctly diagnose patients with macular degeneration with 
respect to inclusion in clinical trials and for future treatment. No curative treatment is 
currently available for dry AMD, though multiple clinical trials are ongoing.4 For clinical trials 
and future therapies for AMD it is important to identify those patients that will benefit most 
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Figure 1. Retinal images of three patients with geographic atrophy secondary to autosomal dominant central 
areolar choroidal dystrophy (CACD) caused by a heterozygous variant in PRPH2 (c.424C>T, p.Arg142Trp)
Patient 1 (A-D). Color fundus photographs of right (A) and left (B) eye of a 67-year-old female with geographic 
atrophy and foveal sparing surrounded by drusen secondary to CACD. On optical coherence tomography (OCT) 
images of both eyes (C+D) drusen are visible near the edges of the central atrophy. Drusen are indicated by arrows, 
atrophy is indicated by a continuous line with dashes just below the atrophic area. Patient 2 (E-F). A 64-year-old male 
with central atrophy in both eyes secondary to CACD. Patient 3 (G-H). A 76-year-old male with extensive geographic 
atrophy and peripapillary atrophy in both eyes. 
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likely from the treatment and to exclude AMD-mimicking dystrophies. Detailed phenotyping 
is necessary for distinguishing different macular diseases, and multimodal imaging can 
be useful. Despite modern imaging technologies, however, it can be difficult to clinically 
differentiate AMD from AMD-mimicking dystrophies. Genetic screening of genes involved 
in AMD-mimicking dystrophies can aid in establishing an accurate diagnosis. Based on the 
findings of this study, genetic screening of the PRPH2 gene is recommended because of the 
significant clinical overlap between CACD and AMD. 
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SUPPLEMENTARY MATERIAL
Supplementary Table 1. Genes associated with AMD‐mimicking diseases 
Gene Chr. Associated disease
Autosomal Dominant
BEST1 11 Adult-onset foveomacular vitelliform dystrophy (AFVD)
Best vitelliform macular dystrophy (BVMD)
C1QTNF5/MFRP 11 Late onset retinal degeneration (LORD)
CTNNA1 5 Butterfly-shaped pigment dystrophy
EFEMP1 2 Malattia Leventinese (ML)/Doyne honeycomb retinal dystrophy
ELOVL4 6 Stargardt-like macular dystrophy (STGD3)
Autosomal dominant macular dystrophy
FSCN2 17 Autosomal dominant macular degeneration
Autosomal dominant retinitis pigmentosa 
GUCA1B 6 Autosomal dominant retinal degeneration
OTX2 14 Autosomal dominant pattern dystrophy
PRDM13 6 North-Carolina macular dystrophy (NCMD)
PRPH2 6 Central areolar choroidal dystrophy
Adult-onset foveomacular vitelliform dystrophy
Autosomal dominant pattern dystrophy
Pseudo-Stargardt pattern dystrophy
RP1L1 8 Autosomal dominant occult macular dystrophy
TIMP3 22 Sorsby fundus dystrophy
Autosomal Recessive
ABCA4 1 (late-onset) Stargardt disease
ABCC6 16 Pseudoxanthoma elasticum related dystrophy (angioid streaks) 
DRAM2 1 Autosomal recessive macular dystrophy
MFSD8 4 Nonsyndromic autosomal recessive macular dystrophy
Autosomal Dominant or Autosomal Recessive
IMPG1 6 Autosomal dominant benign concentric annular macular dystrophy
Autosomal dominant and autosomal recessive vitelliform macular dystrophies
PROM1 4 Autosomal dominant bull’s-eye macular dystrophy
Autosomal dominant stargardt-like dystrophy
Autosomal recessive cone-rod dystrophy
Based on Saksens et al. 2014 (Prog Retin Eye Res 39:23-57) and RetNet, the Retinal Information Network.
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The aim of this thesis was to increase our understanding of the clinical and molecular 
characteristics of AMD development and progression. In this chapter we elaborate on the 
main findings described in this thesis and their clinical relevance, and in particular for genetic 
and predictive testing and for treatment and personalized medicine for AMD. 
GENETIC TESTING IN AMD
The contribution of genetic factors in the development of AMD has been well established 
and genetic studies have yielded important results that contribute to our understanding of 
AMD pathology. Since the discovery of the Y402H risk variant in the CFH gene in 20051-3 and 
rapid technological developments, our understanding of the genetics contributing to AMD 
development have increased significantly. To date more than half of the genomic heritability 
can be explained by both common and rare genetic variants in or near 34 genes.4 The 
explained genomic heritability of AMD is considerably higher than for other multifactorial 
diseases, for which in general only a limited percentage of the genomic heritability has been 
explained.5 AMD may therefore be among the first multifactorial diseases for which genetic 
testing can be offered in a clinical setting. In this section we discuss the value of genetic 
testing in the clinic, provide an overview of genetic tests that are offered for AMD, and provide 
recommendations for which individuals genetic testing for AMD would particularly be useful. 
Value of genetic testing for risk reduction and treatment
Although one’s genetic predisposition cannot be changed, an individual’s AMD risk is based on 
multiple factors of which lifestyle factors, such as smoking and diet, are modifiable. Smoking 
cessation, regular physical activity, and intake of nutrients high in antioxidants and omega-3 
fatty acids have been proven to reduce AMD risk.6-10 Even in those at high genetic risk dietary 
adjustments seem beneficial.11 Therefore, ophthalmologists should advise their patients to 
refrain from smoking, perform physical exercise regularly, increase the intake of dietary food 
groups such as green leafy vegetables and fatty fish, and dietary supplementation of the 
AREDS formulation.12 Determining an individual’s genetic risk might increase motivation for 
lifestyle adjustments in high-risk individuals. A recent study evaluating genetic testing for 
AMD showed that people made lifestyle adaptations after genetic testing.13 However, it must 
be noted that most participants had one or more family members with AMD, which could 
also increase motivation to make lifestyle changes. In general, existing literature suggests 
that communicating genetic risk has little or no effect on risk-reducing health behavior, even 
in people with a high risk for disease.14 The effect of genetic testing on risk reduction might 
be improved if combined with personalized motivational strategies, for example through a 
lifestyle coach. In 2019, measures to adopt a healthy lifestyle will be covered by the Dutch 
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health insurance, as such preventive measures are expected to reduce healthcare costs.15 
Genetic testing can also be helpful for selecting patients for future treatments. For example, as 
suggested in chapter 2.4, patients carrying rare variants in the CFH gene may respond better 
to treatment with complement inhibitors, and/or may benefit from CFH supplementation 
therapy. Selection of patients for treatments targeting the complement system is further 
discussed in section ‘Towards treatment and personalized medicine’. 
Genetic tests for AMD
Several genetic tests are commercially available for AMD risk prediction (Table 1). Some tests 
are offered as direct-to-consumer personal genetic tests, while others are recommended to 
be offered by a healthcare provider or ophthalmologist. Most of these currently available 
tests are not yet suitable for clinical application as prediction is not accurate and there seems 
to be considerable variation in predicted AMD risks between the tests.16 Also, none of these 
tests include rare variants, while such variants have been reported to confer a very high risk 
for AMD.4,17 The EYE-RISK consortium is therefore developing a genetic test for AMD that 
includes all AMD-associated genetic variants and sequence analysis of genes (e.g. CFH, CFI, 
SLC16A8, TIMP3) that have been reported to carry rare variants.4 
Genetic testing for differential diagnosis of AMD‐mimicking macular dystrophies 
The genetic assay in development by the EYE-RISK consortium also contains a number of genes 
that are not associated with AMD, but cause inherited macular dystrophies (e.g. ABCA4 and 
PRPH2). Sometimes it can be clinically challenging to distinguish AMD from other macular 
diseases presenting with geographic atrophy in the elderly patient. In such cases genetic 
testing could help the clinician rule out AMD-mimicking macular diseases, which will become 
more important as therapies are being developed. In chapter 3.4 we identified a heterozygous 
variant in the PRPH2 gene (p.Arg142Trp) in three patients originally diagnosed with dry 
AMD. However, this variant has previously been described to cause autosomal dominant 
central areolar choroidal dystrophy (CACD).18,19 There are strong phenotypic similarities 
between CACD and AMD. The focal parafoveal RPE changes in the early stages, and atrophy 
of the retinal pigment epithelium and choriocapillaris as disease progresses, can very much 
resemble the AMD phenotype.20,21 Additionally, CACD has been described in combination 
with the presence of drusen in some families.22 Furthermore, CACD can be easily overlooked 
and misdiagnosed with AMD based on ophthalmological examination alone, especially in 
families with incomplete penetrance, which may mask the autosomal dominant inheritance 
of CACD. Although we did not discover any other macular dystrophies in our study, other 
reports also underline the importance of detailed phenotyping and genotyping to distinguish 
AMD from other macular diseases such as late-onset Stargardt disease and mitochondrial 
retinal dystrophy (associated with maternally inherited diabetes and deafness).23,24 
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Selecting individuals for genetic testing
Several groups of individuals would potentially benefit more from genetic testing for AMD 
than others. In clinical practice, ophthalmologists are regularly confronted by individuals who 
have family members with AMD, and would like to know what their risk is of developing the 
disease. In chapter 2.1 we show that patients with a positive family history of AMD have a 
lower age of onset of first symptoms and more often progress to geographic atrophy compared 
to individuals with no family history of AMD. Several lifestyle factors, such as nutrition and 
physical activity, tended to play a less important role in familial AMD than in sporadic AMD, 
supporting a stronger genetic component in families. In chapter 2.2 we demonstrate that in 
most families, AMD can be explained by a clustering of common genetic and environmental 
risk factors. However, in a subset of families the number of affected family members was 
much higher than expected based on these factors, and might be rather explained by other 
factors, such as rare genetic variants. Genetic testing could therefore be of added value for 
discovery of novel AMD variants and predicting risk in individuals with a family history of 
AMD. However, other factors such as lifestyle should also be taken into account in predictive 
tests for AMD, which will be further discussed in section ‘Predictive testing in AMD’. 
Chapter 2.4 suggests that phenotypic characteristics may be helpful to select individuals for 
genetic testing. In this chapter, we show that carriers of rare variants in the CFH gene have 
distinct disease characteristics compared to non-carriers. Patients carrying rare CFH variants 
have a more extensive drusen area, and present more often with drusen with crystalline 
appearance, and drusen nasal to the optic disc. These characteristics could therefore aid in 
the selection of patients for genetic testing for AMD. 
As not all patients with early or intermediate AMD will progress to end-stage disease, it is 
important for these patients to assess their risk of developing end-stage AMD. In chapter 
2.3 we demonstrated that genetic variants in the CFH and CETP genes are associated with 
progression to advanced AMD. Other studies have identified additional genetic variants that 
are associated with AMD progression (reviewed in chapter 2.3), suggesting that genetic 
testing could provide some useful information on risk of progression. However, in chapter 2.3 
we also show that clinical characteristics may be helpful for identifying patients who are at 
risk of developing end-stage AMD. Genetic testing alone is therefore not sufficient to predict 
AMD progression, and other parameters should be included as well. In the next section, we 
provide recommendations for factors that should be included in predictive tests for AMD. 
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PREDICTIVE TESTING IN AMD
Clinicians are increasingly using prediction models for several purposes; in order to identify 
high-risk individuals, in order to make therapeutic decisions, recommendations and 
monitoring strategies, as well as selection for clinical trials. As AMD is a complex disease, 
one cannot rely on genetic variants alone for predictive testing. Ideally, risk assessment and 
patient profiling should include a combination of factors: clinical characteristics, genetic 
information and molecular biomarkers. In this section we discuss current prediction models 
for AMD, and provide recommendations for improving predictive tests using molecular and 
clinical biomarkers. 
Prediction models for AMD
Many prediction models for development of (advanced) AMD have already been developed 
with different sets of variables.25-52 The first prediction models published included only a few 
variables and were sometimes limited to genetic factors only.29,31,34-36 The addition of more 
variables, and inclusion of non-genetic (demographic, environmental and phenotypic) risk 
factors has led to increased predictive performance.25,28,40,44,46,53 It is striking though, that none 
of the published models include the same risk variables. This can be easily explained since 
studies use predefined datasets and only include variables that are actually measured in each 
study. Most studies include age, gender, smoking status and some AMD-associated common 
genetic variants in their prediction models. 
Current risk prediction models could be improved by including more AMD-associated 
genetic variants,4 and implementation of molecular biomarkers in blood, environmental and 
phenotypic risk factors. Until now, only few studies include systemic biomarkers or rare genetic 
variants in their prediction model.41,46,47 The addition of plasma complement components in 
one study,41 and the addition of a rare genetic variant in the C3 gene in another study46 led 
to small but significant improvements of the prediction models. However, adding systemic 
biomarkers and rare genetic variants also comes with limitations. Measurement of systemic 
biomarkers often require a strict sample handling protocol to avoid measurement errors and 
these measurements can be costly. Incorporation of rare genetic variants seems important 
since they are have a stronger impact on disease risk compared to most common genetic 
variants, however since occurrence might be limited to certain populations or geographic 
areas (chapter 3.3) models including rare genetic variants will not be applicable to all 
populations. Also, the addition of family history as a risk factor might be of additive value 
(chapter 2.2), since there is still a significant part of unexplained heritability for which family 
history may serve as substitute marker and aid in risk prediction. 
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Molecular biomarkers for AMD
Molecular biomarkers could be helpful in improving prediction models for AMD. In addition, 
they can also be useful for monitoring disease progression, evaluation of treatment efficacy, 
to unravel disease mechanisms, and for identification of new targets for treatment. In 
chapter 3.1 we provide a comprehensive overview of all molecular compounds that have 
been evaluated in association to AMD and discussed their potential as AMD biomarker. 
Based on the existing literature, compounds belonging to the oxidative stress pathway, the 
complement system, and lipid metabolism seem the most promising biomarker candidates 
for AMD.54 
From genetic as well as functional studies, it is known that dysregulation of the complement 
system plays an important role in AMD. However, the exact role of this complex system 
remains unclear because only a limited number of complement components have been 
investigated in relation to AMD and mainly include the central molecule of the complement 
system (C3), its activation products (C3a and C3d) and complement regulators (Factor H and 
Factor I). Future studies might benefit from evaluating the entire pathway in an unbiased 
manner rather than targeting one or more specific single biomarkers in a candidate-driven 
approach. By measuring all complement components simultaneously in one sample one has 
the opportunity to gain a detailed and unprecedented insight into the role of the complement 
system in AMD. Especially, when combining these functional measurements to genetic 
information our understanding of the role of the complement system in AMD could improve 
significantly. Apart from improving prediction models for AMD, molecular biomarkers of 
the complement system could be helpful to interpret genetic test results. For example, rare 
variants in the CFH and CFI gene can lead to either lower protein levels in serum, or can lead 
to a disturbed protein function.17,55-57 Measuring Factor H, Factor I and complement activation 
levels in serum or plasma could help to interpret the effect of rare variants that are identified 
by genetic testing. 
Various classes of lipids and lipid-related genes have been associated with AMD, and lipids 
are one of the main components of drusen, pointing towards an important role of the lipid 
metabolism in AMD. A recent study by the EYE-RISK consortium and the European Eye 
Epidemiology (E3) consortium investigated the association of lipids and lipoproteins in more 
than 30,000 individuals.58 High density lipoprotein (HDL) cholesterol was associated with 
increased risk of AMD, while triglycerides were associated with a decreased risk of AMD. 
The study also evaluated lipid subfractions, which identified extra-large HDL to be the most 
prominent subfraction associated with AMD. Additional and larger lipidomics studies could 
provide more insight into which lipid subfractions are associated with AMD, how these relate 
to AMD-associated variants in the lipid metabolism genes, and whether their concentrations 
change during disease progression. In addition, a more detailed analysis of the composition 
of the lipoprotein particles of these subfractions, for example using proteome studies of 
lipoprotein particles, could potentially identify AMD-specific lipoprotein biomarkers. 
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Many studies reported decreased antioxidant levels and elevated levels of oxidized proteins 
or lipids in AMD. The most thoroughly investigated biomarkers of oxidative stress in AMD 
are malondialdehyde (MDA) and homocysteine (chapter 3.1). These biomarkers could be 
valuable to assess oxidative stress status, and could potentially improve predictive tests for 
AMD. In addition, measuring levels of antioxidants such as carotenes, vitamins and minerals 
in blood could help to assess the nutritional status and to design personalized prevention 
strategies by providing individuals advice on how to alter their diet or lifestyle in order to 
reduce their risk for AMD. 
As described in chapter 3.1, omics studies with an unbiased view are heavily outnumbered in 
the AMD field. Future biomarker research should therefore combine hypothesis-free as well 
as candidate-driven approaches. Quantitative analytical approaches applied in an untargeted 
and targeted fashion, such as metabolomic or proteomic studies, are necessary to identify 
novel biomarker candidates. In chapter 3.2 metabolomics identified an association of 
glutamine with early and intermediate AMD, and larger omics studies may identify additional 
biomarkers in the future. Once validated as robust and reliable markers, they can offer 
more insights into the etiology and pathogenesis of AMD and support prediction, diagnosis, 
stratification, monitoring of treatment, and drug development for AMD.
Although AMD represents a phenotype restricted to the eye, many studies have investigated 
systemic markers in relation to AMD. One might argue to measure biomarkers locally, they 
might be only locally dysregulated inside the eye without a measurable systemic effect 
because of the presence of the blood-retinal barrier. However, due to the invasive character 
and accompanying ethical issues, systemic markers are preferred for implementation as 
clinical biomarkers. 
From a physiological perspective, it is unlikely that biological systems within the human 
body would operate independently from each other in health or in disease, like AMD. 
Therefore, integration of biological systems into a coherent and all-encompassing biological 
understanding is needed to identify the precipitating event(s) that lead to the development 
and progression of AMD. The possibility of an integrative approach is now at our doorstep 
with the deeper and better understanding of genetic, cellular and molecular processes and 
improved prediction.
Clinical biomarkers for AMD progression
Conversion to advanced AMD is a crucial moment for the management of AMD patients. 
As mentioned in section ‘Genetic testing in AMD’, identification of individuals at high-risk 
for progression to advanced AMD and its associated vision loss is highly desirable. Better 
knowledge about possible development of advanced AMD will contribute to more effective 
support and monitoring of those patients. Not all individuals with early or intermediate 
AMD will progress to end-stage, but progression rates in literature vary widely (chapter 2.3). 
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Additionally, studies use different definitions for “progression”. Most commonly progression 
is defined as conversion to advanced AMD in one or both eyes, however, some studies also 
report progression to a more severe stage of AMD and not necessarily advanced AMD. 
Clinical disease stage at baseline has been shown to be one of the strongest predictors of 
progression, with the more severe phenotype conferring the highest risk for progression.40,46,59-62 
In chapter 2.3 we evaluated a combination of genetic factors and phenotypic biomarkers 
on different imaging modalities for progression of early or intermediate AMD to end-stage 
disease. We identified pigment abnormalities, drusenoid pigment epithelial detachment, 
reticular pseudodrusen and hyperreflective foci as relevant imaging biomarkers for 
conversion to advanced AMD. The high predictive value of phenotypic characteristics for 
AMD progression is in concordance with previous studies.37,40 
Large prospective studies in patients with early or intermediate AMD need to be performed 
to validate the identified clinical biomarkers and to search for new potential biomarkers using 
multimodal imaging. In the MACUSTAR project more than 700 patients with intermediate 
AMD will be followed over a period of 3 years in order to identify clinical biomarkers that 
can predict the rate of progression (https://www.imi.europa.eu/projects-results/project-
factsheets/macustar). 
Prediction websites
Although we are still far away from a clinically useful prediction model suitable for individual 
risk prediction, there are already online prediction websites available which integrate 
genotype and phenotype information for risk calculation (Table 2). However, in order to 
calculate risks using these websites one needs all requested information including genotypes 
of certain genetic variants, but genetic testing is not provided by these websites. 
Currently, the EYE-RISK consortium is developing a user-friendly web application for 
personalized risk assessment of AMD based on integration of risk profiles derived from retinal 
imaging, molecular genetics, assessment of lifestyle, and biochemical testing from large-
scale epidemiological data. The website also aims to offer a genetic test that can be ordered 
through the website, and to provide personalized advice on how altering diet and lifestyle can 
lead to risk reduction of AMD. 
TOWARDS TREATMENT AND PERSONALIZED MEDICINE
The main preventive measure to reduce risk of progression to advanced AMD is through 
lifestyle interventions and use of nutritional supplements. Currently, the only treatment 
available for AMD consists of repeated intravitreal injections of anti-vascular endothelial 
growth factor (anti-VEGF), aiming to reduce neovascularization. No treatment is yet available 
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for the early, intermediate and advanced atrophic stages of AMD, however, several clinical 
trials targeting different pathways have been performed or are ongoing (reviewed in chapter 
1 of this thesis). In this section we provide advice on how the effectiveness and design of 
clinical trials can be improved, and discuss which factors can influence response to nutritional 
supplements and to anti-VEGF treatment. 
 
Improving the design and effectiveness of clinical trials
Many clinical trials targeting the complement system – one of the main AMD disease 
pathways - have been performed and are still ongoing, however, they have not yet yielded 
groundbreaking results. To date, many trials focus on reducing atrophy growth, however, 
trials may need to target early stages of the disease rather than the atrophic end-stage, 
when apoptosis is already ongoing. To perform trials in early stages of the disease, adequate 
biomarkers are needed to detect progression and to measure the effectiveness of the 
treatment that is tested. In addition, biomarkers for progression could be helpful to select 
individuals who are at high risk of developing end-stage AMD (chapter 2.3). This will allow the 
selection of high-risk patients, which will reduce time and costs needed to run clinical trials. 
Due to the heterogeneity in the AMD population, it is plausible that the effect of therapeutic 
interventions depends on the biological drivers of disease in each individual patient. 
Therefore, certain treatments might only be effective in a subgroup of AMD patients. One 
of the main drivers in AMD pathogenesis includes the complement system, and therapies 
targeting different components of the complement system are being developed. Carriers 
of rare variants in complement-regulating genes, as described in chapter 2.4, may benefit 
more from complement-inhibiting therapies than patients with AMD in general and therefore 
identification of these patients through genetic testing seems to be important.55 Other studies 
have suggested other common genetic variants in genes of the complement system that 
could be used for selecting patients for trials with complement inhibitors.63,64 Patients with 
rare loss-of-function variants in the CFH and CFI genes may also benefit from supplementation 
therapies for CFH and CFI, respectively.17 
Additionally, to aid patient selection for clinical trials we recommend the use of genetic 
testing to exclude AMD-mimicking dystrophies (chapter 3.4). In particular screening of the 
PRPH2 and ABCA4 genes could be useful to exclude CACD and late-onset Stargardt disease, 
which both progress to chorioretinal atrophy similar to advanced atrophic AMD.23,65,66
Next to patient selection, choice of the target(s) of intervention is very important. Several 
pathways are known to be important in AMD pathogenesis, such as the complement system, 
the lipid metabolism and oxidative stress. However, the exact pathogenesis of AMD is not 
fully understood, and might represent a complex interplay of the different disease pathways. 
Targeting only one of these pathways might not be sufficient to treat or avoid AMD; more 
effective treatment might be reached by targeting multiple AMD disease pathways. In 
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addition, the right targets within the disease pathways need to be chosen for effective 
intervention. For example, clinical trials with complement inhibitors have so far targeted 
complement factor D, C3 and C5 (reviewed in Chapter 1 of this thesis). Other approaches, 
such as supplementation therapy for CFH and CFI, might be more effective, in particular in 
patients carrying rare variants in the CFH and CFI genes. Other targets in the complement 
system might be identified by evaluating all components in the complement system 
simultaneously by proteomics, as mentioned in section ‘Predictive testing in AMD’. Such 
studies and other types of omics studies might identify other possible therapeutic targets for 
effective interventions in AMD. 
 
Response to AREDS supplementation
For the early and dry forms of AMD no curative treatment is available, but nutritional 
supplementation with anti-oxidants and zinc have been shown to reduce risk for progression 
to advanced AMD with 25% in high risk patients.67,68 Since the publication of these results 
ophthalmologists should advise patients with unilateral advanced AMD or bilateral 
intermediate AMD to consider taking nutritional supplements according to the AREDS2 
formula. However, ever since the introduction of nutritional supplements in AMD care there 
is an intense debate ongoing about the influence of genotype on the treatment outcome with 
AREDS supplementation. It has been suggested that response to AREDS supplements may be 
related to CFH genotype. Klein et al. (2008) were the first to publish a possible interaction 
between CFH genotype and response to nutritional supplements. They concluded that despite 
a reduced effect of supplementation in patients carrying CFH Y402H risk alleles, there is still 
a beneficial effect. Thereafter, multiple publications (all using data from the AREDS) followed 
with conflicting results. Several studies implicated that pharmacogenetic selection could be 
beneficial for nutritional supplementation, moreover, supplementation with zinc specifically 
could be harmful in patients carrying CFH risk alleles.69-72 Other studies could not replicate 
these findings and argue that the statistical methods used and conclusions drawn by Awh 
et al. were not correct.73-75 The intense debate on whether the effectiveness of antioxidant 
and zinc supplementation depends on a patient’s genotype underscores the urgency for 
independent studies to resolve the controversy. Since it currently remains the only proven 
beneficial treatment for AMD, it is still recommended to continue AREDS supplementation for 
all patients at risk for progression to advanced AMD, regardless of genotype.
Response to anti‐VEGF treatment
Treatment of neovascular AMD by targeting VEGF through intravitreal injections with anti-
VEGF antibodies has resulted in significant improvements in visual acuity.76 Nevertheless, 
anti-VEGF therapy has not proven beneficial for all patients with neovascular AMD, and 
a small proportion of patients continues to decline in vision despite treatment.77 This 
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variability in treatment response might in part be influenced by genetic variations, and many 
pharmacogenetic studies have been published to date.78 However, due to conflicting results 
and heterogeneity in study designs there is no clear consensus and therefore genetic testing 
is not (yet) warranted to personalize anti-VEGF treatment.78 
FINAL REMARKS
AMD management warrants an integrative approach for risk assessment, combining lifestyle 
factors and phenotypic, genetic and molecular biomarkers (Figure 1). Future predictive tests 
should implement all these factors to provide personalized risks of development of AMD 
and to aid patient stratification for personalized treatment. The American Academy of 
Ophthalmology taskforce on genetic testing has recommended that routine genetic testing 
of patients with complex eye diseases such as AMD is not warranted until clinical trials 
can demonstrate that patients with specific genotypes benefit from specific therapies or 
monitoring.79 However, one could argue that identification of high-risk individuals in an early 
phase could increase awareness and motivation for reducing AMD risk by adopting a healthy 
lifestyle. Offering individuals a genetic or predictive test alone may not be sufficient, but 
could potentially be more effective if combined with personalized motivational strategies, 
such as a lifestyle coach. After all, prevention is better than cure. 
Figure 1. Integrative approach in AMD management, combining lifestyle factors (green), phenotypic (orange), 
genetic (blue) and molecular (red) biomarkers
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SUMMARY
Age-related macular degeneration (AMD) is a complex, multifactorial disease affecting the 
central retina and the leading cause of visual impairment among the elderly in Western 
countries. Both environmental and genetic risk factors have been described to be associated 
with AMD, but the exact pathophysiology is not yet completely understood. Only a small 
proportion of patients is eligible for treatment with intravitreal anti-VEGF injections, while 
no treatment is available yet for the majority of patients. The aim of this thesis is to increase 
our understanding of the clinical and molecular characteristics of AMD development and 
progression. A general introduction to AMD and the outline of this thesis are provided in 
chapter 1. 
In chapter 2, we focus on clinical characteristics of AMD. Familial aggregation of AMD has 
been described and is evaluated in chapter 2.1 and chapter 2.2. Differences in clinical and 
phenotypic characteristics between familial and sporadic AMD patients are described in 
chapter 2.1. We report an earlier onset of first symptoms in patients with a family history 
of AMD compared to those without family history. While increasing age and smoking were 
associated with AMD risk in both familial and sporadic AMD, other environmental factors 
(such as physical activity and consumption of red meat) seemed less important in familial 
AMD compared to sporadic AMD. With regard to phenotype, geographic atrophy and 
cuticular drusen were more prevalent in familial AMD. These findings support the hypothesis 
of a stronger genetic component and smaller contribution of environmental factors in familial 
AMD. Although the majority of AMD families can be explained by clustering of common 
environmental and genetic risk factors, some densely affected AMD families cannot be fully 
explained by known risk factors and may harbor rare genetic variants (chapter 2.2). Risk 
prediction in AMD families therefore remains complex and should encompass evaluation of 
multiple familymembers for accurate risk prediction.
Identification of predictive factors for progression to advanced AMD is important as it 
may contribute to a more efficient and personalized approach in monitoring and support 
of patients with early or intermediate AMD. Chapter 2.3 presents a prediction model for 
conversion to advanced AMD including phenotypic characteristics and genetic, environmental, 
and demographic risk factors. In our cohort progression to advanced AMD was associated 
with advanced age, genetic variants in the CFH gene, and several phenotypic characteristics: 
pigment abnormalities, drusenoid pigment epithelial detachment, reticular pseudodrusen 
and hyperreflective foci. 
Rare genetic variants in the CFH gene are among the variants that confer the highest risk for 
AMD,. Patients carrying these variants seem an ideal patient group for upcoming therapies 
targeting the complement system. In chapter 2.4 we show that patients with an extensive 
drusen area, drusen with crystalline appearance, and drusen nasal to the optic disc are more 
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likely to carry a rare CFH variant. These phenotypical characteristics in combination with 
other patient characteristics could aid selection of patients for genetic testing and upcoming 
therapies. 
Chapter 3 contains several studies focusing on molecular characteristics of AMD. Biomarkers 
can help unravel mechanisms of disease and identify targets for treatment. Additionally, in 
clinical practice they can be useful for detecting disease, monitoring disease progression, 
evaluation of treatment efficacy, and risk assessment. In chapter 3.1 we review all literature 
on potential non-genetic biomarkers and their applicability in AMD. Compounds belonging 
to the oxidative stress pathway, the complement system, and lipid metabolism seem to be 
the most promising biomarker candidates for AMD. Also, the use of hypothesis-free ‘omics’ 
techniques have great potential to uncover biomarkers or pathways that contribute to AMD 
pathophysiology, but so far only limited studies have been performed. In chapter 3.2 we aim 
to contribute to the discovery of novel biomarkers and metabolic pathways for AMD using a 
targeted metabolomics approach. In this study, we found glutamine among the metabolites 
most predictive for AMD. However, larger studies are needed to further resolve the metabolic 
profile of AMD patients. 
Much progress has been made in the discovery of rare genetic variants contributing to AMD 
risk, and carriers of rare variants in genes of the complement system may be a suitable group 
for upcoming therapies. In chapter 3.3 we explored the occurrence of seven rare genetic 
variants that were reported to be independently associated with AMD by the International 
AMD Genomics Consortium. We demonstrate that two rare variants in the CFH gene deviate 
in frequency among different geographical regions. Our findings emphasize that personalized 
treatment targeting rare variants with functional effects may only be applicable to specific 
populations where these variants are sufficiently common. With upcoming therapies it 
is also important to exclude patients with a different retinal disease from clinical trials. In 
chapter 3.4 we evaluated the occurrence of AMD-mimicking dystrophies in a cohort with 
patients diagnosed with intermediate or atrophic AMD. In three of 218 cases we identified a 
pathogenic heterozygous variant in the PRPH2 gene causal for autosomal dominant central 
areolar choroidal dystrophy (CACD). The distinction between AMD and AMD-mimicking 
dystrophies, such as CACD, can be challenging based on fundus examination alone. Genetic 
screening of genes involved in AMD-mimicking dystrophies can be beneficial in establishing 
an accurate diagnosis. 
Finally, chapter 4 elaborates on the main findings described in this thesis and their clinical 
relevance. Particularly, implications and recommendations for genetic and predictive testing 
and for treatment and personalized medicine for AMD are discussed. 
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SAMENVATTING
Leeftijdsgebonden maculadegeneratie (LMD) is een complexe, multifactoriële aandoening 
die de centrale retina aantast, en is de belangrijkste oorzaak van visusverlies onder ouderen 
in westerse landen. Zowel omgevingsfactoren als genetische factoren zijn geassocieerd met 
LMD, maar het exacte ziektemechanisme is nog niet geheel opgehelderd. Slechts een deel 
van de patiënten met LMD komt in aanmerking voor behandeling met intravitreale anti-VEGF 
injecties; voor het merendeel van de patiënten is er nog geen therapie beschikbaar. Het doel 
van dit proefschrift is om onze kennis van de klinische en moleculaire kenmerken van de 
ontwikkeling en progressie van LMD te vergroten. Een algemene introductie over LMD en de 
opzet van dit proefschrift worden beschreven in hoofdstuk 1. 
In hoofdstuk 2 focussen wij op de klinische kenmerken van LMD. Het is beschreven dat LMD 
kan voorkomen in families, en dit wordt geëvalueerd in hoofdstuk 2.1 en hoofdstuk 2.2. 
Verschillen in klinische en oogheelkundige eigenschappen tussen familiaire en sporadische 
LMD patiënten worden beschreven in hoofdstuk 2.1. We vonden dat patiënten met een 
familievoorgeschiedenis van LMD eerder symptomen vertonen vergeleken met patiënten 
zonder LMD in de familie. Toenemende leeftijd en roken waren geassocieerd met zowel 
familiaire als sporadische LMD, echter andere omgevingsfactoren (zoals lichaamsbeweging 
en consumptie van rood vlees) leken minder belangrijk in familiaire LMD vergeleken met 
sporadische LMD. Met betrekking tot het oogheelkundige ziektebeeld zagen wij dat 
geografische atrofie en cuticulaire drusen vaker voorkwamen bij familiare LMD patiënten. 
Deze bevindingen ondersteunen de hypothese dat er een grotere genetische component 
speelt en er een kleinere bijdrage van omgevingsfactoren is in familiaire LMD. Hoewel 
een groot deel van de LMD families verklaard kan worden op basis van clustering van 
veelvoorkomende omgevings- en genetische risicofactoren, kunnen sommige sterk belaste 
families niet volledig door bekende risicofactoren verklaard worden. Mogelijk spelen 
zeldzame genetische varianten een rol in deze families (hoofdstuk 2.2). Risicovoorspelling in 
LMD families blijft daardoor complex en zou evaluatie van meerdere familieleden moeten 
omvatten om een accurate risicovoorspelling te kunnen doen. 
Naast het risico op het ontwikkelen van LMD is de identificatie van voorspellende factoren 
voor progressie naar late LMD belangrijk. Zulke factoren kunnen bijdragen aan een efficiëntere 
en meer persoonsgerichte benadering in het opvolgen en ondersteunen van patiënten met 
beginnende of intermediaire LMD. Hoofdstuk 2.3 beschrijft een predictiemodel voor de 
conversie naar late LMD waarin oogheelkundige kenmerken, genetische, omgevings- en 
demografische risicofactoren worden meegenomen. In ons cohort was progressie naar 
late LMD geassocieerd met toenemende leeftijd, genetische varianten in het CFH gen, en 
verscheidene oogheelkundige kenmerken: pigmentveranderingen, drusenoïde pigment 
epitheel loslating, reticulaire pseudodrusen en hyperreflectieve foci. 
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Zeldzame genetische varianten gelokaliseerd in het CFH gen behoren tot de varianten die 
het grootste risico voor LMD geven, en patiënten die deze varianten dragen lijken een ideale 
patiëntgroep voor opkomende therapieën die gericht zijn op het complement systeem. 
In hoofdstuk 2.4 laten we zien dat patiënten met een uitgebreid drusen oppervlakte, 
kristallijne drusen en drusen nasaal van de papil meer kans hebben om een zeldzame CFH 
variant te dragen. Deze oogheelkundige kenmerken kunnen, in combinatie met andere 
patiëntkarakteristieken, waardevol zijn om patiënten te selecteren voor aanvullend genetisch 
onderzoek en opkomende therapieën. 
Hoofdstuk 3 omvat meerdere studies die focussen op moleculaire kenmerken van LMD. 
Biomarkers kunnen helpen bij het ontrafelen van het ziektemechanisme en het identificeren 
van targets voor therapieën. Daarnaast kunnen ze in de klinische praktijk nuttig zijn om 
ziekte op te sporen en te monitoren, om het effect van therapie te beoordelen en voor risico 
bepaling. In hoofdstuk 3.1 geven wij een overzicht van alle literatuur over potentiële niet-
genetische biomarkers en hun toepasbaarheid in LMD. 
Moleculaire factoren behorende tot het oxidatieve stress mechanisme, het complement 
systeem en het lipiden metabolisme lijken de meest veelbelovende biomarkers voor LMD 
te zijn. Ook heeft het gebruik van hypothese-vrije ‘omics’ technieken grote potentie om 
biomarkers of ziektemechanismen te ontdekken die een rol spelen bij LMD, maar tot nu toe zijn 
er slechts een klein aantal studies uitgevoerd. In hoofdstuk 3.2 hebben we gebruikt gemaakt 
van een grootschalige analyse van metaboliten (metabolomics) om nieuwe biomarkers en 
metabole mechanismen te ontdekken die een rol spelen bij LMD. In deze studie vonden we 
dat glutamine een van de metabolieten is die het meest voorspellend is voor LMD. Er zijn 
echter grotere studies nodig om het metabole profiel van LMD patiënten beter in kaart te 
brengen. 
Verscheidene studies hebben aangetoond dat zeldzame genetische varianten een verhoogd 
risico geven op LMD. Patiënten die een zeldzame genetische variant dragen zijn mogelijk 
goede kandidaten voor nieuwe behandelingen gericht op het complement systeem. In 
hoofdstuk 3.3 hebben we zeven zeldzame genetische varianten onderzocht die geassocieerd 
zijn met LMD. We laten zien dat twee zeldzame varianten in het CFH gen in frequentie 
variëren in populaties van verschillende werelddelen. Onze bevindingen benadrukken dat 
persoongerichte behandelingen gericht op zeldzame varianten mogelijk alleen toepasbaar 
zijn in bepaalde populaties waar deze varianten voorkomen. Met de opkomst van nieuwe 
behandelingen is het ook belangrijk om patiënten met andere retinale aandoeningen te 
excluderen van klinische trials. In hoofdstuk 3.4 evalueren we het voorkomen van op LMD 
lijkende macula dystrofieën in een cohort van patiënten gediagnosticeerd met intermediaire 
of atrofische LMD. In drie van de 218 patiënten vonden we een pathogene heterozygote 
variant in het PRPH2 gen dat autosomaal dominante centrale areolaire choroidale dystrofie 
(CACD) veroorzaakt. Het kan moelijk zijn om op basis van alleen fundusonderzoek onderscheid 
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te maken tussen LMD en op LMD lijkende dystrofieën, zoals CACD. Genetische screening van 
genen betrokken bij op LMD lijkende dystrofieën kan nuttig zijn bij het vaststellen van de 
juiste diagnose. 
Tot slot gaat hoofdstuk 4 dieper in op de belangrijkste bevindingen beschreven in dit 
proefschrift en de klinische relevantie daarvan. In het bijzonder worden implicaties en 
aanbevelingen voor genetische en voorspellende testen voor LMD besproken, en voor de 
behandeling en persoonsgerichte zorg van LMD. 
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Type of data Subject to 
privacy (yes/
no)
Way of anonymization Storage
Informed consents of 
patients included in 
EUGENDA
Yes All patients have been 
assigned a study-ID number 
and the key is stored in a 
password protected SPSS file
Written informed consents of patients 
included at the Ophthalmology 
department in Nijmegen are stored in a 
locked archive. The key file can be found 
on the Ophthalmology H-drive and is 
stewarded by the database manager: 
H:\Onderzoek\Data files EUGENDA 
database
Clinical and 
questionnaire data of 
patients included in 
EUGENDA
Yes All patients have been 
assigned a study-ID number 
and data is stored by study-
ID
Both data can be found on the 
Ophthalmology H-drive: H:\Onderzoek\
Data files EUGENDA database
Images of patients 
included in EUGENDA
Yes All patients have been 
assigned a study-ID number 
and data is stored by study-
ID
Images are stored in an online 
accessible password-protected secured 
database https://www.eugenda-
database.org 
Contact details of 
patients enrolled in 
EUGENDA
Yes NA This information is stored in an online 
password-protected secured database 
https://www.eugenda-database.org. 
Access is limited to a few clinicians 
responsible for ophthalmologic 
examinations of the patients, all other 
researchers can only access anonymized 
data 
DNA of patients 
included in EUGENDA
Yes A DNA number is assigned 
to each individual by the 
cell culture facility of the 
Department of Human 
Genetics
The key is stored in the MCCD database 
and is only accessible by clinicians and 
members of the cell culture facility. DNA 
samples are stored at the Department 
of Human Genetics. Contact person 
for the DNA samples is Saskia van 
der Velde-Visser; saskia.vandervelde-
visser@radboudumc.nl 
Serum and plasma 
samples of patients 
included in EUGENDA
Yes Anonymized with a 
sample-ID number and 
corresponding clinical 
information is stored in a 
password protected excel file
Stored in the -80oC freezers at the 
department of Ophthalmology. 
Contact person where to find the 
samples is Bjorn Bakker; bjorn.bakker@
radboudumc.nl
Clinical information of the samples 
can be found on the H-drive of 
Ophthalmology: 
H:\Onderzoek\Data files EUGENDA 
database
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Type of data Subject to 
privacy (yes/
no)
Way of anonymization Storage
Genotype data of 
individual SNPs of 
patients included in 
EUGENDA
No Data is already anonymized Genotype information is stored in an 
SPSS file in the following folder on the 
Ophthalmology H-drive: H:\Onderzoek\
Data files EUGENDA database 
Exome sequencing 
data of patients 
included in EUGENDA
No Data is already anonymized Exome sequencing data can be 
found in the following folder on the 
Ophthalmology T-drive: 
\\umcsanfsclp01\PIgroup-Anneke-
denHollander\ExomeData
Genotype data of 
patients included in 
IAMDGC
No Data is already anonymized Genotype information is stored 
in an SPSS file in the following 
folder on H-drive: H:\Onderzoek\
Eveline Kersten\Projecten\IAMDGC\
Bronbestanden (Caucasian ONLY)\
Genotypes_8SNPs_20160322_LF.txt 
Files for publications 
presented in this thesis
No NA All files can be found on H-drive of 
Ophthalmology:
H:\Onderzoek\Eveline Kersten\Projecten
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Name PhD candidate: Eveline Kersten 
Department: Department of Ophthalmology
Graduate school: Radboud institute for Health Sciences
PhD period: 1‐9‐2014 to 31‐8‐2017
Promotors: Prof. dr. C.B. Hoyng, 
Prof. dr. A.I. den Hollander
Co‐promotor: Dr. E.K. de Jong
Year(s) ECTS
TRAINING ACTIVITIES
Courses & Workshops
SPSS Statistics course 2014 0.2
RIHS introduction course for PhD students 2015 0.5
Basiscursus Regelgeving en Organisatie voor Klinisch onderzoekers (eBROK) 2015 1.25
Biometrics 2015-2016 2
Adobe InDesign and Illustrator workshop 2016 0.4
How to write a medical scientific paper 2016 0.2
Scientific integrity for PhD students 2016 0.5
Course “R” 2016 0.2
BBMRI-omics: introduction 2017 0.5
Dissertation first aid: How to prepare and print your thesis 2017 0.1
Seminars & Lectures
Radboud Research Round Sensory Disorders (n=4) 2015-2017 0.4
Refereeravonden Oogheelkunde (n=4) 2015-2016 0.4
PhD defences (n=8) 2014-2017 0.8
Orations (n=2) 2015-2016 0.2
Seminar “Selective publication and the replicability crisis” 2016 0.1
Seminar Lars Fritsche “GWAS of AMD…” 2016 0.1
Donders Lecture John O’Keefe 2016 0.1
Lecture Bioinformatics 2017 0.1
BORA lecture^ 2017 0.1
Symposia & Conferences
Macula symposium, Rotterdam 2014 0.25
OOG/ZOG (n=3) 2014-2016 0.3
Dutch Ophthalmology PhD Students conference^ (n=3) 2015-2017 1.5
ARVO conference^ (n=2) 2015-2016 3
International symposium on AMD, Baden-Baden^ 2015 1
Nederlands Oogheelkundig Gezelschap conference^ (n=2) 2016-2017 1
Big data symposium, Rotterdam^ 2016 0.5
Cybergenetics symposium, KNAW 2016 0.1
Young researcher vision camp^ 2017 1
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Other
EUGENDA Retreat (n=3)^ 2014-2017 1.5
EYERISK/E3-consortium meeting (n=6)^ 2015-2017 6
TEACHING ACTIVITIES (LECTURING, SUPERVISION AND OTHER)
Radboud Science Award - Education primary school students and teachers 2014-2015 3
Lecture MD-patient organization (n=2) 2014-2015 0.5
Supervision research internship Master students Medicine 2015-2016 1
5KMP1 Medical Biotechnology - Education Bachelor students 2016 0.2
President & Organizing committee DOPS 2016 2016 2
50+ Beurs - Education patients 2015 0.5
TOTAL 31.5
^Indicates oral or poster presentation
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Het moment is daar, eindelijk ben ik aangekomen bij het schrijven van het laatste en leukste 
gedeelte van mijn proefschrift: het dankwoord! Een promotietraject kent pieken en dalen, en 
soms had ik het gevoel alsof ik er helemaal alleen voor stond, maar dit proefschrift had nooit 
tot stand kunnen komen zonder een heleboel mensen die ik hier graag wil bedanken. 
Allereerst wil ik graag alle personen bedanken die hebben meegedaan aan ons onderzoek 
naar leeftijdsgebonden maculadegeneratie, want zonder jullie medewerking kunnen wij 
geen onderzoek verrichten, hartelijk dank! 
Beste Carel, onder jouw leiding deed ik mijn wetenschappelijk stage tijdens mijn studie 
geneeskunde. Ik heb het erg naar mijn zin gehad tijdens deze stage en jij was degene die 
me geënthousiasmeerd heeft voor het wetenschappelijk onderzoek. Gelukkig voor mij 
melde je op mijn laatste stagedag dat er een promotieplek zou komen, dus ik heb direct die 
maandag een sollicitatiebrief ingeleverd. Dankjewel voor je vertrouwen in mij, waardoor ik 
mijn promotie onderzoek kon starten bij de Oogheelkunde!
Beste Anneke, dankjewel voor je begeleiding en kritische blik op mijn projecten en artikelen. 
Je hield alles goed in de gaten en zorgde voor duidelijke afspraken en deadlines. Ik heb veel 
respect voor jou en je werk. Mede dankzij jouw kennis en kunde zijn veel van mijn artikelen 
net even wat beter geworden!
Beste Eiko, als co-promotor ben jij wat later bij mijn promotie betrokken geraakt. Ik ben heel 
erg blij dat ik bij jou terecht kon voor een luisterend oor naar mijn ongezouten mening, die 
ik niet bij iedereen kwijt kon. Ook bedankt voor een fijne samenwerking met name bij het 
tot stand komen van het biomarker review en het metabolomics project wat een lange adem 
heeft gekost. Veel succes met je carrière buiten de oogheelkunde!
Iedereen die heeft meegeholpen met de AMD-dagen: ontzettend bedankt! Bjorn, Constantin, 
Laura en Bert, dank voor alle labgerelateerde zaken waar ik helemaal geen verstand van 
had. Asha, bedankt voor je enthousiasme en onvermoeibare inzet voor onder andere mijn 
onderzoek maar ook al het andere onderzoek waar je bij betrokken bent. Hacer, Michel, 
Jack, Maartje, Stanley, Roos, Dyon, Vivian, Sanne, Mireille en studenten (Brett, Roel, Enna), 
dankjewel voor het afnemen van saaie vragenlijsten, het eindeloos druppelen van patiënten, 
het maken van allerhande beeldvorming en het bloedprikken. Hierdoor hebben we mooie 
data kunnen verzamelen! 
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Ook Hans Groenewoud bedankt, voor al je statistische hulp bij mijn projecten en je positieve 
houding!  
Also thanks to all people I got the chance to collaborate with during my PhD-time, especially 
the researchers in Cologne, Sascha, Lebriz, Tina and Vasilena, for our joint EUGENDA research, 
and all wonderful people involved in the EYERISK project, in particular Tunde, Cécile, Caroline, 
and Sascha for collaboration on several projects, and of course Annemarie, Fran, Soufiane 
and the other “young researchers” for all great moments during meetings, dinners, ARVO 
and Vision Camp. 
Aan alle promovendi waar ik mee heb samen mogen werken (Yara, Nicole, Myrte, Constantin, 
Michel, Freekje, Laura, Maartje, Nathalie, Stanley, Roos, Sanne, Vivian, Dyon, Tom, Anita, 
Esmée, Susette, Erkin, Sarah), bedankt voor de superleuke tijd die ik heb gehad tijdens mijn 
promotie,  de gezellige momenten in de pauzes, noodzakelijke koffiebreaks, de fantastische 
tijd tijdens congressen, de badminton- en beachvolleybaltoernooitjes, de spelletjesavonden, 
alle lol met het maken van filmpjes en liedjes voor andere promovendi, pubquizen, kleding-
swap-avonden en alles wat ik vergeten ben. In het bijzonder bedankt: Nicole, voor je 
begeleiding tijdens mijn wetenschappelijk stage dat mijn eerste artikel opleverde; Yara, voor 
je nette overdracht van de EUGENDA database en alle moeite die je gestoken in de database; 
Freekje, voor je hulp op statistisch en epidemiologisch vlak en vooral alle Zwelgjesmomenten 
samen met Maartje en Nathalie; Nathalie, voor je vrolijke aanwezigheid en steun waar 
ik altijd op kan rekenen, fijn om zo’n maatje te hebben; Stanley, bedankt dat je het hebt 
volgehouden met mij en Nathalie op een onvergetelijke vakantie na ARVO; Roos, dank voor 
de topsamenwerking bij de organisatie van DOPS2016 en ons hilarische avond evenement. 
En natuurlijk Maartje, mijn onderzoeksmaatje en paranimf, ontzettend bedankt voor alles! 
Het was fijn om met nog zo’n perfectionist samen te werken, database problemen op te 
lossen, projecten te delen, en ons motto “We doen het wel zelf!” heeft mooie resultaten 
opgeleverd;)
Natuurlijk kan een bedankje aan mijn huidige collega’s niet uitblijven: alle AIOS bedankt dat 
jullie de ellende van alle promovendi over het afronden van onze proefschriften nog kunnen 
aanhoren, maar vooral bedankt dat ik het zo naar mijn zin heb in de opleiding! Dat laatste 
woord van dank geldt ook voor alle stafleden, optometristen, orthoptisten, verpleegkundigen, 
OK-medewerkers, dames van het secretariaat, de administratie en het planbureau. 
Ook al lijkt het soms alsof je alleen maar met werk bezig bent, tijd voor ontspanning, familie en 
vrienden is ook nodig. In mijn oude huisje “de Houthof” had ik gelukkig altijd een ontspannen 
en fijne thuisbasis waar ik menig waardevolle herinneringen aan heb met Saskia, Bart, Paul 
en later Yannic. Dank dat jullie er altijd waren, ook al was ik vaak druk met mijn opleiding of 
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promotie. Ook de Smashinghal is voor mij een plek van ontspanning waar ik meermaals per 
week even helemaal mijn gedachten kan verzetten. Ik heb wel jaren iedere training de vraag 
moeten aanhoren “En Eef, is ’t al af?” maar nu kan ik eindelijk vol trots zeggen “Yes Yan, het 
is af!”. 
Lieve familie en vrienden, soms waren er tijden dat ik niets van me liet horen, gelukkig maakte 
dat voor jullie nooit uit en kan ik altijd op jullie rekenen. 
Lieve Saskia, wat begon als een kennis van badminton groeide uit tot een hele goede vriendin 
waar ik een heel aantal jaren veel samen mee heb gedeeld. Sorry dat ik er de laatste tijd 
niet voor je ben geweest, nadat de verdediging van mijn proefschrift is geweest ga ik betere 
prioriteiten stellen.
Lieve Sarah en Meike, dank jullie voor jullie vriendschap sinds onze co-schappen, voor mooie 
herinneringen aan onder andere onze vakantie naar Chersonissos, de weekendjes weg, 
uitstapjes, escaperooms, Q-music foute party, en nog veel meer, maar ook voor de gewone 
chillavonden of -middagen op de bank bij een van ons thuis waar we onze harten konden 
luchten over werk/opleiding/promotie. Hopelijk volgen er nog veel meer mooie momenten 
samen!
Lieve familie en schoonfamilie, dankjewel dat jullie mij de tijd geven om aan mijn carrière te 
werken in tijd die ik ook met jullie had kunnen doorbrengen. Toen ik aan mijn promotie begon 
had ik nog twee opa’s en een oma die trots mijn werk volgde, helaas kunnen zij dit bijzondere 
moment alle drie niet meer meemaken. Gelukkig kan ik altijd op mijn familie rekenen en jullie 
op mij. 
Lieve Madelon, dankjewel dat je er bent voor alles. Ik ben niet van de vele woorden, maar jij 
zegt het wel eens tegen mij en daarom zeg ik het nu tegen jou: ik ben trots op je!
Lieve Papa en Annamarie, dankjewel dat jullie me stimuleren te excelleren. Jullie zijn een 
voorbeeld voor me, ook al zeggen jullie me niet zo te worden als papa. Bedankt voor alle 
ondersteuning en alle leuke momenten samen, want ik kan nergens zo van genieten als een 
lekker glas wijn, heerlijk eten, maar vooral jullie aanwezigheid. 
Lieve Mama, dankjewel dat je er altijd bent. Je hebt je altijd ingezet voor Madelon en mij, 
alles zodat wij het maar goed hadden, op school, sport, studie of werk, het maakt niet uit. 
Zelfs nu zorg je er voor dat ik af en toe wat vitaminen binnen krijg op het werk;) Dankjewel dat 
je zoveel voor ons gedaan hebt en dat ik onvoorwaardelijk bij je terecht kan. 
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Lieve Paul, het klinkt cliché maar zonder jou had ik het niet gered. Behalve dat je een enorme 
steun en toeverlaat voor me bent, zorg jij er de laatste tijd meer dan ooit voor dat ik alle ballen 
in de lucht kan houden: ik hoef me niet druk te maken over boodschappen, eten koken, etc, 
jij regelt het. Dat geeft me enorm veel rust en ruimte om mijn werk goed te kunnen doen. 
Dankjewel voor al je begrip en alle keren dat ik stoom bij je kon afblazen. Liefje, ik hou van je, 
of zoals jij zou zeggen “de tram”;)
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Dames en Heren,
Leeftijdsgebonden natte maculadegeneratie is een belangrijke oorzaak van slechtziendheid 
op oudere leeftijd in de westerse wereld en geassocieerd met een negatieve invloed 
op de kwaliteit van leven van senioren. Het doel van deze klinische les is het belang van 
vroege herkenning en tijdige behandeling van deze veelvoorkomende oogaandoening te 
verduidelijken.
CASUSBESCHRIJVINGEN
Patiënte A is een heer van 75 jaar en belt de praktijk van zijn huisarts met als klacht minder 
goed te kunnen zien. Toen hij gisteren de boodschappen wilde afrekenen in de supermarkt 
merkte hij een vlek in het midden van zijn blikveld en stonden de cijfers van het pinapparaat 
schuin. Het baart hem zorgen dat de klachten na 1 nacht slapen nog steeds bestaan. De 
assistente vraagt naar de oogheelkundige voorgeschiedenis, die blanco is. Meneer krijgt eerst 
het advies zijn bril te laten nakijken, maar op nadrukkelijk verzoek van de patiënt mag hij 
diezelfde dag langskomen. De huisarts bepaalt de gezichtsscherpte van beide ogen. De visus 
van het rechteroog is 0.6 en links 1.0. De Amsler test geeft met het rechteroog beeldvervorming 
(metamorfopsie) aan en een wazige vlek in het centrale gedeelte van het gezichtsveld (relatief 
centraal scotoom). Links is geen sprake van metamorfopsie. Hierop besluit de huisarts 
meneer de volgende werkdag door te verwijzen naar een oogarts met de verdenking op de 
natte vorm van een leeftijdsgebonden maculadegeneratie. De oogarts bevestigt de diagnose 
en dezelfde week wordt een behandeling gestart met vaatgroeiremmende injecties in het 
rechteroog. Als meneer een jaar later terugkomt voor een reguliere controle bedraagt de 
visus rechts 0.8 en vertelt hij blij te zijn dat hij nog goed kan zien na een serie van twee keer 
drie ooginjecties. 
Patiënte B, een vitale dame van 86 jaar, merkt bij de bushalte dat ze het cijfer van de buslijn op 
de bus niet meer goed kan lezen. Dezelfde avond valt bij het skypen met haar kleindochter op 
dat het linkeroog niet goed ziet. De volgende dag lijkt het onveranderd en na twee dagen ziet 
ze met het linkeroog gelukkig weer wat beter. Maar dezelfde dag wordt ‘s avonds plotseling 
de visus links snel minder. Ze gaat de volgende dag meteen naar de opticien, waar men haar 
bril niet kan aanpassen om de visus te verbeteren en wordt doorverwezen naar de huisarts. 
Daar kan ze na twee weken terecht. Bij onderzoek blijkt de visus rechts 1.0 en links 0.2. Er 
wordt niet gevraagd naar metamorfopsie. Patiënte wordt doorverwezen naar de oogarts, 
waar ze na drie weken terecht kan. Deze stelt als diagnose een natte leeftijdsgebonden 
maculadegeneratie links in een gevorderd stadium en start onmiddellijk een behandeling 
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met vaatgroeiremmende injecties in het linkeroog. Een jaar later en 9 ooginjecties verder is 
de visus links niet verder verslechterd dan de uitgangswaarde. De oogarts vertelt desgevraagd 
dat de kans op een betere visus dan 0.2 minimaal is. Er wordt een Amsler kaart meegegeven als 
hulpmiddel ter zelfcontrole mee en hij waarschuwt: als ze metamorfopsie of een visusdaling 
rechts ervaart, moet ze direct de huisarts bellen.
BESCHOUWING
Klinisch beeld en diagnostiek
Leeftijdsgebonden maculadegeneratie (LMD) is een veelvoorkomende oogaandoening 
boven de leeftijd van 50 jaar. De incidentie bedraagt ongeveer 1.8 per 1000 personen per 
jaar in Nederland,1 en de prevalentie van vroege LMD is 13.2% bij personen boven de 70 
jaar in Europa.2 Het beginstadium van LMD verloopt meestal asymptomatisch en wordt 
gekenmerkt door drusen, dit zijn ophopingen onder het retinaal pigment epitheel die 
zichtbaar zijn als gelige vlekjes in de retina. Naarmate de ziekte voorschrijdt kunnen er 
twee vormen onderscheiden worden: een atrofische (“droge”) en een exsudatieve (“natte”) 
vorm waarbij choroidale neovascularisaties zijn ontstaan. Beide vormen kunnen leiden tot 
ernstige slechtziendheid, het beloop is echter verschillend. Droge LMD kenmerkt zich door 
een geleidelijke, meestal bilaterale afname van de centrale gezichtsscherpte. Patiënten 
hebben moeite met lezen, herkenning van gezichten en zien minder goed in schemerige 
omstandigheden. Natte maculadegeneratie daarentegen kenmerkt zich meestal door een 
eenzijdige visusdaling ontstaan binnen enkele dagen en metamorfopsie (beeldvervorming). 
Hierbij staan rechte lijnen schijnbaar krom en dit is vaak één van de eerste klachten bij natte 
LMD. 
Het is belangrijk om metamorfopsie vroegtijdig te signaleren, zowel door de patiënt als de 
arts want in de dagelijkse praktijk blijkt nogal eens dat patiënten metamorfopsie zelf niet 
aangeven, maar wel bevestigen als er expliciet naar gevraagd wordt. De Zwitserse oogarts 
Marc Amsler (1891-1968) schreef hier al in 1953 over en introduceerde daarom de Amsler 
testkaart.3 Patiënten A en B klaagden beide over minder goed zien, niet over beeldvervorming. 
Met behulp van de Amsler test kwam bij patient A de metamorfopsie naar voren en werd 
patiënt direct met een verdenking op neovascularisatie doorverwezen. Echter bij patiënt B 
is er niet gevraagd naar metamorfopsie danwel een Amsler test uitgevoerd, waardoor een 
belangrijk symptoom van natte LMD niet meteen aan het licht gekomen is. Vraag dus bij 
visusklachten bij ouderen altijd expliciet naar vervorming van het beeld (bijvoorbeeld “Ziet u 
de deurpost als een rechte lijn?”) en test hierop met behulp van de Amslerkaart (zie figuur 1). 
De Amsler test is ook zeer geschikt voor de patiënt als zelfcontrole. Het verdient aanbeveling 
dat zowel de oogarts als de huisarts dit met patiënten bespreekt. Ook bij droge LMD ontstaat 
uiteindelijk metamorfopsie, maar het beloop daarvan is geleidelijk en beiderzijds.
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Behandeling
Bij natte LMD is er in de macula sprake van vaatnieuwvormingen met fragiele vaatwanden, 
waaruit makkelijk lekkage en bloedingen kunnen ontstaan die een acute visusdaling 
veroorzaken (figuur 2). Sinds 2007 is het is mogelijk om hiervoor intravitreale injecties met 
vaatgroeiremmende medicatie te geven, beter bekend als anti-VEGF medicatie, en daarmee 
de visus te stabiliseren of verbeteren. De belangrijkste anti-VEGF medicijnen zijn bevacizumab 
(Avastin), ranibizumab (Lucentis) en aflibercept (Eylea). Deze medicijnen hebben een 
vergelijkbare effectiviteit en verschillen in veiligheid konden niet worden aangetoond.4 
Hoewel bij gebruik van Eylea minder injecties nodig zijn, is in verband met het grote verschil 
in kosten Avastin het middel van eerste keuze in Nederland. 
Figuur 1. De Amslerkaart
Instructies aan de patiënt: houd de kaart op leesafstand, dek één van beide ogen af en focus op de stip in centrum 
van de kaart. Wat is het verloop van de lijnen (recht of schijnbaar krom)? Zijn er plaatsen waar de hokjes minder of 
helemaal niet zichtbaar zijn? Herhaal de test voor het andere oog. Indien de lijnen vervormd (A), wazig of verminderd 
(B) worden waargenomen is het van belang om snel het netvlies te laten beoordelen door een oogarts. 
Figuur 2. Natte LMD 
Een kleurenopname van de macula bij natte LMD. Er is een zichtbare bloeding in de macula door een onderliggende 
subretinale neovascularisatie. 
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Er is veel onderzoek gedaan naar de effectiviteit van deze vaatgroeiremmers. Verschillende 
factoren zijn geassocieerd met een betere uitkomst van de behandeling onafhankelijk van 
het soort vaatgroeiremmer: de duur van de klachten, de gezichtsscherpte bij aanvang 
van de therapie, en de uitgebreidheid van de neovascularisatie. Hierbij geldt dat een 
kortere klachtenduur, een kleinere vaatnieuwvorming en een betere visus bij aanvang 
van de behandeling (zie figuur 3) de kans vergroten op een betere visus één jaar na start 
van de behandeling.5 Om de laatste reden, meer kans op een betere visus bij een hogere 
uitgangsvisus, is snel handelen door alle betrokkenen (patiënt, huisarts en oogarts) van 
het grootste belang zo opdat therapie zo vroeg mogelijk gestart kan worden. Bij patiënt A 
was de behandeling succesvol mede dankzij de snelle interventie door alle betrokkenen. 
Daarentegen was de kans op visuswinst bij patiënt B beperkt doordat de therapie pas werd 
gestart na enkele weken. 
De behandeling van natte LMD met vaatgroeiremmers heeft geleid tot een sterke vermindering 
van het aantal ernstig slechtzienden.6 LMD en visusverlies door LMD is geassocieerd met 
moeilijkheden bij het uitvoeren van dagelijkse activiteiten, verhoogde emotionele distress 
en depressie. Het heeft een negatieve invloed op de kwaliteit van leven, niet alleen van de 
patiënt zelf maar vaak ook van de nabije omgeving.7 Tijdige herkenning van LMD en daarmee 
Figuur 3. Gezichtsscherpte vóór de behandeling als voorspeller van de visus één jaar na de behandeling met 
vaatgroeiremmende injecties
Hoe beter de gezichtsscherpte bij aanvang van behandeling (uitgangsvisus) hoe beter de gezichtsscherpte één jaar 
na start van de behandeling. Deze belangrijke figuur is gebaseerd op onderzoeksresultaten van Ying en collega’s.5
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samenhangend vroege behandeling kan de kwaliteit van leven gunstig beïnvloeden. Vroege 
herkenning heeft tevens een bewezen gunstig effect op de zorgkosten.8 Voor de droge vorm 
van LMD is tot op heden geen curatieve behandeling mogelijk. 
Voorlichting en leefstijladvies
Goede voorlichting en leefstijladviezen kunnen het beloop van LMD positief beïnvloeden 
en progressie naar een gevorderd stadium vertragen. Stoppen met roken is daarbij één van 
de belangrijkste maatregelen (ook op hoge leeftijd!),9 alsmede het zorgen voor een gezond 
lichaamsgewicht10 en voldoende beweging.11 Een voedingspatroon met veel groenten 
en fruit (antioxidanten) wordt geadviseerd.12 Resultaten van een belangrijke studie in 
de Verenigde Staten tonen aan dat het gebruik van speciale voedingssupplementen kan 
leiden tot een milde verlaging van het risico op progressie van de ziekte. Deze zogenaamde 
AREDS2 formule voedingssupplementen bestaan uit een hoge dosering zink (25-80 mg), 
luteïne (10 mg), zeaxantine (2 mg), vitamine C (500 mg) en vitamine E (400 IE). Ze worden 
geadviseerd aan LMD patiënten met gevorderde stadia van droge of natte LMD aan één oog 
of beide ogen.13 LMD patiënten die roken of de afgelopen 5 jaar gerookt hebben mogen 
geen voedingssupplement met bètacaroteen gebruiken vanwege een verhoogde kans op de 
ontwikkeling van longkanker.
Hoewel voor natte LMD een goede behandeling voorhanden is, bestaat er nog steeds een 
aanzienlijk patient- en doctor’s delay.14 Ouderen zien vaak slechter dan ze zelf denken. “Het zal 
wel bij de leeftijd horen” lijken ouderen vaak te veronderstellen. Daarnaast is er vaak sprake 
van co-morbiditeit en/of verminderde mobiliteit waardoor men afhankelijk van anderen is 
om een bezoek aan de oogarts te brengen. Naarmate de leeftijd toeneemt wordt het patient 
delay groter.14 Daar komt bij dat LMD voor veel mensen een onbekende oogaandoening is; 
slechts 4-30% van de mensen in westerse landen zijn in meer of mindere mate bekend met 
LMD.7 Voorlichting is dan ook erg belangrijk. Aan patient empowerment bij LMD wordt in 
Nederland veel aandacht gegeven door de maculadegeneratie patiëntenvereniging en de 
WHO preventieprojectgroep VISION 2020 Netherlands.
CONCLUSIE 
Dames en Heren,
Natte LMD is een aandoening die in de westerse wereld veel voorkomt, waarbij de 
vroegdiagnostiek nog te wensen overlaat terwijl een adequate behandeling voorhanden is. 
Dit klemt te meer daar ouderen metamorfopsie vaak zelf niet aangeven, de resultaten van de 
kosteneffectieve behandeling bij een hogere uitgangsvisus beter zijn en de kwaliteit van leven 
van ouderen sterk gecorreleerd is aan een goede visus. Actieve voorlichting aan senioren 
Klinische les
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en huisartsen speelt dan ook een belangrijke rol en kan de kwetsbaarheid van ouderen 
structureel verminderen. Het verdient aanbeveling om bij ouderen met visusklachten 
expliciet te vragen naar metamorfopsie en dit te testen met behulp van een Amslerkaart. Bij 
acute metamorfopsie is het wenselijk de patiënt binnen enkele werkdagen door te verwijzen 
naar een oogarts. 
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